

ANNUAL REPORT 2024-2025



Vallabhbhai Patel Chest Institute
University of Delhi, Delhi, India



ANNUAL REPORT

2024-25



Vallabhbhai Patel Chest Institute
University of Delhi, Delhi, India

Published by

Professor Raj Kumar, Director, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi-110 007;
Phone: 27667102, 27667441, 27667667, 27666182

Compiled and Edited by

Publication Division, VPCI

Printed at

India Offset Press, Phase-I, Mayapuri, New Delhi (Phone: 011-28116494, 28115486)

This Annual Report can be accessed at website: www.vpci.org.in

From the Director's Desk



It is my privilege to present the Institute's Annual Report for the year 2024-25. The Institute with the support of the University of Delhi and Ministry of Health and Family Welfare, Government of India, has been able to strive and thrive to achieve its objectives: to conduct research in basic and clinical aspects related to chest diseases, to train post-graduates in Pulmonary and Critical Care Medicine (DM and MD in Pulmonary Medicine) and allied disciplines (MD Microbiology, Biochemistry, Physiology and Pharmacology), and PhD in various subjects, to develop new diagnostic technology and disseminate scientific knowledge related to Chest Medicine to other Institutions of the country and, over and above all, to provide specialised patient care services to patients from India as well as other countries of the Asia during the year under report.

A large number of physicians, paramedical staff and students from other Universities/Institutions/Colleges got training in disciplines, such as Biochemistry, Microbiology, Physiology, Pathology etc in various departments of the Institute during the year. The research laboratories of the Institute are being equipped with the latest technology to keep pace with the rest of the world.

The research contributions from the Institute are widely acclaimed, funded by various Government Departments, like ICMR, CSIR, Ayush, DHR-MoHFW and DRDO. The faculty members and students of the Institute delivered orations, guest lectures and presented papers in the International and National conferences through webinar and virtual mode. The faculty members and students of the Institute received several Awards and Honours in their field of their specialisation. The Institute also organised workshops and eminent experts (virtual mode) shared their experiences.

The Viswanathan Chest Hospital (VCH), the clinical wing of the Institute, is a tertiary care Chest Hospital with state-of-the-art patient-care facilities.

National Tobacco Quitline Services (NTQLS) at VPCI is a pioneering concept in our country to tackle the growing menace of tobacco addiction in a cost-effective manner.

With the aim to disseminate scientific knowledge and latest developments in the field of chest diseases and allied sciences, the Institute continued the publication of its reputed quarterly publication The Indian Journal of Chest Diseases & Allied Sciences, in collaboration with the National College of Chest Physicians (India). The journal has wide national and international circulation. Institute also continues to publish its biannual Newsletter.

Thrust areas identified for special attention in near-future include COPD, Bronchial Asthma and Lung Cancer.

Prof. Raj Kumar

Annual Report (2024–25)

CONTENTS

	<i>Pages</i>
Milestones of Institute	7
Orations	11
Prof. R. Viswanathan-VPCI	11
Prof. A.S. Paintal Memorial	13
Prof. H.S. Randhawa	15
Dr V.K. Vijayan	16
The Institute	17
Objectives	17
Administration	17
Organisation and Management	17
Governing Body	18
Standing Finance Committee	19
Scientific Advisory Committee	20
Human Ethics Committee	21
Institutional Animal Ethics Committee	22
Organisational Structure	23
Viswanathan Chest Hospital	25
Multidisciplinary Research Unit	35
National Centre of Respiratory Allergy, Asthma and Immunology	39
National Tobacco Quitline Services	41
E-Hospital Services	44
Animal House	46
Library	47
Publication Division	49
Departmental Activities	50
Biochemistry	50
Biostatistics	52
Microbiology	53
Pathology	55
Pharmacology	58
Physiology	60
Pulmonary Medicine	61

Postgraduate Training and Teaching	63
MD Degrees (Ongoing)	63
DM Degrees (1 st Year)	63
MD Theses (Awarded)	63
MD Theses (Submitted)	64
MD Theses (ongoing)	65
MD 1 st First	66
PhD (Awarded/ Submitted)	67
PhD (ongoing)	67
Faculty Members Associated as Co-supervisors for MD/ PhD Theses of DU and Other Institutions	68
Distinguished Visitors	69
Awards/Honours	70
Sponsored Research Projects	75
Fellowships	77
Conferences/Symposia/Seminars/Workshops/CMEs	78
Participation in Advanced and Specialised Training Programme by Faculty Members	104
Short-term Specialised Training Imparted by Faculty Members	104
Glimpses of the Events held at VPCI	107
List of Publications	122
Media Recognition	126

MILESTONES OF INSTITUTE

April 6,	1949	Foundation stone of the Institute was laid down by Sardar Vallabhbhai Patel.
November,	1951	Ad-hoc Governing Body was appointed by the Executive Council of University of Delhi for administrative affairs of the Institute.
December,	1951	Main building of the Institute was completed.
January 12,	1953	The Institute was formally opened by Rajkumari Amrit Kaur, the Union Minister of Health, Government of India.
		Prof. R. Viswanathan was appointed as the Founder-Director. The grant for 1953- 54 was Rs. 2 lakhs.
January 21,	1955	A regular Governing Body was constituted by the Executive Council of the University of Delhi for the management and administration of the Institute.
April 4,	1955	The first meeting of the regular Governing Body was held.
	1955	Prof. A.S. Paintal reported the discovery of lung deflation receptors, a historical landmark in understanding the functioning of lung and its diseases.
July 1,	1957	Prof. R. Viswanathan took over as full-time Director of the Institute. Previously, he was the Deputy Director-General of Health Services, Government of India and Honorary Director of the Institute.
September 24,	1957	Pt. Jawaharlal Nehru said in a message: "It was a brave act of the University of Delhi to start the V.P. Chest Institute".
October 24,	1957	Clinical Research Centre was inaugurated by Dr Rajendra Prasad, the President of the Republic of India.
January 24,	1959	Indian Association for Chest Diseases was inaugurated by Sir A.L. Mudaliar. It was re-named as the National College of Chest Physicians (India) in January 1981.
July,	1959	<i>The Indian Journal of Chest Diseases</i> , a Quarterly Journal, was started under the joint auspices of the V.P. Chest Institute and the Indian Association for Chest Diseases.
July,	1959	A ward of 20 beds was opened to admit patients.
	1959	By a resolution of the Governing Body, V.P. Chest Institute was nominated as a "National Institute for Teaching and Research in Chest and Allied Diseases".
January,	1960	A Diploma course in Tuberculosis Diseases, started in March 1947, was re-named as "Diploma in Tuberculosis and Chest Diseases" (DTCD) from XIV Course. The XV DTCD Course started from July 1960.
April 6,	1961	Foundation Day Celebrations of the Institute was started.
April 7,	1962	Foundation stone of Patel Niwas, a Post Graduate Hostel, was laid down by Dr. C.D. Deshmukh, Vice-Chancellor, University of Delhi.
January 26,	1963	A contingent of the Institute staff participated in the Republic Day parade.
February 20-24,	1963	VII International Congress on Diseases of the Chest was held at Vigyan Bhawan under the auspices of V.P. Chest Institute, Indian Association for Chest Diseases and the University of Delhi.
August 1,	1964	Prof. A.S. Paintal joined as the Director of the Institute.
April 6,	1965	Patel Niwas (a PG Student Hostel) was inaugurated by Dr. C.D. Deshmukh on the XVI Foundation Day of the Institute.
	1966	Prof. A.S. Paintal was elected as the Fellow of the Royal Society of Edinburgh.

	1969	Padma Shree was awarded to Prof. R. Viswanathan.
	1974	Padma Bhushan was awarded to Prof. R. Viswanathan.
	1981	Prof. A.S. Paintal was elected as the Fellow of the Royal Society of London.
	1984	Prof. A.S. Paintal was elected as the General President of the Indian Science Congress Association [1984-85].
	1985	Prof. H.S. Randhawa was elected as the Vice-President of the International Society for Human and Animal Mycology [1985-88].
	1986	Prof. A.S. Paintal was appointed as the Director-General of the Indian Council of Medical Research.
	1986	Padma Vibhushan was awarded to Prof. A.S. Paintal.
	1986	Prof. A.S. Paintal was elected as the President of the Indian National Science Academy [1986-88].
November 10,	1991	Prof. H.S. Randhawa joined as the Director of the Institute.
October 5,	1998	Dr. V.K. Vijayan joined as the Director of the Institute.
April 6,	1999	Golden Jubilee Celebrations of the Foundation Day of the Institute. VPCI Oration was started.
June 14,	1999	24-hour Respiratory Emergency Services were started.
November 12,	1999	His Excellency, Shri K.R. Narayanan, the President of India, received the copy of Compendium of Activities (VPCI) 1949-99.
August 30,	2000	A New Ward (with an additional 40 beds) was inaugurated by Dr. A.K. Walia, Honourable Minister for Health, Govt. of NCT of Delhi.
	2000	Dr. V.K. Vijayan was elected as the International Regent, American College of Chest Physicians [2000-06].
March,	2001	A Respiratory Critical Care Unit was started.
March 15,	2001	CT Scan Centre was inaugurated by the Honourable Padma Shree Dr. C.P. Thakur, the Union Minister of Health and Family Welfare, Government of India.
November 21,	2001	Tobacco Cessation Clinic was started.
August 14,	2002	A State-of-the-Art Oxygen Plant was installed and started.
January 12-14,	2003	International Conference on Chest Diseases and Allied Sciences was held at India Habitat Centre, New Delhi, to commemorate the Golden Jubilee of the Inauguration of the Institute.
	2004	Website of the Institute was started (www.vpci.org.in).
September 24,	2005	Prof. Autar Singh Paintal Memorial Oration was started.
January 10,	2006	An 8-bedded Intensive Care Unit was started.
December 8,	2006	Inauguration of the Golden Jubilee Auditorium by organising an International Symposium on Herbal Drug Research and Therapy in Chest Medicine.
March 2,	2007	The Hospital wing of the Institute, Clinical Research Centre was re-named as "Viswanathan Chest Hospital" in honour of the Founder-Director of the Institute and the Golden Jubilee Auditorium was re-named as "Paintal Memorial Golden Jubilee Auditorium" in honour of the former Director of the Institute by a resolution of the Governing Body.
June 22,	2007	Yoga Therapy and Research Centre [in collaboration with the Morarji Desai National Institute of Yoga (MDNIY), New Delhi], was started.
September 18,	2007	Cardio-pulmonary Rehabilitation Clinic was started.

September 17,	2009	Approval by the University of Delhi to start Superspeciality DM Course in Pulmonary and Critical Care Medicine with an intake of two students per year.
August 3,	2010	Approval by the University of Delhi to start Diploma Course in Allergy and Clinical Immunology in VPCI with an intake of two students per year.
February 12,	2011	National Centre of Respiratory Allergy, Asthma and Immunology was started.
March 15,	2011	Permission from Medical Council of India to start DM (Pulmonary Medicine) course with intake of two students per year from the academic year 2011-12.
June 1,	2011	Prof. S.N. Gaur joined as the Acting Director.
November 21,	2012	Prof. Rajendra Prasad joined as the Director of the Institute.
May 7,	2013	DOTS Centre was started.
August 18,	2013	DMA Centenary Institution Award received from Smt. Sheila Dikshit, the Hon'ble Chief Minister, Government of NCT, Delhi for the "Outstanding Contribution in the Field of Patient Health Care".
August 23,	2013	New Ward (44 beds) was started. VPCI Newsletter was started.
September 15,	2014	VPCI Gym was inaugurated.
January 6,	2015	In the memory of Prof. A.S. Paintal, a museum was opened, which was dedicated to Prof. Paintal's life and contributions in the world of science, inspiring young scientist, researchers and academicians.
May 30,	2016	National Tobacco Quit Line Services, which functions from the Institute was inaugurated by Shri J.P. Nadda, Union Minister of Health and Family Welfare, Government of India, during the "World No Tobacco Day" programme organized by WHO-India, Ministry of Health and Family Welfare, Government of India and the National Heritage City Development and Augmentation Yojana (HRIDAY), at New Delhi.
September 30,	2016	Release of VPCI Postal Envelope by Prof. S.N. Gaur, Director (Acting), VPCI at "Neelambari-2016", a District Level Philately Exhibition organized by Sr. Superintendent of Post Offices, Delhi.
February 20,	2017	VPCI Indoor Games Center was inaugurated.
June 6,	2017	Prof. A. Ray joined as the Acting Director.
November 3,	2017	Prof. Raj Kumar joined as the Acting Director.
December 8,	2017	An MOU was signed between Vallabhbhai Patel Chest Institute (VPCI), University of Delhi, Delhi and Department of Allergology, University Hospital, Munster, Germany (UKM) on Teaching and Training; Exchange of Information and Academic Materials and Exchange of Faculty, Research Scholars and Administrative and Other Staff.
January 12,	2018	Patient Education Centre was inaugurated.
April 6,	2018	Daily Digital Pollen Count Information for Public was inaugurated by Shri J.P. Nadda, Hon'ble Union Minister of Health and Family Welfare, Government of India
	2018	DM (Pulmonary Medicine) was re-started.
October 15,	2018	The Renovated Kitchen of Viswanathan Chest Hospital (VCH) was inaugurated, which is dedicated to the patients admitted at VCH and ensures hygienic meal.
September 28,	2018	Prof. Raj Kumar joined as the Director of the Institute.
April 1	2019	Started Short-Term Training Programme on Pulmonary Function Test (3 Months Duration).

May 31,	2019	Prof. Raj Kumar, Director VPCI, received the prestigious World No Tobacco Day Award for 2019.
May 31	2019	Prof. CG Uragoda Oration-2019 was awarded to Prof. Raj Kumar in the field of Allergy and Immunotherapy by Sri Lanka College of Pulmonologists at Sri Lanka.
June 7,	2019	Renovated Canteen of the VPCI was re-opened.
September 16,	2019	Registration and Waiting Hall for Patients at VCH was inaugurated.
	2019	VPCI declared as Centre of Excellence for climate sensitive allergic diseases under National Program for Climate change and human Health in 2019.
March 4,	2020	Pradhan Mantri Jan Arogya Yojana (PMJAY) Counter at VCH was inaugurated by Shri Ashwini Kumar Choubey, Hon'ble Minister of State for Health and Family Welfare, Government of India.
March 4,	2020	Inauguration of Expanded National Tobacco Quit Line Services by Shri Ashwini Kumar Choubey, Hon'ble Minister of State for Health and Family Welfare, Government of India.
June 16,	2020	Tele Medicine for registered patients was started.
October 1,	2020	Composter-A unit of Solid Waste Management Machine was installed at the Institute by Prof. V.S. Chauhan, Chairman, Governing Body, VPCI.
October 1,	2020	VPCI Mobile Application was launched.
	2020	Post COVID-19 Respiratory Management: Expert Panel Report was published.
May 24,	2021	Inauguration of VPCI Post Covid Respiratory Management Center by Prof. P C Joshi, Hon'ble, Pro Vice-Chancellor, Delhi University.
January 06,	2022	Inauguration of Allergy Testing Centre by Prof. V.S. Chauhan, Chairman, Governing Body, VPCI.
March 11,	2022	Release of Indian Guidelines for Diagnosis of Respiratory Allergy by Prof. V. S. Chauhan, Chairman Governing Body, VPCI
June 12,	2022	Prof. Raj Kumar awarded Dr. N. L. Bordia Oration-2022 in the field of Respiratory Medicine by Department of Respiratory Medicine at MGM Medical College, Indore, MP
July 4,	2022	Started Short-Term Certificate Course in Clinical Pathology (3 Months Duration).
July 13,	2022	Inauguration of Official Website of the Indian Journal of Chest Diseases and Allied Sciences by Dr. Vijay Chauthaiwale, Chairman Governing Body, VPCI
July 12,	2023	Vallabhbhai Patel Chest Institute (VPCI) was awarded the NABH Accreditation Certificate by the Constituent Board of the Quality Council of India
September 1,	2023	Started M.Sc in Respiratory Therapy
September 27	2023	Inauguration of passenger cum bed lift at VCH by Dr. Vijay Chauthaiwale, Chairman, Governing Body, VPCI
March 17,	2024	Prof. Raj Kumar received the prestigious American Thoracic Society (ATS) Public Service Award for his exemplary leadership and advocacy in advancing public health initiatives related to air quality enhancement, tobacco control, communicable respiratory disease management, and critical care
September 18,	2024	Inauguration of new toilet block and May I help you desk by Prof. Raj Kumar, Director, VPCI
December 19-22,	2024	Vallabhbhai Patel Chest Institute hosted the 58 th Annual National Conference of the Indian College of Allergy, Asthma & Applied Immunology (ICAAICON 2024) on a grand scale

Prof. R. Viswanathan-VPCI Oration

1 st Oration	April 6, 1999	Prof. N.K. Ganguly, Director-General, Indian Council of Medical Research, New Delhi
2 nd Oration	April 6, 2000	Prof. A.S. Paintal, former Director-General, ICMR and former Director, VPCI.
3 rd Oration	April 6, 2001	Dr. S. Lakshminarayanan, University of Washington School of Medicine, Washington, Seattle, USA.
4 th Oration	April 6, 2002	Dr. S. Padmavati, President, All India Heart Foundation and Director, National Heart Institute, New Delhi.
5 th Oration	April 7, 2003	Prof. J.S. Bajaj, former Member, Planning Commission, Government of India and former Professor and Head, Department of Medicine, All India Institute of Medical Sciences, New Delhi.
6 th Oration	April 6, 2004	Prof. H.S. Randhawa, former Director, V.P. Chest Institute, University of Delhi, Delhi.
7 th Oration	April 6, 2005	Prof. Naranjan S. Dhalla, Distinguished Professor and Director, Institute of Cardio-vascular Sciences, St. Boniface General Hospital and Research Centre, University of Manitoba, Winnipeg, Canada.
8 th Oration	April 6, 2006	Prof. C.N. Deivanayagam, Former Medical Superintendent, Hospital for Thoracic Medicine, Chennai.
9 th Oration	April 6, 2007	Prof. K.K. Talwar, Director, Postgraduate Institute of Medical Education and Research, Chandigarh.
10 th Oration	April 6, 2008	Prof. C.R. Babu, former Pro-Vice-Chancellor, University of Delhi, Delhi.
11 th Oration	April 7, 2009	Prof. Peter J. Barnes, Head of Respiratory Medicine, Imperial College, London and Professor of Thoracic Medicine and Head of Airway Disease at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London.
12 th Oration	April 6, 2010	Prof. M.K. Bhan, Secretary, Government of India, Department of Biotechnology, New Delhi.
13 th Oration	April 6, 2011	Dr. Vishwa Mohan Katoch, Secretary to the Government of India, Department of Health Research, Ministry of Health and Family Welfare and Director-General, Indian Council of Medical Research, New Delhi.

14 th Oration	April 6, 2012	Prof. Sami Bahna, Chief, Allergy and Immunology Section, Louisiana State University, LA, USA, and Past-President, American College of Allergy, Asthma and Immunology, USA.
15 th Oration	April 6, 2013	Dr. W. Selvamurthy, Former Distinguished Scientist and Chief Controller R&D (LS&IC), DRDO, Ministry of Defence, Government of India, New Delhi.
16 th Oration	April 6, 2014	Prof. P.S. Shankar, Emeritus Professor of Medicine, Rajiv Gandhi Institute of Health Sciences, Bangalore, Karnataka.
17 th Oration	April 6, 2015	Prof. K.C. Mohanty, former Director-Professor, Department of Chest and TB, K.J. Somaiya Medical College and Hospital, Mumbai.
18 th Oration	April 6, 2016	Prof. S.K. Jindal, former Head, Department of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh.
19 th Oration	April 6, 2017	Prof. S.K. Katiyar, former Principal and Dean and Professor and Head, Department of Tuberculosis and Respiratory Diseases, Ganesh Shankar Vidhyarthi Memorial (G.S.V.M.) Medical College, Kanpur.
20 th Oration	April 6, 2018	Prof. Randeep Guleria, Director, All India Institute of Medical Sciences, New Delhi.
21 st Oration	April 5, 2019	Dr. Rohit Sarin, Director, National Institute of Tuberculosis and Respiratory Diseases (NITRD), New Delhi
22 nd Oration	April 6, 2023	Prof. S.K. Sarin, Director, Institute of Liver and Biliary Science (ILBS), New Delhi
23 rd Oration	April 8, 2024	Prof. A.K. Janmeja, Prof. & HOD, Dept. of Pulmonary Medicine, MM Institute of Medical Sciences & Research, Solan

Prof. A.S. Paintal Memorial Oration

1 st Oration	September 24, 2005	Prof. M.S. Valiathan, Honorary Adviser, Manipal Academy of Higher Education, Manipal (Karnataka).
2 nd Oration	September 24, 2006	Prof. P.N. Tandon, President, National Brain Research Centre Society, Gurgaon.
3 rd Oration	September 24, 2007	Prof. P.N. Srivastava, First Chancellor, Manipur Central University, Imphal and former Vice-Chancellor, Jawaharlal Nehru University, New Delhi.
4 th Oration	September 24, 2008	Prof. Nanduri R. Prabhakar, Director, Centre for System Biology of Oxygen Sensing, Department of Medicine, University of Chicago, USA.
5 th Oration	September 24, 2009	Prof. Arun Dharmarajan, Winthrop Professor, School of Anatomy and Human Biology, Faculty of Life and Physical Sciences, The University of Western Australia, Nedlands, Perth, Western Australia.
6 th Oration	September 24, 2010	Prof. Chulani Tissa Kappagoda, Professor of Medicine, University of California, Davis, USA.
7 th Oration	September 23, 2011	Prof. J.S. Guleria, Senior Consultant (General Medicine), Sitaram Bhartia Institute of Science and Research, New Delhi and former Professor and Head, Department of Medicine, and Dean, AIIMS, New Delhi.
8 th Oration	September 24, 2012	Prof. S.K. Jain, Senior Consultant, Respiratory Medicine, Max Hospital, Noida, Coordinator, DNB (Respiratory Medicine), Metro Hospital, Noida, Ex-Advisor and Member, Scientific Advisory Committee, NIREH (ICMR), Bhopal and Ex-HOD, Cardio-respiratory Physiology, VPCI.
9 th Oration	September 24, 2013	Prof. Samir K. Brahmachari, Secretary, Government of India, Department of Scientific and Industrial Research, and Director-General, CSIR, New Delhi.
10 th Oration	September 24, 2014	Prof. M. Fahim, Adjunct Research Professor, Department of Physiology, Hamdard Institute of Medical Sciences and Research, Jamia Hamdard, New Delhi and former Professor and Head, Department of Physiology, VPCI.

11 th Oration	September 24, 2015	Prof. A.K. Prasad, Chairman, Influenza Foundation of India, and President, Indian Virological Society and former Professor and Head, Department of Respiratory Virology, VPCI.
12 th Oration	September 23, 2016	Dr. Ashima Anand, Principal Investigator, DST Research Project, V.P. Chest Institute, university of Delhi, Delhi.
13 th Oration	September 22, 2017	Dr. K. Ravi, Former Professor and Head, Department of Physiology, V.P. Chest Institute, University of Delhi, Delhi.
14 th Oration	September 24, 2018	Dr. A.K. Jain, Professor of Excellence, Department of Physiology, Maulana Azad Medical College, New Delhi.
15 th Oration	September 24, 2019	Prof. V.S. Chauhan, ICGEB, Jawaharlal Nehru University, New Delhi -110067
16 th Oration	September 26, 2022	Prof. Anil Gurtoo, Director Professor, Department of Medicine, Lady Hardinge Medical College, New Delhi.
17 th Oration	September 27, 2023	Prof. Nikhil Tondon, Professor and Head, Department of Endocrinology and Metabolism, AIIMS, New Delhi
18 th Oration	September 24, 2024	Prof. Ashok Shah, Former Director-Professor, VPCI

Prof. H.S. Randhawa Oration

1 st Oration	January 12, 2015	Prof. Ziauddin Khan, Chairman, Department of Microbiology, Kuwait, University, Kuwait.
2 nd Oration	January 12, 2016	Prof. Indira Nath, former Faculty Member, Department of Pathology, All India Medical Institute of Medical Sciences, New Delhi.
3 rd Oration	January 12, 2017	Prof. Subrata Sinha, Director, National Brain Research Centre, Gurugram, Haryana.
4 th Oration	January 12, 2018	Prof. Rajesh S. Gokhale, Former Director, CSIR-IGIB, Delhi.
5 th Oration	January 12, 2019	Prof. Yogendra Singh, Department of Zoology, University of Delhi, Delhi.
6 th Oration	March 4, 2020	Prof. Rakesh Bhatnagar, Vice Chancellor, Banaras Hindu University, Varanasi, Uttar Pradesh.
7 th Oration	January 12, 2023	Prof. Atul Goel, Director General of Health Services, Ministry of Health and Family Welfare, New Delhi.
8 th Oration	January 15, 2024	Dr. Sauvik Maiti, Director, CSIR-Institute of Genomics and Integrated Biology
9 th Oration	January 13, 2025	Dr. C.P. Baveja, Former Professor of Excellence and Head, Department of Microbiology, Maulana Azad Medical College, New Delhi

Dr V.K. Vijayan Oration

1 st Oration	October 26, 2015	Dr. Soumya Swaminathan, Secretary, Department of Health Research, Ministry of Health and Family Welfare, Government of India, and Director- General, ICMR, New Delhi.
2 nd Oration	October 26, 2016	Prof. Digambar Behera, Head, Department of Pulmonary Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh.
3 rd Oration	October 24, 2017	Prof. Seyed Ehtesham Hasnain, Vice-Chancellor, Jamia Hamdard, New Delhi.
4 th Oration	October 24, 2018	Dr. J.C. Suri, former Consultant, Professor and Head, Department of Pulmonary, Critical Care and Sleep Medicine, VMMC and Safdarjung Hospital, New Delhi.
5 th Oration	October 24, 2019	Dr. S.K. Luhadia, Professor and Head, Department of Respiratory Medicine, Geentanjali Medical College and Hospital, Udaipur, Rajasthan.
6 th Oration	October 26, 2022	Prof. Surender Kashyap, Vice Chancellor, Atal Medical and Research University, Mandi, Himachal Pradesh.
7 th Oration	October 26, 2023	Prof. Anant Mohan, Professor and Head, Department of Pulmonary, Critical Care, and Sleep Medicine, AIIMS, New Delhi
8 th Oration	October 28, 2024	Dr. Radha P. Munje, Professor & Head, Department of Pulmonary Medicine, Indira Gandhi Government Medical College & Hospital, Nagpur

THE INSTITUTE

The Vallabhbhai Patel Chest Institute (VPCI) is a post-graduate medical Institution devoted to the study of chest diseases. It is located in the Delhi University main campus providing the requisite academic environment in which a wide range of scientific facilities are available in various departments along with an excellent Institute Library.

Objectives

The main objectives of VPCI have been to conduct research on basic and clinical aspects of chest medicine, to train post-graduates in Pulmonary Medicine and allied subjects, to develop new diagnostic technology and to disseminate it to other institutions in the country and to provide specialised clinical and investigative services to patients.

Administration

The VPCI is a maintained Institution of University of Delhi and is fully funded by the Grants-in-Aid received from the Ministry of Health and Family Welfare, Government of India. The Institute is governed and administered by its own Governing Body as Constituted under Ordinance XX (2) of the University of Delhi Act. The Director, who is appointed by the Executive Council of University of Delhi, is the Chief Executive of the Institute. The Director of the Institute also functions as Member-Secretary (Ex-Officio) to the Governing Body of the Institute. The Institute also has a Standing Finance Committee constituted by the Governing Body to make recommendations about its budgetary requirements.

Organisation and Management

The organisation and management of the Institute is through Departmentation of activities based on various areas of specialisation and functions. The Academic, Scientific and Clinical services are organised under the Departments of Anaesthesiology, Cardio-respiratory Physiology, Radiodiagnosis and Imaging, Respiratory Allergy and Applied Immunology, Pulmonary Medicine and Thoracic Surgery. These Departments along with Outdoor/ Indoor patient care services and Respiratory Emergency section are housed in the Viswanathan Chest Hospital. The other Departments of the Institute include Biochemistry, Clinical Biochemistry, Biostatistics, Medical Mycology, Microbiology, Pathology, Pharmacology, Physiology and Respiratory Virology. These Departments are headed by the Faculty Members in the respective fields. The General and Personnel Management including various maintenance activities required for the Institute are supported by administrative services of the Institute, controlled by the Deputy Registrar who reports to the Director.



May I help you desk inaugurated by Prof. Raj Kumar,
Director, VPCI



New toilet block inaugurated by Prof. Raj Kumar,
Director, VPCI

GOVERNING BODY

CHAIRMAN

The Vice-Chancellor, University of Delhi
(Ex-Officio) or a person nominated by him

Dr. Vijay Chauthaiwale

MEMBERS

Treasurer, University of Delhi (Ex-Officio)

Shri Nawal Kishore

Two members nominated by the Executive
Council, University of Delhi

Prof. Chand Wattal
Prof. Neeta Sehgal

Dean, Faculty of Medical Sciences,
University of Delhi

Prof. Sunita Kalra

Three members nominated by the Ministry of
Health and Family Welfare, Government of India,
New Delhi

Prof. (Dr.) Atul Goel
Director General of Health Services

Shri Jaideep Kr. Mishra
Additional Secretary & Financial Advisor

Dr. Manashvi Kumar
Joint Secretary

One member, not connected with the
University, nominated by the Executive
Council, University of Delhi

Prof. Mahesh Verma

One Professor of the Institute by rotation
according to seniority for a period of one year

Prof. Vishal Bansal (*till 02.11.2024*)
Prof. Vishwajeet Rohil (*03.11.2023 onwards*)

One Associate Professor or Assistant Professor
of the Institute by rotation according to Seniority
for a period of one year

Dr. Siddharth Raj Yadav (*till 02.11.2024*)
Dr. Nitin Goel (*03.11.2024 onwards*)

Representative of Non-teaching Staff
of the Institute by rotation (as Special Invitee)
according to seniority for a period of one year

Ms. Tarika Pruthi (*till 28.02.2025*)
Shri Giridhari Pal (*01.03.2025 onwards*)

MEMBER-SECRETARY

Director, Vallabhbhai Patel Chest
Institute, University of Delhi, Delhi (Ex-Officio)

Prof. Raj Kumar
Director, VPCI

Standing Finance Committee

Additional Secretary and Financial Advisor

Ministry of Health and Family Welfare
Government of India
Nirman Bhawan
New Delhi-110 001

*Chairman***Joint Secretary or Nominee**

Ministry of Health and Family Welfare
Government of India
Nirman Bhawan
New Delhi-110 001

*Member***Prof. Ritu Kulshrestha**

Department of Pathology
V.P. Chest Institute
University of Delhi, Delhi -110 007

*Member***Deputy Registrar**

V.P. Chest Institute
University of Delhi,
Delhi-110 007

*Member***Director**

V.P. Chest Institute
University of Delhi,
Delhi-110 007

Member-Secretary

Scientific Advisory Committee

Dr. D. Behera

Department of Pulmonary Medicine
Post Graduate Institute of Medical Education and Research
Chandigarh - 160 012

Chairman

Deputy Director-General (Medical)

Ministry of Health and Family Welfare
Government of India
New Delhi-110001

Member

Principal

University College of Medical Sciences (UCMS)
Delhi-110095

Member

Director

National Institute of TB and Respiratory Diseases
Sri Aurobindo Marg, New Delhi-110030

Member

Dean, Faculty of Science

University of Delhi, Delhi-110007

Member

Dean, Faculty of Medical Sciences

University of Delhi, Delhi-110007

Member

Prof. Madhu Khanna (Basic Science)

Respiratory Virology Unit
Department of Microbiology
Vallabhbhai Patel Chest Institute
University of Delhi, Delhi-110007

Member (01.08.2022 to 31. 03.2023)

Dr. Nitin Goel (Clinician)

Department of Pulmonary Medicine
Vallabhbhai Patel Chest Institute
University of Delhi, Delhi-110007

Member (01.08.2022 to 31.03.2023)

Dr. Anant Mohan

Professor and Head
Department of Pulmonary Medicine,
Critical Care and Sleep Medicine
3rd Floor, Near SBI Bank
All Indian Institute of Medical Sciences
Ansari Nagar,
New Delhi-110 029

Member

Director

V.P. Chest Institute
University of Delhi, Delhi-110007

Member-Secretary

Human Ethics Committee

Dr. D. Behera

Department of Pulmonary Medicine
Post Graduate Institute of Medical Education and Research
Chandigarh - 160 012

*Chairman***Prof. B.D. Banerjee**

Department of Biochemistry
University College of Medical Sciences (UCMS)
Dilshad Garden, Delhi-110 095

*Member (Basic Medical Scientist)***Dr. Kavita Gulati**

Department of Pharmacology
Vallabhbhai Patel Chest Institute
University of Delhi, Delhi-110 007

*Member (Basic Medical Scientist)***Dr. Anant Mohan**

Professor and Head
Department of Pulmonary Medicine
All Indian Institute of Medical Sciences
New Delhi - 110 029

*Member (Clinician)***Dr. Balakrishnan Menon**

Department of Pulmonary Medicine
Vallabhbhai Patel Chest Institute
University of Delhi, Delhi-110 007

*Member (Clinician)***Shri K Sunil**

K Sunil and Associates, Advocate and Advisors
Chamber NO 69, C L. Josef Block, Tis Hazari Court
New Delhi-110 054

*Member (Legal)***Shri Suman Kumar**

Advocate, Hight Court of Delhi
New Delhi

*Member (Social Scientist, w.e.f. 26.03.2021)***Dr. Udhay K. Sinha**

Institute of Human Behaviour and
Allied Sciences (IHBAS), Dilshad Garden
Delhi-110 095

*Member (Philosopher)***Director**

V.P. Chest Institute
University of Delhi,
Delhi-110 007

Member-Secretary

Institutional Animal Ethics Committee

Chairman

(Biological Scientist)

Dr. Malini Shariff

Head, Department of Microbiology
V.P. Chest Institute
University of Delhi, Delhi-110 007

Member

(Scientist from Different Discipline
of the Institute)

Dr. Mandira Varma-Basil (28.3.2018 onwards)

Department of Microbiology

Member

(Scientist from Different Discipline
of the Institute)

Dr. Madhu Khanna

Department of Virology

Member

(Scientist Incharge of Animal House
Facility of the Institute)

Dr. Kavita Gulati (28.03.2018 onwards)

Department of Pharmacology

Main Nominee of CPCSEA**Dr. Harmeet Singh Rehan** (28.03.2018 onwards)

Head, Department of Pharmacology
Lady Hardinge Medical College
New Delhi-110 001

Link Nominee of CPCSEA**Dr. Bal Gangadhar Roy** (28.03.2018 onwards)

EFA, Institute of Nuclear Medicine and
Allied Sciences Delhi-110 054

Nominee of CPCSEA

(Scientist from Outside the Institute)

Dr. H.B. Singh (28.03.2018 onwards)

Ministry of Science and Technology,
New Delhi-110 001

Nominee of CPCSEA

(Non-Scientific Socially Aware Member)

Dr. S. Gowri Shankar (22.07.2020 onwards)

A-702, Gayatri Apartments, Sector 10
Dwarka, New Delhi-110 075

Member-Secretary

(Veterinarian of the Institute)

Dr. Rajinder Bajaj

ORGANISATIONAL STRUCTURE

DIRECTOR

Raj Kumar, MD (Pul. Med.), FAMS, MNASc, MNAMS, FICAAI, FICS, FNCCP(I), FIAMS

Biochemistry (including Clinical Biochemistry)

Vishwajeet Rohil, MD

Professor

Jayeeta Bhadra, MD

Associate Professor

Juhi Aggarwal

Associate Professor

Biostatistics

Ravishankar N., PhD

Assistant Professor

Microbiology (including Medical Mycology and Respiratory Virology)

Malini Shariff, MD, PhD

Professor

Mandira Varma-Basil, MD, DNB

Professor

Anuradha Chowdhary, MD

Professor

Madhu Khanna, MSc, PhD

Professor

Pathology

Ritu Kulshrestha, MS (Biomedical Sciences), DNB (Pathology), PhD, MNAMS

Professor

Divya Sharma

Associate Professor

Pharmacology

Kavita Gulati, MSc, PhD

Professor

Ankit Arora, MD

Assistant Professor

Physiology

Vishal Bansal, MD, DNB, PhD, MNAMS, FCCP (USA)

Professor

Swati Mittal

Associate Professor

Pulmonary Medicine

Raj Kumar, MD (Pul. Med.), FAMS, MNASc, MNAMS, FICAAI, FICS, FNCCP(I), FIAMS

Professor

Balakrishnan Menon, MD, DMRD

Professor

Nitin Goel, MD

Associate Professor

Sonam Spalgais, DNB

Associate Professor

Parul Mrigpuri, DNB

Associate Professor

Siddharth Raj Yadav, MD

Associate Professor

Vidushi Rathi, MD, DM

Assistant Professor

Radiology

Pallavi, MD

Assistant Professor

Anesthesiology

Tanuja, MD

Associate Professor

Viswanathan Chest Hospital

Officer-in-Charge

Raj Kumar

Professor

Library

Uma Tyagi, MPhil (Physics), MLib Sci, PhD

Librarian

Animal House

Rajinder Bajaj, BVSc and AH

Consultant (Animal House)

Administration

Omkar Nath Pandit, MA (History), MA (Pol. Sci.), PGDHR, DLL&LW, MBA (HRM)

Deputy Registrar

Sunil Kumar Yadav, MA (History), PGDHRM, MBA, LLB, LLM

Assistant Registrar

Srikanth, B.Tech, MA, MBA, PGDT

Assistant Registrar

Satish Kumar, BA [Hons], C & SP Certificate Course

Assistant Registrar

Viswanathan Chest Hospital

The Viswanathan Chest Hospital (VCH) attached to the Vallabhbhai Patel Chest Institute has the following Departments/Facilities to provide specialised investigations and treatment to patients referred to this Institute.

Clinical Facilities

The Viswanathan Chest Hospital (VCH), formerly known as Clinical Research Centre, is the hospital wing of the Institute with the following Departments:

- Pulmonary Medicine
- Radiodiagnosis and Imaging
- Clinical Laboratories of Biochemistry, Microbiology and Pathology
- Anaesthesia
- Thoracic Surgery

Facilities available at Viswanathan Chest Hospital

- Out-patient Department
- In-patient Facility with 128 Beds
- 24 Hours Respiratory Emergency
- 8-bedded Respiratory Intensive Care Unit (with 6 Ventilators)
- Pulmonary Function Laboratory
- Cardio-pulmonary Rehabilitation Clinic
- Sleep Laboratory
- Allergy and Applied Immunology Laboratory
- Clinical Hematology and Pathology Laboratory
- Clinical Biochemistry Laboratory
- Microbiology Laboratory
- Radiology Unit with 64 Slice MDCT Scan Center
- Picture Archiving and Communication Systems (PACS)
- Tobacco Cessation Clinic
- Yoga Therapy and Research Centre

Specialized investigations available at VCH

- Fibreoptic bronchoscopy
- Guided FNAC/Biopsy
- Medical thoracoscopy
- Respiratory allergy skin tests
- Clinical immunology
- BACTEC system for tuberculosis

Detailed data of patients attending VCH and investigations conducted during the period are as follows:

Number of new patients attending OPD	9719
Number of follow up patients visiting OPD	47841
Total Outdoor Patients	57560
Number of indoor patients	
General Wards	13771
Emergency Wards	2981
Total number of patients treated in ICU	1547
Total Indoor Patients	18299
Emergency treatment provided	27567
Number of routine and specialised investigations done at VCH during the year	
Arterial blood gases	16234
Bronchoscopy	445
Bronchoalveolar lavage	356
Pulmonary function tests	9400
CT scans	0
Ultrasounds	0
X-rays	24025
Electrocardiogram	4432
Polysomnograms	164
HIV testing	2003
Skin tests	34645
Serum IgE test performed	3226
ANA	0
c-ANCA	0
p-ANCA	0
SCL-70	0
HBsAg	1563
HCV	1563
Serum ACE	490
Vitamin D	0
Thyroid Profile	0
Biochemistry Tests (Blood and Pleural fluid): Patient care	
Blood glucose	1210
Liver function tests	42505
Kidney function tests	16982
Pleural fluid biochemistry	173
HbA1c	2544
Lipid profile	1851
Total Protein and Albumin	12890
Serum Electrolytes	22908
Serum Calcium	402

Serum Phosphorus	85
Serum Uric Acid	193
Total	1,01,743

Microbiology

1. Bacteriology Laboratory

Clinical specimens processed for isolation and identification of aerobic pathogens

Nature of Specimen	
Sputum	3186
Urine	473
Bronchial aspirate/ lavage	289
Pleural fluid	93
Blood	366
Endotracheal aspirate	126
Pus/(FNAC/Tips)	105
Curtain swab	5
Total	4643

2. Serology Laboratory

Rheumatoid factor	605
C-reactive protein	710
Widal	07
Total	1322
Hospital Surveillance Samples	31

3. Anaerobic Culture

4. Mycobacteriology Laboratory

Nature of Specimen			
	LJ medium	MGIT	GeneXpert
Sputum	8450	266	3493
Bronchial aspirate	219	42	219
Pleural fluid	107	27	105
ET aspirate	43	14	41
CSF	05	05	05
Pus/Biopsy	21	18	20
FNAC	17	14	17
Gastric aspirate	04	04	04
Total	8866	390	3904
Drug susceptibility test (DST) for M. tuberculosis:	150		
Line probe assay for <i>Mycobacterium</i> sp.: 25			
DST for NTM: 20			

5. Mycology (VPCI and other hospitals)

Nature of Specimen	
Sputum	3462
Blood specimens	2176
BAL/Bronchial aspirate	556
Endotracheal aspirate	61
Blood culture	60
Biopsy, EBLB, TBLB, TBNA, Pus, CSF	19
Urine	9
Total	6343

Besides, referral service for identification of clinical isolates of fungi was extended to other institutions on request.

Pathology**1. Hematology Laboratory**

A total of 29995 tests were done during the period as per details given below;

Hemogram (including Hb, TLC, DLC)	14742
Platelet count	10210
Absolute eosinophil count	4184
Peripheral smear	202
P/S for malarial parasite	05
ESR	652
Total	29995

2. Coagulation Laboratory

A total of 1409 tests were done during the period as per details given below;

Prothrombin Time (PT)	623
Activated Partial Thromboplastin Time (APTT)	622
D-Dimer	134
Bleeding time and clotting time	30

3. Clinical Pathology Laboratory

Total of 785 Urine analysis were done during the period, including Specific gravity, pH, Albumin, Sugar, Microscopic examination and Ketone Bodies.

4. Histopathology Laboratory

A total of 426 lung biopsies were processed and evaluated on Patient and experimental samples during the period as per details given below;

Lung/Pleura Biopsies processed	Number
TBLB	137
EBLB	102
Thoracoscopic biopsy	06
Pleural biopsy	13
Cell Block	31
Core Biopsy (EBUS)	56
Cryo Biopsy	15
Experimental lung biopsies	66

5. Cytopathology Laboratory

A total of 1302 samples of exfoliative and aspiration cytology were done during the period as per details given below. Each sample was stained with routine and histochemical stains for further categorisation. Cell block was prepared when required.

Sputum	459
BAL fluid	364
FNAB: Percutaneous	124
FNAC:Transbronchial (TBNA)	65
Bronchial aspirate	29
Pleural fluid	206
CSF	02
Pus Cytology	09
Bronchial Brush	05
EBUS TBNA	39
ROSE	10

6. Immunohistochemistry Laboratory:

Immunohistochemistry was performed on lung /pleural biopsies and cell blocks on a total of 680 samples, using a panel of 42 antibodies as per details given below;

Name of Antibody	No of Tests	Name of Antibody	No of Tests	Name of Antibody	No of Tests
Panck	23	KRAS	21	MMP7	01
CEA	3	CD20	02	TLR2	09
EMA	10	NSE	12	Kappa	01
Calreterin	10	CD68	18	Lambda	01
WT-1	08	S-100	06	p63	07
TTF-1	24	CD-133	23	CD34	03
SMA	01	CK5/6	03	CD-15	03
ALK	37	CD-86	14	CD-30	04
PDL-1	30	CD-4	25	FGF	02
P40	39	CD-206	24	P16	05
Synaptophysin	22	TGF-b	20	CD8	23
CGA	19	ROS-1	16	CK-7	33
vimentin	05	Napsin	53	CD-45	10
CK-20	36	FGFR-1	02	FGFR2	02
CTLA-4	07				

7. Molecular Pathology Laboratory

Total number of 228 molecular tests were done on lung biopsies as per details given below;

Name of Test	No. of Tests	Total
HRM		
• EGFR	25	73
• KRAS	23	
• BRAF	25	
qRT-PCR		
• EGFR	18	28
• KRAS	05	
• BRAF	05	
qRT-PCR		
• Furin	50	127
• TGF-B	77	

8. Cell Culture Laboratory

9. The A-549 and THP-1 macrophage cell lines were cultured and studied using (i) Immunofluorescence after labelling with FITC, Rhb-ITC, FAM ; (ii) qRT-PCR for Furin, TGF-B, Smad-1-7; (iii) Flow cytometry and other techniques

10. Nanoparticle Laboratory

The nano drug delivery systems to the lung for treatment of lung fibrosis in pre-clinical models were designed and characterised. These included polymeric (PLA, PCL, MePEG-PLA/ PCL), MSN and MSN-PEI nanoformulations. Characterisation was performed using Electron microscopy, DLS, FTIR, TGA, EDX, Gel chromatography etc techniques.

Tobacco Cessation Clinic

The Tobacco Cessation Clinic (TCC) at Vallabhbhai Patel Chest Institute was established in November 2001. Its activities were expanded in 2002 with financial support from the World Health Organization (WHO) and the Ministry of Health and Family Welfare, Government of India, to create a more comprehensive program. In 2009, the TCC was upgraded to a Resource Centre for Tobacco Control.

The TCC addresses the significant health issues caused by tobacco consumption and aims to protect individuals from tobacco addiction. It operates an outpatient department from Monday to Friday, 9 AM to 5 PM, providing services to smokers and tobacco chewers willing to quit. Services include counseling, nicotine replacement therapy (NRT), non-NRT options, registration, CoHb monitoring, quit date planning, follow-up sessions, telephonic follow-up, and pulmonary function tests.

Additionally, the TCC raises awareness about the harmful effects of tobacco through Powerpoint presentations, booklets, pamphlets, and videos. Registered individuals are called for regular follow-ups at intervals of 2 weeks, 1 month, 2 months, 3 months, 6 months, and 1 year. The TCC also conducts workshops in Delhi and the National Capital Region (NCR) to train physicians, counselors, volunteers, and other stakeholders involved in smoking cessation.


Since its inception, the TCC has conducted 57 educational programs for physicians, paramedical professionals, and the general public. From the start of the TCC until March 31, 2025, 9245 new tobacco users and 3746 follow-up users

have utilized its services. Between April 1, 2024, and March 31, 2025, 200 new and 43 follow-up individuals sought assistance from the TCC for tobacco cessation.

Total new subjects registered for TCC from 1st April, 2024 to 31st March, 2025	200
Number of subjects set a quit date	191 (95.5%)
Number of subjects followed up	43
Telephonic routine follow up of registered subjects in the during	450+
Number of subjects prescribed medication	01
Number of subjects Quitted with medication	None
Subject contacted	132 (66%)
Reduction >50%	33 (16.5%)
Reduction < 50%	5 (2.5%)
Total number of quitters (n=200)	87 (43.5%)
Number of trainees	02

During this period, 87 subjects successfully quit their tobacco habit for at least one month. Follow-up calls were made to the 200 registered tobacco users to assess their current quitting status. Out of these, 132 subjects (66%) were reached, while 68 calls (34%) were unsuccessful due to various reasons such as the phone being switched off, the person not being available, the individual being expired, calls not being answered, individuals being out of station, callers being busy, the number not existing, the phone being dead, the incoming facility not being available, or the individuals not turning up for follow-up.

A total of 87 subjects (43.5%) quit their tobacco habit with sessions of behavioral counseling alone. Additionally, three subjects quit their tobacco habit with a combination of behavioral counseling and medication.



The continuous abstinence rates among the 87 subjects at, 1 month, 3 months, 6 months, 9 months, and 12 months were 65.90%, 55.75%, 41.25%, 36.96% and 10% respectively.

Abstinence Rate	Subjects	(%)
1 month abstinence rate (n=132)	87	65.90%
3 month abstinence rate (n=113)	63	55.75%
6 month abstinence rate (n=80)	33	41.25%
9 month abstinence rate (n=46)	17	36.96%
12 month abstinence rate (n=10)	1	10%

Yoga Therapy and Research Centre

The Yoga Therapy and Research Centre conducts yoga classes in collaboration with the Morarji Desai National Institute of Yoga (MDNIY), New Delhi, from Monday to Friday between 8 AM and 4 PM at VPCI. Yoga training classes are organized into different batches: a general group class from 8 AM to 9 AM, a therapy class from 11 AM to 12 PM, and a VPCI staff class from 1 PM to 2 PM.

The yoga sessions are specially designed for the management and eradication of various health disorders such as bronchial asthma, hypertension, stress, and obesity. Patients first report to the yoga OPD at VPCI from 9 AM to 3 PM, Monday to Friday. Doctors and yoga staff record the patients' case histories, and necessary counseling is provided by the yoga ARO. Patients are then advised to undergo yoga training and educational sessions tailored to their individual health problems for a specific period until the disease is healed. Patients are re-examined by the yoga therapist to note their improvement. They are then advised to follow a regular home program and attend training sessions once or twice a week at the Yoga Centre for better health and quality of life. Special yoga sessions for VPCI staff are also arranged regularly.

The Yoga Therapy and Research Centre, VPCI, in collaboration with the Morarji Desai National Institute of Yoga, New Delhi, organized the 10th International Day of Yoga program on the theme "Yoga for self and society" on June 21, 2024, at the institute. Under the supervision of Prof. B.K. Menon, Nodal Officer, Prof. Raj Kumar, Director, and Mr. Likhith Raj KN, Yoga Therapist. The yoga team adopted the common yoga protocol and provided training to faculty, students, staff of VPCI and their family members and general public.



10th International Day of Yoga programme on June 21, 2024 at VPCI

Cardio-Pulmonary Rehabilitation Clinic

Cardio-pulmonary Rehabilitation Clinic (Monday to Friday: 9.00 AM to 1.00 PM)

Cardio-Pulmonary Rehabilitation Clinic:

The Cardio-Pulmonary Rehabilitation Clinic at Vishwanathan Chest Hospital, VPCI, is dedicated to managing chronic respiratory patients who experience disability in daily activities and exercise limitations due to shortness of breath, despite being on optimal pharmacological treatment.

Clinic Timings: Monday to Friday: 9.00 A.M. to 1.00 P.M.

Number of patients attended Cardio-Pulmonary Rehabilitation Clinic: (April 1, 2024 - March 31, 2025)

Breathing retraining & education : 348

Enrolled for Supervised Rehabilitation program : 31

(Intensive & Maintenance)

Division of Sleep Medicine

Division of Sleep Medicine

Sleep Disorders and Sleep Therapy is a cross-disciplinary area concerned with the psychological and physical health conditions related to sleep disorders and conventional and advanced sleep therapies.

VPCI started the Division of Sleep Medicine in 1999. There has been dramatic growth in clinical activity. The number of patient visits has increased approximately five-fold from fiscal year 2002 to the present. It caters to the need of all in-patients & out-patients with three diagnostic machines functioning.

The Division is managed by experienced staff under the headship of Prof. Raj Kumar and it provides a broad range of studies: overnight sleep studies, split overnight sleep study, WatchPAT diagnostic sleep study, OSA screener and auto CPAP.

The mission at the Sleep Division is to provide comprehensive diagnostic evaluation to individuals having symptoms occurring during sleep or while awake and management to respiratory patients of age 18 yrs and above. Technical staff of the Sleep Medicine Division are fully equipped with knowledge required for sleep studies.

VPCI has trained technical staff dedicated to the diagnosis and treatment of sleep/wake disorders in adults and develop research to lead to a better understanding of normal and abnormal sleep.

The expanded Sleep Medicine Division, located on the first floor of the Vishwanathan Chest Hospital building is 338 square feet in size and has one bed, which is dedicated to research also. The Sleep Division is spacious enough for patients to spend the night and has attached private bathroom with shower. The Division is equipped with new, state-of-the-art equipment and it continues to cater to a wide variety of sleep complaints.

Past clinical research projects include "Prevalence of Obstructive sleep apnea syndrome in Delhi, India"; "A study of sleep-related breathing disorders in chronic obstructive pulmonary disease patients with or without cor-pulmonale"; "Obstructive sleep apnoea, oxidative stress and renal function"; "Obstructive sleep apnoea, oxidative stress and liver function"; "Role of some inflammatory markers in obstructive sleep apnoea: effects of grape seed extract".

Clinical care for the full spectrum of sleep disorders is provided by the outpatient practices.

The Division at present has the following aims and objectives: (1) to provide exceptional health care and support through quality service to all patients with sleep disorders and (2) to conduct high quality research related to sleep disorders (with emphasis on local disease and disorders).

Evaluation and Treatment Options

- CPAP/BiPAP, Mask fitting/Desensitization
- Sleep consultation/Evaluation/ Sleep Counseling
- Sleep studies
- Polysomnography (Includes: EEG, EOG, chin and leg EMG, respiratory monitoring, oxygen saturation, and EKG)
- CPAP titration
- WatchPAT sleep study.
- Split night polysomnography

Research in Sleep Medicine Division

Research activities continued to be a major part of the Institute from the year 2002 onwards. **Thirteen Scientific papers** were written and published in national and international medical meetings and journals from this Division.

Multidisciplinary Research Unit

The Multi-disciplinary Research Unit (MRU) at Vallabhbhai Patel Chest Institute (VPCI) was approved by the Department of Health Research, Government of India in 2013 and became operational in the financial year 2015–16. Since its inception, the MRU has been actively engaged in a range of research initiatives.

The VPCI-DHR-ICMR-MRU focuses on studies related to both communicable and non-communicable diseases, as well as other need-based research endeavours. It aims to promote and encourage high-quality medical research within the institution, leveraging advanced methodologies and innovative tools. In addition to its core research activities, the MRU plays a dynamic role in broader academic engagement, including participation in workshops, organization of symposia and training programs on contemporary topics, and facilitation of new research proposal approvals. These efforts collectively support the overarching goal of strengthening and empowering the landscape of medical research.

Research projects approved in 2024-25

1. A Comparative Study of Skin Prick Test, Specific IgE and FeNo in Bronchial Asthma- Dr. Nitin Goel, Pulmonary Medicine.
2. Predisposing factors for readmission within three months after acute exacerbation of COPD- Dr. Nitin Goel, Pulmonary Medicine.
3. Effects of Nitric Oxide donors and Arginase Inhibitor on inflammation and oxidative stress in stress in an experimental model of asthma in rats and the possible mechanisms- Prof. Kavita Gulati, Pharmacology.
4. A clinical study to monitor adverse drug reaction in elderly and non -elderly patient of COPD. Dr. Ankit Arora, Pharmacology.
5. 8-Hydroxy-2'-Deoxyguanosine as oxidative DNA damage biomarker of severity in COPD patients among North Indian population in a tertiary care hospital- Prof. Vishwajeet Rohil, Biochemistry
6. Examining the impact of PXR gene polymorphisms on serum aminophylline levels in the context of inflammation- Prof. Vishwajeet Rohil, Biochemistry.
7. Genetic variants and their association with phenotypic resistance to linezolid in *Mycobacterium Tuberculosis*, Prof. Mandira Varma-Basil, Microbiology.
8. Microplastic contamination in Bronchoalveolar Lavage Fluid of Pulmonary Patients in Delhi NCR: Characterization, Occurrence Patterns and Health Implications- Dr. Jayeeta Bhadra, Biochemistry.
9. A cross-sectional study on Sleep hygiene (knowledge, beliefs and practice) as a determinant of insomnia in college students in Delhi NCR region (SHIND STUDY)- Dr. Siddharth R Yadav, Pulmonary Medicine.
10. Assessment of change in health-related quality of life in Interstitial Lung Disease after three months of treatment. Dr. Libin Mathew, Pulmonary Medicine.
11. Comparison of predictive value of different scoring system in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) Patient in Intensive Care Unit. Dr. Subhankar Chakraborty, Pulmonary Medicine.

Research Projects completed in 2024-25: (02)

1. Comparative evaluation of anti-oxidative potential and compositional analysis of extract from *Aerva lanata* (Linn.) *Withania Somnifera* and *Hibiscus Rosa-sinesis*- Prof. Kavita Gulati, Dept. of Pharmacology.
2. Evaluation of nitric oxide signaling mechanisms during airway inflammation and remodeling in experimental model of bronchial asthma in rats- Prof. Kavita Gulati, Dept. of Pharmacology.




Meeting of Local Research Advisory Committee (LRAC) of Multidisciplinary Research Unit (MRU), June 13, 2024



Meeting of Executive Committee,
MRU-VPCI, March 7, 2025



Meeting of Local Research Advisory Committee (LRAC), MRU on March 13, 2025



A two-days Conference "Medical Colleges Research Connect-2025 Bharat Mandapam, New Delhi Leader's Lounge, Bharat Mandapam, New Delhi from 20-21 March, 2025. Poster Presentation entitled "Performance of MRU"

Adverse Drug Reaction Centre

Adverse Drug Reaction Monitoring Centre (AMC) at Vallabhbhai Patel Chest Institute (VPCI) was approved in 2014 under the Pharmacovigilance Programme of India (PvPI), initiated by the Central Drugs Standard Control Organization (CDSCO), Government of India. As a Coordinator of Adverse Drug Reaction Monitoring Centre (AMC) of Pharmacovigilance Program of India, MoH & FW, GOI, at V. P Chest Institute, the ADRs are reported to Indian Pharmacopoeia Commission (IPC).

During the current financial year (April 2024 to March 2025), a total of 433 Individual Case Safety Reports (ICSRs) were submitted via Vigiflow—the official PvPI reporting software—to the National Coordination Centre (NCC) at IPC. Causality assessments were conducted using the WHO scale, categorizing 347 cases as “Possible” and 86 cases as “Probable.” These reports were forwarded to IPC and subsequently transmitted to the Uppsala Monitoring Centre, Sweden.

In addition, 200 ICSR submitted by Marketing Authorization Holders (MAHs) were reviewed and analyzed. Score sheets for each case were prepared accordingly. The AMC also processed 47 voluntary ADR reports submitted by non-AMC entities, forwarding them to NCC-PvPI, IPC, Ghaziabad.

To promote pharmacovigilance awareness, VPCI observed National Pharmacovigilance Week from 17–23 September 2024, conducting several outreach and educational initiatives:

- 17-09-2024: Sensitization programmes for doctors and patients at the OPD and W.U.S Healthcare Centre
- 19-09-2024: Training session for nurses aimed at fostering a culture of ADR reporting for patient safety
- 20-09-2024: Essay writing competition for students and staff on the topics “Role of Clinicians in Pharmacovigilance” and “Everything is Toxic—Dose Matters”
- 23-09-2024: E-poster competition on the theme “You Share, We Care: Know How to Report Adverse Drug Reactions”



17-09-2024: Sensitization Programme for Doctors, Patients at OPD, VCH



20-09-24: Public Awareness Programme for Building ADR Reporting culture for Patient Safety



19-09-24: Sensitization of Nurses for Building ADR Reporting culture for Patient Safety

National Centre of Respiratory Allergy, Asthma and Immunology

1. VPCI-Pollen Count Station

The pollen count station was established on the roof of the VPCI multi-storeyed building, where two “Burkard Air Samplers”: a seven-day sampler and a one-day sampler have been installed. Both samplers operate continuously, with air samples collected and studied daily. The details of the work done during the tenure are as follows:


From 1st April 2024 to 31st March 2025, a total of 730 slides were mounted and analyzed, comprising 365 seven-day slides and 365 one-day slides. Additionally, since the establishment of the pollen count station, a total of 8162 slides have been mounted and analyzed, including 4247 seven-day slides and 3935 one-day slides.




Table 1. Month wise mean Pollen's Count/m³, Temperature & Humidity during 1st April 2024- 31st March 2025

Date	1day Pollen Count/m ³	7day's Pollen Count/m ³	Humidity (%)	Temperature (Max°C)
1 st April 2024	135.80	132.03	72.90	36.93
May-24	32.03	34.23	64.39	41.20
Jun-24	12.07	12.77	66.93	41.73
Jul-24	43.48	44.10	85.68	35.22
Aug-24	53.90	57.84	88.74	33.84
Sep-24	45.80	47.60	88.97	33.29
Oct-24	23.58	26.39	83.45	34.68
Nov-24	9.63	6.33	88.70	29.22
Dec-24	1.16	1.03	85.13	21.98
Jan-25	1.06	1.10	91.19	17.36
Feb-25	143.43	139.61	82.96	25.98
01 st March 2025	191.03	182.55	82.96	31.95

*IARI Metrological Database System Division of Agricultural Physics, IARI, New Delhi IARI: Latitude 28°38'23"N, Longitude:77°09'27"E., Altitude:228.61m above were used to calculate the mean of the maximum temperatures (°C) for weather monitoring stations within IARI, New Delhi



1-day pollen count/m3 month wise mean from 1st April 2024 to 31st March 2025



7 day's pollen count/m3 month wise mean from 1st April 2024 to 31st March 2025

National Tobacco Quitline Services

The NTQLS is India's first telephonic counseling-based service sponsored by the Ministry of Health & Family Welfare Government of India. The department is working successfully since May 2016 at the Vallabhbhai Patel Chest Institute University of Delhi, under the supervision and guidance of Prof. Raj Kumar, Director, VPCI. The NTQLS was established with the aim of reaching out to the masses and provide confidential and quality counseling services all over India. This service can be easily accessed six days a week (Tuesday to Sunday), through a toll-free number 1800112356 from 8 AM to 8 PM.

In the period of 1st April 2024 – 31st March 2025, the National Tobacco Quitline Service has reached its pioneer by making people quit the use of tobacco through telephonic counseling. From April 2024 to March 2025, the total number of calls landed on the Interactive Voice response (IVR) was **889782**. The total number of inbound calls during this period was **328141** whereas, the total number of outbound calls was **679816**. In this period a total number of **94157** callers were registered who were provided counseling and **18527** were quitted. The success rate of National Tobacco Quitline Service during this period is **20%**.

TRAINING OF THE 7th BATCH

This year, NTQLS proudly introduced and successfully conducted the training for its seventh batch of counselors, a significant step forward in its mission to combat tobacco addiction through skilled and empathetic telephonic counseling. Designed to adhere to WHO-recommended protocols, the training program focused on enhancing counselors' capabilities in providing personalized, evidence-based support while addressing the unique needs of quitters. Through interactive sessions, real-time call simulations, and practical exercises, the program equipped participants with advanced communication skills and the confidence to handle diverse cases with sensitivity and professionalism. The training proved to be highly impactful, empowering counselors to navigate the psychological and emotional aspects of tobacco addiction effectively. This initiative not only fortified the expertise of the seventh batch but also reinforce NTQLS commitment to fostering a skilled workforce dedicated to its vision of a healthier, tobacco-free India.



WORLD NO TOBACCO DAY

The Institute celebrated World No Tobacco Day with great impact, focusing on the critical theme, "Protecting Children from Tobacco and Tobacco Industry Interference" on 30th May, 2024. The event was graced by the Chief Guest, Dr. L. Swasticharan, Additional DDG, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, along with distinguished Guests of Honour, including Dr. D. Behera, Emeritus Professor and former Head, Department of Pulmonary Medicine, PGIMER, Chandigarh; Prof, Dinesh Khattar, Principal, Kirori Mal College, University of Delhi; and celebrated Bollywood Actor, Mr. Srikant Verma. A major highlight of the observance was the theatrical play performed by team NTQLS (National Tobacco Quit Line Services) entitled, "Protecting Children from Tobacco and Tobacco Industry Interference" which powerfully depicted the dangers of tobacco and the subtle interference of the tobacco industry in targeting children. This was followed by

a creatively organized group song performance on tobacco by the team, which further emphasized the importance of protecting future generations from tobacco's harmful effects.



ICAAICON 2024

The 58th Annual National Conference of Allergy, Asthma & Applied Immunology (ICAAICON 2024) was successfully organized by Vallabhbhai Patel Chest Institute (VPCI), University of Delhi, from December 19-22, 2024. Held under the aegis of the Indian College of Allergy, Asthma & Applied Immunology, this prestigious event brought together eminent experts from India and abroad to discuss the latest advancements in allergy, asthma, and immunology. Hosted in the historic Paintal Memorial Golden Jubilee Auditorium of VPCI, the conference featured workshops, symposia, panel discussions, lectures, and research presentations, fostering valuable knowledge exchange and collaboration.

Adding to the conference's unique offerings, the National Tobacco Quitline Services (NTQLS), operating under the Ministry of Health and Family Welfare, actively participated by setting up an exclusive stall at the venue. This exhibit provided attendees with a comprehensive overview of NTQLS's operations, including how calls are handled, the support provided to quitters through personalized counseling, and the organization's role in guiding individuals toward a tobacco-free lifestyle. NTQLS's participation underscored its commitment to promoting health and well-being, aligning with the overarching goals of ICAAICON 2024.



FELICITATION CEREMONY FOR NTQLS COUNSELLORS

BEST COUNSELLORS: JANUARY TO DECEMBER 2023

On the occasion of the World No Tobacco Day-2024 the National Tobacco Quit Line Services celebrated the best three counsellor of the month award ceremony on 30th May, 2024. The event honored Ms. Khushi Singh, Ms. Manisha, Ms. Meenu, Ms. Pooja, Ms. Rashi Sarwang, Mr. Jitender Kumar, Ms. Ruchi Salaria, Ms. Nisha Rani, Ms. Savitri, and Mr. Bhairav Dutt Sharma for remarkable performance, hard work, and dedication in motivating and enhancing the performance of his peers throughout the year from January to December 2023. Among them, Mr. Bhairav Dutt Sharma received the prestigious Best Counselor of the Year 2023 award.

The awards were distributed by the Chief Guest, Dr. L. Swasticharan, Additional DDG, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India; Guests of Honour, including Dr. D. Behera, Emeritus Professor and former Head, Department of Pulmonary Medicine, PGIMER, Chandigarh; Prof. Dinesh Khattar, Principal, Kirori Mal College, University of Delhi; celebrated Bollywood actor, Mr. Srikant Verma; and Prof. Raj Kumar, Director, VPCI, Delhi.



BEST COUNSELLORS: JANUARY 2024 TO JULY 2024

On the occasion of 48th Workshop on Respiratory Allergy: Diagnosis & Management the National Tobacco Quit Line Services celebrated the best three counsellor of the month award ceremony on 21st Oct., 2024. The event honored Ms. Ruksar, Ms. Manisha, Ms. Deepti Raj, Mr. Rajneesh Kumar, Ms. Ruchi Salaria, Ms. Pinki, and Mr. Bhairav Dutt Sharma for remarkable performance, hard work, and dedication in motivating and enhancing the performance of his peers from January to July 2024.

The awards were distributed by the Chief Guest Dr. Narendra Singh, Chairman, Guests of Honour Dr. ML Jaipal Medical Superintendent, World College of Medical Science, Jhajjar, Haryana; World Coll and Prof. Raj Kumar, Director, VPCI, Delhi.



E-Hospital Services

Prof. Vishal Bansal (Nodal Officer) and Mr. Sunil Kumar (Technical-in-Charge) were entrusted with the implementation of the E-hospital system and its associated modules at the Institute, in accordance with the directives from the Ministry of Health and Family Welfare, Government of India.

These modules include:

1. E-hospital : Phase-I (Patient registration and Billing)
2. ORS : Online Registration System
3. Mera Aspataal : Patient feedback services
4. Digital Payment: Promotion of digital payment services


Implementing National Medical Council (NMC) DMMP (Digital Mode Mission Project) directives at VPCI.

It includes:

1. Installing Aadhaar Enabled Biometric Attendance System (AEBAS) for VPCI faculty.
2. Installing 25 IP based CCTV cameras for providing live feed to central command center of NMC.



E-hospital login page



Dashboard of E-hospital

Telemedicine Services

Telemedicine, a term that originated in the 1970s, literally means “healing at a distance.” It signifies the use of information and communication technology (ICT) to improve patient outcomes by increasing access to care and medical information. At VPCI, telemedicine services are conducted from Patient Education Centre (PEC) room no. 26 in the hospital block, between 2:30 PM and 5:00 PM. Doctors on duty use landline telephones, mobile phones, and video calls via WhatsApp to communicate with patients who are unable to attend the OPD due to reasons such as old age, transportation issues, living in remote areas etc.



Telemedicine services at VPCI

Animal House

The Animal House of the Institute is registered with the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Animal Welfare Division, Government of India, for breeding and conducting experiments on small laboratory animals under registration no. 170/GO/ReBi/S/99/CPCSEA. All experiments involving animals are approved by the Institutional Animal Ethics Committee (IAEC), constituted by CPCSEA. The IAEC ensures a humane approach to animal experimentation, aiming to enhance animal care and quality in the pursuit of advancing scientific knowledge relevant to both humans and animals.

The Animal House provides an optimal environment for experimental animals, which is essential for obtaining reliable research results. It is maintained under controlled environmental conditions as specified by CPCSEA guidelines, including regulated temperature, relative humidity, a timer-controlled light-dark cycle, and air changes per hour with 100% fresh air.

The Animal House is managed by a team of well-qualified professionals, including a veterinarian, technical assistants, and attendants, all experienced and trained in modern methods of animal care, breeding, and husbandry.



Library

The VPCI Library is a vital part of the institute's support services, providing patient care information support and catering to the academic needs of the faculty members, resident doctors, researchers, and students in the field of Biomedical Sciences, with a specialization in Pulmonary Diseases and Allied Sciences. It was established in 1955 and has since acquired back volumes of several journals that are more than 100 years old, forming a comprehensive collection of serial publications, annual reviews, and recent advances. Most journals have complete sets of volumes originating from their treatises of medicine, which are readily available for fundamental and historical insights. The institute has one of the best Pulmonary Disease and Allied Sciences libraries, having **10142 Books, 25026 bound Journals, 178 CDs, 595 Thesis, and 32 National and International Reports. A total of 16 Journals (05 International and 11 National) are being received on an exchange program with the Institute's Journal, and 04 journals are accepted on a complimentary basis.** To cover the need for daily news related to the medical field, the library also subscribes to four English and four Hindi newspapers. This has encouraged the inculcation of reading habits of all alike.

The library renders its services not only to the scientist's/research scholars of the institute but also to other colleges and institutes at the University of Delhi. The institute has been a National Level ERMED Consortium (e-journals) member since 2018. ERMED Consortium subscribed to **238+ e-journals from five publishers and e-databases from Access Medicine, BMJ Publishers, Clinicalkey, and MedOne Education under NML- ERMED Consortium. All e-journals and other resources are configured on Static IP / IPs of our Institute.** The library initiates appropriate efforts from time to time to create awareness among staff, research scholars, students, etc. to enhance maximum utilization of e-journals through customized e-journals gateway <http://www.ermmed.in> and benefit of access/download of articles from the 'Cochrane Library'. This is an initiative by the 'National Medical Library', a collection of six databases containing different types of high-quality, independent evidence to inform healthcare decision-making and a seventh database that provides information about Cochrane groups through a single gateway <http://www.cochranelibrary.com>. Much emphasis is also placed on providing abstracts, references, and specific information if required. Besides this, online searches are conducted to provide instant access to Information Resources on researchers' desktops through LAN (Local Area Network). The Internet services have been provided right on the desktop of each Faculty Member through the DUCC network /LAN and a separate Leased line connectivity (VPCI) with 10 Mbps from MTNL. The library also provides inter-library loan facilities and reprographic services on demand.

The library took a significant step forward by enabling seamless access to **ONOS (One Nation, One Subscription)**, a flagship initiative by the Government of India that provides free and unified access to around **13,000 international scholarly journals** from 30 leading publishers. Coordinated by **INFLIBNET**, ONOS ensures that students, faculty, and researchers across Indian higher education institutions can access high-quality academic content across diverse disciplines. Our institution is successfully enrolled under ONOS, granting access through **On-Campus Access** via the institute's IP network and **Off-Campus Access** through the **INFED Access Federation**, allowing remote login on any device using institutional credentials. The integration of ONOS has significantly enhanced our academic infrastructure, supporting equitable access to global research and aligning with the library's mission to foster quality education and advanced research.

The library follows an open-access system. The library is equipped with modern information technology equipment. It continues to provide Internet/ e-mail services to the users to access CAS (Current Awareness Services) and SDI (Selective Dissemination of Information) services. These are provided to the users in the form of online/offline through e-mail and/or in print during the year. The library uses "LibSys4.0" Library Management Software, an integrated multi-user management system that supports all in-house Library operations. The 'LibSys' consists of modules on acquisition, cataloguing, circulation, serials, article indexing, and OPAC.

The Library facilities are available to Members/Users of Delhi University from Monday to Friday from 8:30 A.M. to 5:30 P.M. & on Saturdays from 9.00 A.M. to 5:30 P.M.



Publication Division

The Publication Division is responsible for publishing the institute's journal "The Indian Journal of Chest Diseases and Allied Sciences (IJCDAS)" and Annual Report. The IJCDAS is published quarterly by the VPCI in association with the National College of Chest Physicians (India). The journal was founded in the year 1959 by (late) Prof. Raman Vishwanathan, Founder-Director of VPCI as an official publication of the VPCI and the Indian Association for Chest Diseases [renamed as National College of Chest Physicians (India) in 1976]. The journal was published as "Indian Journal of Chest Diseases" from 1959 to 1975 and it was renamed as "The Indian Journal of Chest Diseases and Allied Sciences" in 1976. Currently, Prof. Raj Kumar is the Editor-in-Chief of the IJCDAS.

The IJCDAS has a wide National and International circulation and it covers Clinical and Experimental work dealing with all aspects of Chest Diseases and Allied Sciences. It publishes Original Articles, Review Articles, Radiology Forum, Case Reports, Short Communications, Book Reviews. Many eminent scientists and clinicians have served as the Editors, Editorial Board Members and Reviewers of the journal and all of them have contributed immensely to the growth of the journal.

The hardcopy of the journal will be delivered to the subscribers across the globe by speed post. Full text articles published in the Journal (2010 onwards) can be also be accessed online at <http://www.ijcdas.com>. The recent issue of the IJCDAS is Vol 66, issue 1.

Annual report is a compilation of all major activities, events and research output of the institute.



The IJCDAS Jan-Mar, 2025 issue



Annual report of VPCI, 2023-24

DEPARTMENTAL ACTIVITIES

Biochemistry

(Including Biochemistry and Clinical Biochemistry)

Summary of the work done:

1. **To study the genetic polymorphisms of CHI3L1 gene and its association with the oxidative-antioxidative balance in Chronic Obstructive Pulmonary Disease in North Indian population**

The proposed project is an attempt to study and establish the role of single nucleotide polymorphisms in CHI3L1 gene as potential biomarker of COPD susceptibility as well as to assess Oxidative Stress and study its association with genetic polymorphism of CHI3L1 in patients with COPD. Quantifications of Vit. C, MDA and GSH levels have been done in all study groups and DNA sequencing is undergoing.

2. **8-Hydroxy-2'-deoxyguanosine as oxidative DNA damage biomarker of severity in COPD patients among North Indian population in a Tertiary Care Hospital**

The study has been initiated after getting approval from the Institutional Ethical Committee. Screening of Patients, Consent, Case History record, Sample Collection and Storing samples have been completed. Estimation of 8-Hydroxy-2'-Deoxyguanosine and Glutathione are undergoing.

3. **Examining the Impact Of PXR Gene Polymorphisms on Serum Aminophylline Levels in the Context of Inflammation**

The study has been initiated after getting approval from the Institutional Ethical Committee. Printing of forms for Consent and Case History Record in Hindi and English has been completed. Procurement of Reagents, Chemicals, Kits and consumables is undergoing. Screening of Patients, Consent, Case History record has been started.

4. **Microplastic contamination in Bronchoalveolar Lavage Fluid of Pulmonary Patients in Delhi NCR: Characterization, Occurrence Patterns and Health Implications**

Phase I consisting of printing of forms for Consent and Case History Record, Procurement of Consumables is under process.

Patient Care:

The department is actively involved in patient care by providing diagnostic services for indoor and outdoor patients. Blood and pleural fluid samples are analysed using fully automatic analyzers- Beckman Coulter AU480 and Dirui CS-T240. The tests with total tally for 2024-25 are as mentioned below:

Biochemistry Tests (Blood and Pleural fluid): Patient care	No. of Tests
• Blood glucose	1210
• HbA1C	2544
• Liver function tests	42505
• Kidney function tests	16982
• Total Protein and albumin	12890
• Serum Electrolytes	22908
• Serum Calcium	402
• Serum Phosphorus	85
• Serum Uric acid	193

• Lipid Profile	1851
• Pleural fluid biochemistry	173
Total No. of tests	1,01,743

In our endeavor towards continuous quality improvement for better patient care, the diagnostic Laboratory is enrolled in the NABL accredited proficiency testing provider for Clinical Biochemistry, CMC external quality assurance scheme, and successfully completed the participation for year 2024.

The Department of Biochemistry, VPCI, successfully organized a workshop on **Good Clinical Laboratory Practices (GCLP)** on September 27, 2024. This workshop fulfilled one of the mandatory requirements for obtaining a Doctor of Medicine degree, as per the Gazette notification dated December 29, 2023. Notably, our department was among the first in Delhi NCR to implement this requirement, underscoring our commitment to academic excellence.

The workshop garnered overwhelming interest, with all 100 seats filling within a week of registration opening and additional requests pouring in. The venue was packed to capacity, reflecting the enthusiasm and relevance of the event. A significant highlight of the program was the **launch of the handbook on Good Clinical Laboratory Practices** by the **Chief Guest, Prof. Rakesh Bhatnagar** and the **Director of VPCI, Prof. Raj Kumar**. The handbook was warmly received, with participants raising queries and placing immediate orders for its procurement.

The event featured esteemed speakers who delivered insightful content, earning high praise from the attendees. Participants lauded the workshop for its well-structured content and engaging delivery, making it a resounding success.

This initiative not only met the regulatory requirements but also contributed significantly to the professional development of the participants, reinforcing VPCI's reputation as a leader in academic and clinical training.



Biostatistics

The Department of Biostatistics plays a vital role and forms a supportive department of the research activities of the Institute. It is entrusted to teach basic and advanced Bio-statistical techniques to MD, DM and PhD students of the institute, organize periodical training programs/ workshops related to biostatistics, provide statistical guidance/support on identifying the correct study design, sample size computation, data entry & management, data analysis, interpretation and reporting of the results to faculty and students of the institute, preparation of reports (monthly, quarterly, half yearly and yearly) for the Ministry of Health & Family Welfare, Government of India and Directorate General Health Services, Government of Delhi, Data collection of number of patients attending OPD, ward admits, ICU admits, emergency admits, diagnostic tests, radiological tests done at VCH on a daily basis and Online registration of vital events (deaths).

The Department has identifiable and collaborative research projects with other departments of the Institute.

Research

1. Gender inequities regarding the HPV vaccination coverage in high-income countries: a systematic review and meta-analysis

The objective of the study was to systematically map the evidence and identify the knowledge gaps in the universal HPV vaccine coverage in high income countries. An electronic search of the PubMed/MEDLINE, Scopus, Google Scholar, and official websites was carried out for articles reporting the HPV vaccination coverage in high income countries. The data was analysed systematically based on the updated Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) checklist. The meta-analysis component was modified appropriately to synthesise the pooled prevalence of the HPV vaccine uptake among adolescents, men having sex with men and transgender persons with 95% confidence interval (CI). The random effects meta-analysis was performed in STATA version 13.0 (College Station, TX, USA) to evaluate and summarise the results. The forest plots were made using the midas package in STATA. The heterogeneity between qualified studies was reported using I^2 index. Twenty-three articles regarding the HPV vaccination coverage were qualified for the quantitative synthesis including 27,80,307 adolescents, 11,909 men having sex with men and 207 transgender women. The pooled prevalence of the adolescent HPV vaccine uptake among adolescent girls was 67.75% (95% CI: 62.81%, 72.69%) and adolescent boys was 58.32% (95% CI 48.88%, 67.76%). The pooled prevalence among men having sex with men (MSM) was 27.94% (95% CI 14.35, 41.53) and the pooled prevalence in transgender women was 32.59% (95% CI 8.35%, 56.83%). The study concluded that Significant gender inequities exist in the HPV vaccination coverage and less number of gender minorities were vaccinated against HPV in high income countries. The major challenges were low awareness, lack of recommendations from clinicians, and public mistrust towards all vaccines.

2. Clinically significant biomarkers of dengue in adults and children: a systematic review and meta-analysis

Dengue is the most prevalent arboviral disease, and about 5% of infected individuals develop severe dengue, including haemorrhagic manifestations, organ failure or death. Even though commercially available assays can diagnose dengue fever at the point of care, no prognostic biomarkers accurately predict the possibility of severe manifestations. Predictive biomarkers may lower dengue-associated morbidity and mortality by timely management. A systematic review and meta-analysis were performed to analyze dengue-specific biomarkers quantitatively. The study protocol was designed based on updated PRISMA guidelines, and the meta-analysis component was modified to synthesize the pooled area under the curve (AUC) of ROC (Receiver Operating Characteristic) with a 95% confidence interval (CI). The overall pooled AUCROC of selected biomarkers was 0.86 (95% CI 0.81-0.90). The pooled AUC ROC curve for serum ferritin was 0.88 (95% CI 0.82-0.95), and the pooled AUC ROC curve for serum chymase was 0.82 (95% CI 0.77-0.87). This meta-analysis concludes that elevated serum ferritin levels within the initial 4-5 days of fever predict severe dengue accurately.

Microbiology

(Including Microbiology, Medical Mycology and Respiratory Virology)

Research

1. Characterization and Molecular typing of clinical, colonising, and environmental isolates of *Staphylococcus aureus*.

A total of *Staphylococcus aureus* (*S. aureus*) isolates, 50 clinical, 40 colonizers and 10 environmental, were included in the study. Out of these 46 were Methicillin-resistant and 54 were Methicillin-sensitive *S. aureus*. Isolates were tested for virulence genes, Panton-Valentine Leukocidin (PVL), Staphylococcal protein A (SpA), α Hemolysin (Hla), Fibronectin-binding protein A (FnbpA) and MecA by PCR using published protocols. 31, 70, 53, 92 and 63 isolates were positive for PVL, SPA, HLA, FNBP and MecA genes, respectively. The study is underway for the typing of these isolates by Rep PCR and MLST.

2. Hospital Infection Control Surveillance

Routine surveillance of the hospital was performed at regular intervals to screen for pathogens. Various samples from ICU and wards like suction ports, oxygen masks and ports, Mattresses, airbeds, bed railings, hand swabs from health professionals working in these units, and environment samples including air. A total of 83 samples were tested. Pathogenic organisms like *Acinetobacter*, *Klebsiella pneumoniae*, *Escherichia coli*, *Staphylococcus aureus* and *Pseudomonas* were isolated from healthcare workers and hospital environments resistant to most antibiotics. The reports were submitted along with the recommendations.

TB Laboratory

1. Characterization of phenotypic and molecular determinants of Bedaquiline and Linezolid resistance in clinical isolates of *Mycobacterium tuberculosis*.

This study aims to generate baseline data on bedaquiline (BDQ) and linezolid (LZD) resistance in *Mycobacterium tuberculosis* clinical isolates from India. We seek to establish epidemiological cut-off values (ECOFFs) and assess resistance-associated variants (RAVs) to inform the development of improved diagnostic tools. Sputum samples were collected from previously treated pulmonary TB patients, both with and without prior exposure to BDQ and/or LZD. Minimum inhibitory concentrations (MICs) were determined using the microplate alamar blue assay (MABA). A total of 497 pulmonary tuberculosis patients were enrolled in the study. These included 85 new smear-positive patients recruited from VPCI, 186 multidrug resistant TB (MDR-TB) patients not receiving BDQ/LZD, and 215 MDR-TB patients undergoing BDQ and/or LZD therapy. Additionally, 11 samples were obtained from patients with treatment failure. Samples were cultured on Löwenstein-Jensen (LJ) medium and MGIT. We successfully isolated 65 strains from new smear-positive patients, 43 from MDR-TB patients, 27 from patients on BDQ/LZD therapy, and 2 from treatment failure cases. All isolates were confirmed as *M. tuberculosis* using an inhouse duplex PCR. Drug susceptibility testing (DST) results for first-line drugs are available for 77 isolates. Second-line DST has been initiated for MDR isolates. MIC testing for BDQ and LZD has been standardized and performed. PCR assays have been standardized for key resistance-related genes, including *atpE*, *Rv0678*, *pepQ*, *rplC*, *rrl*, *mmpS5*, and *mmpL5*.

2. Antimicrobial Resistance and Labour Migration across Healthcare Boundaries in Northern South Asia

The project addresses the growing global threat of antimicrobial resistance (AMR), projected to become the leading cause of death by 2050 and focuses on labour migrants in northern India and southern Nepal—a vulnerable group due to mobility, occupational exposure, and limited healthcare access. Biosocial network analysis has been carried out in TB patients and labour migrants to link individuals, pathogens, workplaces, medicines, and healthcare providers to examine how these relationships influence the development and spread of antimicrobial resistance and drug resistant TB.

3. Characterization of the phenotypic and genetic determinants of delamanid resistance in clinical isolates of *Mycobacterium tuberculosis* in Delhi

The study was performed on 127 isolates of *M. tuberculosis*. None of the patients from whom the samples were obtained had been on delamanid therapy. MIC for 58 isolates was evaluated using 7H11 agar proportion method. MIC testing for DLM was performed using the following concentrations: 0.004, 0.008, 0.016, 0.03, 0.06, 0.12, and 0.25 µg/ml. Interpretation of susceptibility was based on the WHO-recommended critical concentration of 0.016 µg/ml—isolates with MICs ≤0.016 µg/ml were classified as susceptible, while those with higher values were considered resistant. Among the 58 isolates tested till date, 47 (81%) were susceptible and 11 (19%) were resistant to delamanid. The sequences of genes involved in delamanid resistance i.e. *ddn*, *fgd1*, *fbiA*, *fbiB*, *fbiC*, *fbiD*, *dpr E1*, and *dprE2* were obtained from tuberculist. Primers were designed for each gene. Gradient PCR for each gene was put up using H37Rv DNA. A panel of 68 isolates was also subjected to whole genome sequencing, and the resistance associated variants were obtained for the genes responsible in delamanid resistance. The chromosomal mutations were correlated with the MIC. No delamanid resistance associated mutation was observed in the isolates tested.

4. Efflux Pump Gene Expression in Response to Delamanid Exposure in *Mycobacterium tuberculosis*

Efflux pump overexpression is linked to drug resistance in *Mycobacterium tuberculosis*, though its specific role in delamanid resistance remains unclear. This study aimed to identify efflux pump genes influenced by delamanid exposure using transcriptomic analysis. Cultures of *M. tuberculosis* H37Rv were exposed to delamanid at ½ MIC for 24 hours, followed by RNA sequencing of treated and untreated samples. Differentially expressed genes (DEGs) were annotated using the UniProt database. Transcriptomic analysis revealed 23 efflux pump genes significantly upregulated under delamanid stress. Of these, 73.9% belonged to the ABC family, 17.4% to the RND family, and 8.7% to the MFS superfamily. qRT-PCR validation confirmed upregulation of 20 genes at ½ MIC. In contrast, only 3 genes showed upregulation at ¼ MIC. These findings suggest that ½ MIC is optimal for evaluating efflux pump gene expression under delamanid exposure and highlight potential targets for further resistance mechanism studies.

5. Efflux Pump Activity in *M. tuberculosis* Under Linezolid Exposure

Linezolid is a key drug in treating drug-resistant tuberculosis (DR-TB), but resistance is emerging. While mutations in *rplC* and *rrl* explain some cases, others lack known resistance markers, suggesting a role for efflux pumps. This study examined efflux pump gene expression in *M. tuberculosis* H37Rv exposed to sub-inhibitory concentrations of linezolid. Transcriptomic analysis after ¼ MIC exposure revealed 9 upregulated efflux pump genes from the ABC, MFS, RND, and SMR families. qRT-PCR at ½, ¼, and ⅛ MIC showed maximal upregulation (8/9 genes) at ⅛ MIC. These results point to efflux pump involvement in linezolid response and suggest ⅛ MIC as optimal for studying efflux-related mechanisms in *M. tuberculosis*.

Virology Unit

Research work of virology unit is focused on basic and translational research on emerging and re-emerging viruses viz. influenza, chikungunya, and dengue. The unit is working on viral pathogenesis, the development of novel antiviral strategies, and vaccine delivery approaches against influenza, dengue and chikungunya viruses. Recent achievements of virology unit include the development of a chimeric polyepitope-based vaccine candidate against dengue virus (DENV). It has demonstrated stable interaction of our DENV vaccine with host TLR4, that is further validated in mice for the induction of active cellular immunity against all DENV serotypes. An engineered virus against the influenza virus using antiviral elements such as si-RNA, ribozyme, and antiviral peptides to inhibit the viral replication has also been designed. PhD students are also working on investigation of differential proteome expression profiling of influenza virus infection and NGS sequencing based analysis of genome-wide splicing changes in the host upon influenza virus infection. In DST- sponsored project, the unit is also working on targeted engineered exosomes mediated delivery in dendritic cells as vaccine candidate against influenza virus. The ultimate aim of the virology unit is to improve prevention strategies, diagnostic techniques, treatment methods, and control measures for viral diseases that pose significant threats to human health and well-being.

Pathology

Research

Nanotherapy

1. Preparation and characterisation of Inhaled polymeric nanocomposites for treatment of lung diseases

Oral antifibrotics are the FDA approved mainstay of therapy of lung fibrosis as of date. These are limited by their low patient compliance caused by their adverse events, high cost of therapy and toxicities. The most common side effects of pirfenidone include diarrhea, photosensitization and liver function derangement with elevation of serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) and bilirubin. Therefore we have developed and characterised biodegradable polymeric nanocomposites with pyridone-containing compounds and evaluated their pharmacokinetics for providing targeted therapy to treat infectious, fibrotic and malignant lung diseases. The results have been filed for Indian Patent in 2024.

2. Surface modification of Polymeric nanocomposites and their significance

The polymeric nanoparticles show promise for the in vitro delivery of therapeutic and diagnostic agents. These polymeric NPs have been surface modified using a number of compounds such as graphene, carbon, Silver, copper etc to enhance their mechanical and physical properties. In this study, the biodegradable polymeric nanocomposites were prepared and surface modified using methoxy polyethylene glycol. Polyethylene glycol (PEG) is a polymeric material with unique hydrophilicity and electrical neutrality. These surface modified NPs were characterized for their morphology, charge, toxicity and chemical properties. Their invitro uptake and invivo efficacy before and after surface modifications were assessed. In vitro uptake was demonstrated by using coumarin labelling and fluorescent microscopy in A-549 cells. Their action on TLR2, VEGF gene expressed by M2 macrophages was demonstrated. An upregulation of VEGF and TLR2 was seen after 2 and 24 hours respectively in M2 polarised macrophages. The efficacy of conjugated surface modified polymeric NPs in significantly suppressing the TLR-2 and VEGF expression was confirmed.

3. siRNA-Conjugated Nanoformulations in Diffuse Parenchymal Lung Diseases

The diffuse parenchymal lung diseases (DPLD) such as lung fibrosis and lung cancer are increasing in prevalence and mortality worldwide. In this ongoing study we are exploring the siRNA conjugated nanoformulations for treatment of DPLD- malignant and non-malignant. These Nano-formulations can confer numerous additional benefits for drug delivery to lung as they can deliver poorly water-soluble drugs to the lung at an enhanced drug concentration. Further the nanoformulations are being modified for increasing their efficiency, targeted delivery, enhancing biodegradability and reducing side effects. This Targeted RNA interference (RNAi) or gene silencing therapies will enable early interventions due to their ability to effectively downregulate the expression of target genes.

4. Nanotherapeutic approaches to target Lung microenvironment and EMT

The lung microenvironment comprises of a complex interplay of cells (fibroblasts, endothelial cells, macrophages, immune cells), signaling molecules (TGF, FGF, Furin etc), stroma, vasculature, and extracellular matrix (collagen, fibrin, elastin) and is emerging as a critical determinant of cancer progression and non-neoplastic DPLD. However, conventional microenvironment-targeted therapies often face challenges. Therefore, lung microenvironment modulation strategies using nanoparticle (NP)-based therapies are being explored for their therapeutic potential. These offer promising prospects for improved targeted drug delivery and uptake with reduced toxicity, but they require optimization to reduce off-target effects. In this ongoing study we are studying the action of targeted conjugated nanohybrids in reversing the dysregulated immune responses and ongoing EMT within the lung microenvironment both invitro and invivo.

Non-neoplastic Lung diseases

1. Targeting oxidative stress and FGF/FGFR1,2 to attenuate lung injury and remodeling in radiation induced lung fibrosis and chronic lung disease

Radiation exposure generates significant oxidative stress, increases cytokine expression signaling in lung and predisposes to EMT, collagen production and lung fibrosis. We simulated and assessed the oxidative stress induced cytokine expression and lung parenchymal changes in bleomycin model of lung fibrosis. Male Wistar rats: Group-I(Saline), Group-II(Bleomycin), Group-III(Bleomycin+Sildenafil) were euthanized on day-7, 14 & 28. Lung-ROS, XO, LPO, GPX and bFGF, FGFR1-2 mRNA, and protein levels were assessed. Bleomycin induced parenchymal and vascular remodeling from day-7 to 28, was associated with upregulation of ROS, XO, LPO, bFGF, FGFR1(Day-7 onwards), FGFR2(day-14 onwards), and downregulation of GPX levels. The phosphodiesterase-5 inhibitor, Sildenafil significantly reduced-ROS, XO, LPO, bFGF, FGFR-1,2 levels, upregulated GPX and attenuated lung fibrosis. Thus, demonstrating that bFGF-FGFR-1,2 signaling can be used as biomarker of radiation induced oxidative stress, EMT and lung fibrosis. The repurposed drug-Sildenafil effectively downregulates oxidative stress and attenuates lung fibrosis.

2. Immunohistochemical and Pathological differential diagnosis of lung granulomatosis

Granulomatous lung diseases (necrotizing and non-necrotizing) require precise clinical evaluation, radiological imaging, microbiological and histopathological assessment in order to reach a confident etiological diagnosis (mycobacterial, sarcoidosis, GPA, Cryptococcosis, Foreign body etc). In the present study we evaluate the efficacy of immunohistochemical profile analysis of the granulomas in improving the diagnostic dilemma. The retrospective study of 179 patients who presented to VPCI from January 2022 to December 2023 with granulomatous lung and pleural inflammation was done. The granulomas were categorised based on the presence/absence of Caseous necrosis, open/closed granulomas, type of Multinucleated giant cells, intracytoplasmic inclusions-asteroid body, Schauman body, surrounding microenvironment inflammatory infiltrate- neutrophils/lymphocytes/Foamy macrophages, histochemistry for reticulin, Ziehl-Neelsen, Von Kossa stains. These were correlated with Immunohistochemical expression of lymphocyte markers (CD-4, CD-8), macrophage phenotype (CD-68, CD-206), fibrosis (TLR-2, TGF- β) in the granulomas and surrounding parenchyma. Patients-males (n=83, 13-79 years), females-(n=96 11-66 years). Diagnosis of tuberculosis was confirmed in total of 97/179, 54.2% using (i) morphological identification of well defined, coalescing granulomas with caseous necrosis and Langhans type of giant cells (ii) M.TB detection in sputum/FNAC by AFB smear/culture and gene expert techniques. In remaining patients the granulomas were categorised on the basis of their morphology into ill-defined/Non-caseating/hard granulomas and the careful identification of associated interstitial inflammatory infiltrate, types of inclusion bodies, fungus, NSIP/DIP/OP pattern, anthracosis, calcification, etc. The alveolar interstitium was examined for microcystic change, and fibrosis, if any to rule out interstitial lung disease.

Lung Cancer

1. Immunohistochemical profiling of Lung cancer

Lung cancer represents a group of histologically and molecularly heterogeneous subtypes. Immunohistochemistry is increasingly being used for classifying lung cancer into specific subtypes and assess biomarkers relevant to molecular-targeted personalised therapies. This is based on the applicability of the drugs in targeting protein and not the altered nucleic acid sequence, which exerts oncogenic drive. In this study we assess the efficacy of immunohistochemistry in classifying lung cancer, including (i) adenocarcinoma vs squamous cell carcinoma; (ii) neuroendocrine carcinomas; (iii) Primary lung Vs metastatic carcinoma. (iv) Pulmonary lymphoma, plasmacytoma etc. Using a panel of 42 antibodies total 680 tests were performed in lung cancer biopsies this year. These have included Adenocarcinoma markers(TTF-1, Napsin A), Squamous carcinoma markers (p40, CK-5/6, p63), Primary Vs Secondary metastasis to lung- CEA, EMA, P16, CK-7, CK-20, Calretinin, WT-1), Mesenchymal markers- Vimentin, FGF/FGFR-1/FGFR-2, SMA, S-100, CD-133, CD-34, MMP-7), Neuroendocrine markers (chromogranin A, synaptophysin, NSE), Tumour infiltrated lymphocytes/Lymphoma- CD4, CD-8, CD-15, CD-30, CD-45), Plasma cell markers- Kappa, Lambda, and macrophage markers- CD-86, CD-206, CD-

68. The correlation between immunohistochemical protein expression and response levels will generate better scoring algorithms to increase the targets in the IHC panel for the selection of patients with NSCLC.

2. Integrative proteogenomics for early diagnosis, biomarker assay and designing personalised therapy of Lung Adenocarcinoma

Over the past decade the department of Pathology has been meticulously carrying out the Genomic profiling of Lung cancer patients presenting to VPCI. The driver tyrosine kinase oncogene mutations (EGFR, KRAS, BRAF, etc) and immune check point inhibitor (ICI) expressions elaborated, have accelerated targeted therapy of lung carcinoma patients. However a variable proportion of lung cancer patients initially responsive to TKI and ICI therapy, eventually develop mechanisms to evade the drug's effects and develop drug resistance leading to disease progression. Thus emphasizing the need of proteomics profiling of lung cancers and their integration with the Clinical/histopathological and genomic data for their subtyping prior to start of targeted therapy. Therefore the proteomic expression of KRAS (9.13), ROS (D4D6), ALK (D5F3) is being correlated with oncogene drivers EGFR, BRAF and KRAS in the RAS/RAF/MEK/MAP-kinase signaling pathway and in the stratification of Lung cancer. This Integrated proteogenomic enumeration of lung cancer-associated characteristics is the way forward for precise and early diagnosis and for designing personalised treatment.

3. Combination of Immune Check point inhibitors Markers expression (CTLA4, PD-L1) in lung cancer

Immune checkpoint inhibitors (ICI) are revolutionizing lung cancer therapy, by improving survival across advanced malignancies. They are also now becoming a standard therapy for earlier stage, resectable lung cancer. While Programmed death-ligand 1 (PD-L1) protein is encoded by the Cancer cells to deactivate host T cells. CTLA-4 is a member of the immunoglobulin superfamily that is expressed by activated T cells and transmits an inhibitory signal to T cells. Studies in preclinical models have previously shown synergy between combinations of ICIs. Dual checkpoint blockade may be associated with a higher and durable tumour response, however carries the risk of greater toxicity when compared to single agent immunotherapy. Therefore in this ongoing study we are evaluating the lung tumor tissue expression of PD-L1 and CTLA-4, prior to initiation of mono/combo combination immunotherapy. PD-L1 expressed by Lung cancer cells [low (<1%), medium (1-49%), high (≥50%)] (n=170) (2018-2025) is being analyzed and correlated with CTLA-4 expression, histopathology and tumour microenvironment. This will help in guiding dual immune checkpoint blockade therapy alone or in combination with chemotherapy in lung cancer.

4. Correlation of EGFR HRM with Allele specific PCR analysis

Identification of the specific molecular driver mutations in the epidermal growth factor receptor (EGFR) gene in Non small cell lung carcinoma is necessary for personalized therapy with tyrosine kinase inhibitors. These activating mutations are located across the coding region of the exons 18, 19, 20, and 21 of the EGFR gene and detected using Amplification Refractory Mutation System (ARMS-PCR) and Sangers sequencing techniques. These are expensive techniques and time consuming. Therefore screening for EGFR mutation analysis by High resolution melt curve analysis can help in reducing the costs. In the present two year study we have assess the efficacy of polymerase chain reaction (PCR)-high-resolution melting (HRM) as a cost-effective rapid screening method for detection of somatic gene mutation. We demonstrate the performance characteristics of HRM technique as compared to the ARMS-PCR for screening and detection of mutated EGFR gene. A total of 116 lung cancer patients samples were analyzed for EGFR mutation study from 2023-25. Both HRM and ARMS-PCR were done in 64/84 cases (76.19%). Concordance between the 2 methods was seen in 45/64 (70.31%) (Positive-29/45 (64.44%) and negative (16/45, 35.56%) cytology and biopsy samples. HRM-ve/ARMS-PCR+ve cases 10/19 (52.63%) indicated the need for definitive analysis in such cases. The HRM-PCR gave exon specific results with higher sensitivity while the ARMS-PCR showed both Exon and Allele or mutation-specific amplification and with higher specificity.

Pharmacology

Research

1. Pharmacological studies on *Hedychium spicatum* on airway inflammation and remodeling in experimental model of bronchial asthma

The results of our current study showed significantly reduced levels of 8-isoprostane after treatment with *Hedychium spicatum* treatment in lung homogenate of OVA immunized and challenged rats. ROS or lipid peroxidation is one of the important characteristics of lung fibrosis and airway remodeling, *Hedychium spicatum* may be beneficial in the treatment and reduction of lung fibrosis and airway remodeling. 8-Hydroxy-2'-deoxyguanosine (8-OHdG) is continuously generated in living cells and produced from the reaction between DNA and 2-deoxyguanosine with hydroxyl-free radicals. Also, 8-OHdG levels were found to be increased in serum and BAL fluid of OVA-sensitized and challenged rats as compared to that of normal control rats which is an indicator of an increase in DNA damage. Administration of herbal drug, *Hedychium spicatum* attenuated 8-OHdG levels and suggested decreased DNA damage which may be due to reduced degree of oxidative stress. Taken together, the results of anti-inflammatory, immunomodulatory and remodeling studies demonstrated the attenuating effects of *H.spicatum* extract on airway inflammation in an experimental model of allergic bronchial asthma. Both cellular and molecular markers of airway inflammation were influenced in a manner suggestive of the anti-inflammatory, immunomodulatory, and antioxidant effects of the plant extract. Since airway inflammation is central to the pathophysiology of asthma, and *H.spicatum* suppressed inflammatory cell infiltration and downregulated several inflammatory and pro inflammatory cytokines, it could have good potential as a disease modifying agent and/or therapeutic adjunct in bronchial asthma. Interactions of traditional and modern medicinal concepts are a rapidly emerging concept and the present results are thus of translational value.

2. Evaluation of nitric oxide signalling mechanisms during airway inflammation and remodelling in experimental model of bronchial asthma in rats

The study investigated how nitric oxide (NO) modulation—through its precursor L-arginine and specific inhibitors targeting different nitric oxide synthase (NOS) isoforms (eNOS inhibitor L-NAME, nNOS inhibitor 7-NI, and iNOS inhibitor aminoguanidine)—affects airway inflammation, remodeling, and oxidative stress in a rat model of bronchial asthma. Asthma was induced by sensitizing rats with intraperitoneal ovalbumin (OVA, 40 mg/rat) combined with 2 mg of aluminum hydroxide. Fourteen days later, the animals were exposed to 1% OVA aerosol for 20 minutes daily over eight consecutive days. All treatments, including the test drugs and control vehicles, were administered 30 minutes prior to each OVA challenge during this period. Results showed that both the NO precursor (L-arginine) and NOS inhibitors (L-NAME, 7-NI, and aminoguanidine) significantly reduced airway inflammation and structural remodeling in this asthma model. This is particularly noteworthy, as agents with opposing actions on NO levels produced similar protective effects. One possible explanation is that inhibiting NOS leads to a reduction in NO levels, thereby exerting anti-inflammatory and anti-fibrotic effects. The interaction between NO and oxidative stress pathways may have played a role in the observed outcomes.

3. Effects of nitric oxide (NO) donors and arginase inhibitor on inflammation and oxidative stress in an experimental model of asthma in rats and the possible mechanisms

The research evaluated the therapeutic potential of modulating nitric oxide (NO) pathways in an experimental model of allergic asthma. In this study, rats were sensitized to ovalbumin (OVA) with aluminium hydroxide, followed by repeated OVA aerosol challenges to simulate key features of asthma such as airway inflammation and hyper-responsiveness. Recognizing that conventional therapies mainly relieve symptoms without preventing long-term structural changes, the study focused on how agents targeting NO synthesis might mitigate these issues. Effects of NO modulators, NO donor (ISDN), NO precursor (L-arginine), and an arginase inhibitor (ABH) were evaluated. These agents were administered both independently and in combination prior to OVA exposure. In untreated disease control rats, OVA challenge resulted in significant elevations in total leukocyte, eosinophil, and neutrophil counts in blood and bronchoalveolar lavage (BAL) fluid. Elevated levels of OVA-specific IgE and the proinflammatory cytokine TNF- α , suggested the inflammatory response. When pre-treated with NO modulators, the rats showed a marked reduction in inflammatory cell counts and cytokine levels, along with significant restoration of antioxidant defenses. The anti-inflammatory cytokine IL-10 was increased. Although the combination treatment of L-arginine and ABH sometimes offered additional benefits regarding inflammatory markers. Thus, NO donors and arginase inhibition appear to mitigate inflammation, in allergic asthma.

4. A clinical study to monitor adverse drug reactions in elderly and non-elderly patients of COPD

This is a cross-sectional observational study designed to monitor ADRs in patients undergoing drug treatment for COPD at the Clinical Research Centre, Vallabhbhai Patel Chest Institute, Delhi. National policy for elderly persons has defined elderly or senior citizens as people with age more than 60 years (National policy for older persons, 2011). Therefore, in this study elderly patients taken were above 60 years and non-elderly patients taken were those below 60 years. The data is being collected from patients with COPD from both the age groups as per the approved exclusion and inclusion criteria. The protocol was approved by the Institutional Ethical Committee. At present, data has been collected from a total of 200 COPD patients of both the age groups. Comorbidities are present in both the groups, but more predominant in the elderly group, with hypertension being the most common followed by diabetes mellitus. Polypharmacy (taking more than 5 medications) was present more in above 60 years old COPD patients. Adverse drug reactions (ADRs) were present in both, but was more reported by the elderly COPD patients above 60 years. Most commonly reported adverse drug reaction was throat irritation in both groups followed by myalgia and insomnia, which was more present in elderly group which might be due to the lack of following oral hygiene after taking inhalers.

Physiology

Providing IT & E-hospital Services, Implementing National Medical Council (NMC) directives and Swachhtha Action Plan (SAP):

1. Nodal officer along with Mr. Sunil Kumar, Technical-in-charge for implementing E-hospital and associated modules at the Institute as per directions of Ministry of Health and Family Welfare, Government of India.
2. Implementing National Medical Council (NMC) DMMP (Digital Mode Mission Project) directives at VPCI.
3. Implementing Swachhtha Action Plan (SAP) as a Nodal Officer for VPCI.

Research

1. **To explore the Effects of Yoga and Pulmonary Rehabilitation in Patients with Interstitial Lung disease and examine their Molecular basis**

It has been seen that non-pharmacological treatments such as yoga and pulmonary rehabilitation (PR) programs appear as a safer way to manage interstitial lung diseases (ILD). Yogic exercises and PR programs have been shown to improve overall cardiorespiratory functions in severe cardiovascular and respiratory disorders. Pulmonary rehabilitation has a well-documented beneficial role in ILD, likewise, improvement with yogic exercises has also been observed in this cohort of patients. Since both Yoga and PR individually improve quality of life and functional capacity in patients with ILD, it is anticipated that addition of yogic exercises to conventional PR program will provide additive benefits on various physiological parameters of these patients. This study will also examine various molecular mechanisms by which these beneficial effects are conferred. Work is in progress.

Pulmonary Medicine

(Including Pulmonary Medicine, Cardio-respiratory Physiology
and Respiratory Allergy and Applied Immunology)

Research

1. Smoking cessation and its significant role in the Indian scenario

Given the increased health dangers of tobacco use, particularly in developing countries, smoking cessation intervention is crucially important. The aim of this study is to determine and assess the effectiveness of a comprehensive smoking cessation intervention program, incorporating behavior modification, counseling, and pharmacologic treatments, in the context of the Indian scenario. The process of initiating smoking or tobacco cessation begins with the evaluation of the distinct stages that smokers undergo as part of their journey toward behavioral change. There are five different levels of preparation for quitting smoking, i.e., i) not prepared (pre-contemplation); ii) unsure (contemplation); iii) prepared (preparation); iv) action; and v) maintenance. Behavior modification and counseling are essential. The “5 A’s”-based intervention uses ask, advise, assess, assist, and arrange as part of its strategy. First-line treatments such as nicotine replacement therapy, bupropion, and varenicline, as well as second-line treatments such as clonidine, cytosine, and nortriptyline, are the foundation of pharmacologic care. Every healthcare professional has a duty to help smokers stop using tobacco, and the intervention should be both therapeutic and diagnostic. Combining behavioral and social support yields the best results, along with pharmacotherapy whenever needed.

2. Bilateral diffuse multiple cavitory nodules: a radiological presentation of adenocarcinoma

The common causes of multiple cavitory lesions of lung are fungal pneumonia, pulmonary abscess, rheumatoid nodules, viral pneumonia, tuberculosis, and septic emboli. The cavitory lesions are seen in nearly 20% of lung cancers with most commonly squamous cell carcinoma. We present an adenocarcinoma of lung with bilateral cavitory lesion presenting as cough, breathlessness, and chest pain for 2 months. The cavitory lung lesions have multiple differential diagnosis and are difficult to differentiate on computed tomography findings. All cavitory lung diseases should be investigated with invasive procedure like bronchoscopy to confirm the diagnosis before empirical treatment.

3. Emerging AI impact in the healthcare sector: A review

Artificial intelligence (AI) methods have become prevalent in the healthcare sector for patient risk assessment, medication discovery and disease diagnosis. Intelligent healthcare systems and a variety of duties related to patients can benefit from AI. For accurately diagnosing illnesses using AI techniques, an extensive variety of health data sources are required, which includes genetics, computed tomography tests, ultrasound, electromagnetic resonance imaging, mammograms etc. We discussed the role of AI in developed and developing nations and also the regulative issues and perspectives in health science. This article is based on an analysis of numerous studies and research publications providing information for early illness prediction for different kinds using AI-based methods. This article explores how AI might improve healthcare by looking at cutting-edge technologies, inventive applications, challenges and upcoming seismic shifts. AI-enabled virtual health assistants have the potential to drastically alter the way healthcare is delivered.

4. Combustion of Biomass Fuel and Chronic Obstructive Pulmonary Disease in Rural Population of India.

Globally, chronic obstructive pulmonary disease (COPD) has a substantial and growing burden. Thus, among rural adults in Delhi National Capital Region (Delhi NCR), the study examines the prevalence of COPD among

nonsmokers and the relationship between biomass fuel (BMF) use and COPD. This cross-sectional study, conducted among adults in rural Delhi NCR areas with or without COPD, was community based. Enrolment comprised 1,564 individuals from 561 households. Information was gathered using a standard questionnaire, indoor particulate matter (PM) (PM1, PM2.5, and PM10) aerosol spectrometers were used to measure the concentrations, and pulmonary function tests (PFTs) were performed using a portable spirometry (GRIMM). In adults in rural areas of Delhi NCR, 8.95% prevalence of COPD were found in which females were found significantly high COPD as compared with males (7.1% males and 92.9% females, $p < 0.001$). The concentration levels of PM10 (249.28 ± 189.33 vs 174.54 ± 76.40 ; $p < 0.003$), PM2.5 (134.78 ± 95.25 vs 108.66 ± 53.67 ; $p = 0.039$), and PM1 (107.22 ± 82.65 vs 89.51 ± 51.43 ; $p = 0.025$) were found significantly high in households of COPD patients as opposed to controls. Only COPD patients had airway obstruction (64.1%) as opposed to controls. Indoor air factors, that is, BMF smoke ($p = 0.042$), exhaust fan (0.047), and poor ventilation ($p = 0.003$), were found significantly associated with COPD. Factors such as combustion of BMF, kerosene oil, lack of exhaust fan, poor ventilation, and increased concentration of indoor PM, that could be very important in the onset of COPD in adults, especially in women and old age persons.

5. House dust protein level of pigeon drooping and feather in environmental bird exposure related hypersensitivity pneumonitis "A pilot study"

Bird fancier's disease is a type of HP occurring due to exposure to bird's antigen. The diagnosis is quite difficult as it requires the identification of an inciting agent with findings of HRCT and lung biopsy. The exposure is usually done by history with antigen specific IgG and/or specific inhalational challenge testing. The study aimed to investigate the role of pigeon allergens in house dust in bird exposure related HP patients. This was a descriptive, mixed method observational study. We retrospectively screened all the files of HP patients for exposure history and pigeon specific IgG of one year duration. Finally, house dust from 18 cases with HP was collected for analysis of concentration of pigeon droppings and feather proteins. The mean age was 47.8 ± 11.5 years with 78% being female. The median duration of symptoms was 1.75 years with a median exposure history to pigeons of 7 years. The level of specific IgG was raised in 11 (60%) patients with a mean level of 50.6 ± 39.5 . The concentration of pigeon drooping protein was present in all the dust samples with a mean of 17.6 ± 5.6 $\mu\text{g}/\text{mg}$. The highest concentration was 27 $\mu\text{g}/\text{mg}$ and the lowest of 9 $\mu\text{g}/\text{mg}$. The concentration of pigeon feather protein was present in nearly 50% of the dust sample with a mean of 5.6 ± 6.7 $\mu\text{g}/\text{mg}$ and the highest concentration was 15.8 $\mu\text{g}/\text{mg}$. The confirmation history of exposure in bird exposure related HP is difficult because bird antigen exposure can be presents anywhere. The house dust bird protein concentration measurement is a simple, non invasive, adjunct test for confirmation of bird exposure.

Postgraduate Training and Teaching

The Institute was initially started with a Diploma Course in Tuberculosis and Chest Diseases (DTCD). Later the MD, DM and PhD courses were started. The Institute continues to conduct the MD, DM and PhD courses in Pulmonary Medicine, Biochemistry, Microbiology, Pharmacology and Physiology. The details of the students currently enrolled in these courses are presented here.

DM Degrees (Ongoing) (Session: 2023-2026)

S. No.	Name (Discipline)	Title of Theses	Supervisor
1.	Dr. Kaushik N (Pulmonary Medicine)	Analysis of risk factors for the development of a post-bronchoscopy complications among patients undergoing flexible bronchoscopy in a tertiary care hospital in North India: A prospective observational study.	Prof. Raj Kumar
2.	Dr. Anjali MS (Pulmonary Medicine)	Assessment of delay in the diagnosis of ILD and factors affecting the delay.	Prof. Raj Kumar

DM Degrees (1st Year) (Session: 2024-2027)

S. No.	Name (Discipline)	Supervisor
1.	Dr. Jimy Sherin M (Pulmonary Medicine)	Prof. Raj Kumar
2.	Dr. Adrija Guha (Pulmonary Medicine)	Prof. Raj Kumar

MD Theses (Awarded) (Session: 2021-2024)

Name	Discipline
Dr. Pranab Sarma	Pulmonary Medicine
Dr. Lehar Batra	Pulmonary Medicine
Dr. Anushree Kesarwani	Pulmonary Medicine
Dr. Katasani Giridhar Reddy	Pulmonary Medicine
Dr. Arathy Jayakumar	Pulmonary Medicine
Dr. Karishma Birde	Biochemistry
Dr. Navnika Kapoor	Pharmacology

MD Theses (Submitted)

(Session: 2022-2025)

S. No.	Name (Discipline)	Title of Theses	Supervisor
1.	Dr. Milli Rawat (Pulmonary Medicine)	Predisposing factors for readmission within three months after acute exacerbation of COPD.	Dr. Nitin Goel
2.	Dr. Shweta Yadav (Pulmonary Medicine)	Evaluation of Asthma Control in Obesity Phenotype of Bronchial Asthma.	Prof. B. K. Menon Prof. Raj Kumar Dr. Parul Mrigpuri Dr. Vishal Bansal
3.	Dr. Priyam Gupta (Pulmonary Medicine)	To Study the Serum Biomarkers (KL-6, SP-A, SP-D, MMP-1 and MMP-7) in Fibrotic and Non-Fibrotic Interstitial Lung Disease Patients.	Dr. Sonam Spalgais Prof. Raj Kumar Dr. Parul Mrigpuri
4.	Dr. Meera P Nair (Pulmonary Medicine)	Study on Chronic Rhinosinusitis in Patients with Post Tubercular Bronchiectasis.	Prof. B. K. Menon
5.	Dr. Sarika Sunil (Pulmonary Medicine)	Aspergillus Hypersensitivity in Smoker Vs Non-Smoker COPD.	Dr. Parul Mrigpuri Prof. Raj Kumar Prof. B. K. Menon Dr. Sonam Spalgais Prof. Anuradha Chowdhary
6.	Dr. Protick Kumar Mondal (Microbiology)	Molecular Characterization and Antifungal Susceptibility Pattern of Dermatophytes with Special Reference to Trichophyton Indotineae: A Clinico Mycological Study.	Prof. Anuradha Chowdhary
7.	Dr. Arza Naseem (Microbiology)	Characterization and Molecular Typing of Clinical, Colonizing and Environmental Isolates of Staphylococcus Aureus.	Prof. Malini Shariff
8.	Dr. Rashmi Dhir (Pharmacology)	Effects of Nitric Oxide donors and Arginase inhibitor on inflammation and oxidative stress in an experimental model of asthma in rats and the possible mechanisms.	Prof. Kavita Gulati
9.	Dr. Mohammad Azharuddin Mulla (Biochemistry)	8-Hydroxy-2' Deoxyguanosine as Oxidative DNA Damage Biomarker of Severity in COPD patients among North Indian Population in a Tertiary Care Hospital.	Prof. Vishwajeet Rohil Dr. Sonam Spalgais Prof. Ritu Kulshrestha

MD Theses (Ongoing)

(Session: 2023-2026)

S. No.	Name (Discipline)	Title of Theses	Supervisor
1.	Dr. Prateek Jain (Pulmonary Medicine)	A Comparative Study of skin prick test, Specific IgE and FeNO in Bronchial Asthma	Dr. Nitin Goel
2.	Dr. Anupam Roy (Pulmonary Medicine)	Study on Gas Exchange in Patients with On-Fibrotic Interstitial Lung Diseases after Pulmonary Rehabilitation	Dr. B. K. Menon Dr. Raj Kumar Dr. Vishal Bansal
3.	Dr. Sagar Rai (Pulmonary Medicine)	Home based versus Supervised Pulmonary Rehabilitation in Patients with post Tuberculosis Lung Disease – A Randomized Control Trial	Dr. Parul Mrigpuri Dr. Vishal Bansal Dr. Sonam Spalgais Prof. B. K. Menon Prof. Raj Kumar
4.	Dr. Vikram Singh (Pulmonary Medicine)	Study on relationship between Bronchodilator Responsiveness with asthma control	Prof. B. K. Menon
5.	Dr. Sanjay Meena (Pulmonary Medicine)	To study the Clinical, Radiological and Physiological parameters in Post TB Bronchiectasis and non-post TB Bronchiectasis	Dr. Sonam Spalgais
6.	Dr. Akhil Sathyanathan (Pharmacology)	A clinical study to monitor adverse drug reactions in elderly and non-elderly patients of COPD	Prof. Kavita Gulati
7.	Dr. Vishnu Priya. V (Biochemistry)	Examining the impact of PXR Gene Polymorphisms on serum aminophylline levels in the context of inflammation	Prof. Vishwajeet Rohil
8.	Dr. Komal Chaudhary (Microbiology)	Genetic variants and their association with Phenotypic resistance to Linezolid in Mycobacterium	Prof. Mandira Varma Basil
9.	Dr. Srishti Singh (Microbiology)	Aspergillus lateral flow assay for IgG and IgM antibody in serodiagnosis of Pulmonary Aspergillosis	Prof. Anuradha Chowdhary
10.	Dr. Mohd. Rizwan Khan (Physiology)	Evaluation of Cardiac Autonomic and Cognitive function in Patients with Post-TB sequelae	Dr. Vishal Bansal Dr. Parul Mrigpuri Prof. (Dr.) Raj Kumar Dr. B.K. Menon Dr. Sonam Spalgais

MD – Ist Year*(Session: 2024-2027)*

Name	Discipline
Dr. Aastha Rai	Pulmonary Medicine
Dr. Annwesha Sarkar	Pulmonary Medicine
Dr. Anvita Bajpai	Pulmonary Medicine
Dr. Sukrit Singhal	Pulmonary Medicine
Dr. Uttkarsh Rastogi	Pulmonary Medicine
Dr. Ann	Microbiology
Dr. Astha	Microbiology
Dr. Sarvesh	Physiology
Dr. Bhavna Nagpal	Biochemistry
Dr. Sumit Biswas	Pharmacology

PhD Awarded/Submitted

S. No.	Name (Discipline)	Title of Theses	Supervisor(s)	Status
—	—	—	—	—

PhD (Ongoing)

S. No.	Name (Discipline)	Title of Theses	Supervisor(s)	Year of Registration
1	Ms. Suhani Yadav (Microbiology)	Exploration of multi-omics approaches to reveal mechanism of resistance in multidrug resistant <i>Candida auris</i>	Prof. Anuradha Chowdhary	2023
2	Ms. Shriya Srivastava (Microbiology)	Elucidation of molecular epidemiology, antifungal susceptibility profile and resistance mechanism in non-albicans <i>Candida</i> species with special reference to <i>Candida parapsilosis</i>	Prof. Anuradha Chowdhary	2023
3	Ms. Swati Kathait (Microbiology)	Genotypic diversity of candidate and putative loci associated with resistance to Delamanid in clinical isolates of <i>Mycobacterium tuberculosis</i>	Prof. Mandira Varma Basil	2023
4	Ms. Meenu Rani (Pathology)	Development of Nano drug delivery systems and study of their efficacy in attenuating lung fibrosis	Prof. Ritu Kulshrestha	2023

Faculty Members Associated as Co-supervisors for MD/PhD Theses of DU and Other Institutions

S. No.	Name (Discipline) and Institution's Name	Title of Theses	Supervisor(s)	Status
1.	Ms. Kajal Sharma (PhD, Respiratory Virology)	Role of host cellular proteins in influenza virus genome delivery and associated innate immune response	Dr. Madhu Khanna Department of Microbiology (Virology Unit)	Ongoing
2.	Ms. Archana (PhD, Respiratory Virology)	Role of Splicing and Post translational modification in pathogenesis of influenza virus infection	Dr. Madhu Khanna Department of Microbiology (Virology Unit)	Ongoing
3.	Ms Varsha Chauhan (PhD in Microbiology) MDU, Rohtak	Efflux Pumps: Contribution to Drug Resistance in Various lineages of <i>Mycobacterium tuberculosis</i>	Dr Sanjay Kumar (MDU, Rohtak) and Dr Mandira Varma-Basil	Ongoing
4.	Mrs. Nitika C. Panakkal (PhD, Medical Imaging Technology), Manipal College of Health Professionals (MCHP), Manipal Academy of Higher Education (MAHE), Manipal	Influence of Low Kilo-Voltage Protocol on Image Quality, Radiation and Iodine Dose for Abdominopelvic Computed Tomography.	Dr. Rajagopal K V, Professor, Dept. of Radio-diagnosis & Imaging, Kasturba Medical College & Hospital, MAHE, Manipal and Dr. Ravishankar N	Awarded

Distinguished Visitors



Prof. Rakesh Bhatnagar [National Science Chair, School of Biotechnology, Jawaharlal Nehru University, Delhi, Formerly Vice Chancellor, Banaras Hindu University, Varanasi] attended as Chief Guest in the Workshop on Good Clinical laboratory Practices organized by department of Biochemistry, Vallabhbhai Patel Chest Institute on 27.09.2024. The handbook on Good Clinical Laboratory Practices was launched by Prof. Rakesh Bhatnagar and Prof. Raj Kumar, Director VPCI on this occasion



Dr. Sanjeeva Srivastava, Professor, Dept of Biosciences and Bioengineering, IIT Mumbai, visited the Department of Pathology on 19th March 2025 and addressed the students and Faculty of Department of Pathology and discussed present and future collaboration

Prof. Hardeep Kaur, Vice Principal, Ramjas College, University of Delhi, visited the Virology Unit, Department of Microbiology, VPCI. Professor Kaur expressed interest for research collaboration on development of vaccines against influenza A virus and other pathogens of epidemic/pandemic potential. Prof. Kaur had a tour of the laboratory and acknowledged the infrastructure and instruments in the virology unit. The possible collaborative research projects were discussed based on the common research interests.

Assistant Controller of Patent and Design, DPIIT, Ministry of Commerce and Industry, GoI, Delhi, visited Department of Pharmacology, March 05, 2025

Awards/Honours

Prof. Raj Kumar

- **University Representative**, Reappointment for Governing Body of Swami Shardhanand College, University of Delhi, Delhi w.e.f. 04.05.2024 dt. 24.04.2024.
- **ATS Public Service Award**, Outstanding contributions towards improvement of air quality, eradication of tobacco usage, and prevention of lung disease during ATS International Conference, San Diego Convention Center, American Thoracic Society dt. 18.05.2024.



- **Member**, Technical Expert Group for Chronic Respiratory Diseases under the National Program for Prevention and Control of Non-Communicable Diseases (NP-NCD) dt. 20.07.2024.
- **Late Dr. Ramkrishna Modi Smriti Samman – 2024**, Contribution in the field of Allergy, Modi Allergy Clinic, Patna dt. 18.09.2024.



- **Member**, Nominated by Vice Chancellor regarding guest faculties in Faculty of Law for the appointment of academic year 2024–25 dt. 17.09.2024.
- **Chief Guest**, Annual Function “Pratibimb” of Nutan Vidhya Mandir at NVM Sr. Sec. School, Dilshad Garden, Delhi dt. 26.10.2024.
- **ESDA National Pride Award – 2024**, Outstanding achievement and remarkable contributions in the field of tobacco cessation, Environmental and Social Development Association dt. 17.11.2024.



- **Lifetime Achievement Award**, Great recognition and appreciation in Respiratory Allergy, Asthma and Immunology during ICAAICON–2024 Conference (December 19-22, 2024), Indian College of Allergy Asthma and Applied Immunology dt. 20.12.2024.



Prof. Kavita Gulati

- **General Secretary**, Society of Nitric Oxide and Allied Radicals (SNOAR).
- **Treasurer**, Delhi Pharmacological Society.
- **Coordinator**, ADR Monitoring Centre (AMC) of Pharmacovigilance Program of India, Indian Pharmacopeia Commission, MoHFW, Govt. of India.
- **Coordinator**, Medical Device Adverse Event Monitoring Center (MDMC) of Materiovigilance Program of India (MvPI), Indian Pharmacopeia Commission, GOI.
- **Nodal Officer**, Multidisciplinary Research Unit of Department of Health Research, ICMR at VPCI.
- **Coordinator**, ADR Monitoring Center of VPCI during 12th Induction-cum-Training Programme via virtual platform to orient newly recognized MDMCs under Materiovigilance Programme of India dt. 30.07.2024.

- **Subject Expert**, Scientific Advisory Research Committee (SARC) of PhD, Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard dt. 19.08.2024.
- **Chairperson**, National Conference of Society for Nitric Oxide and Allied Radicals (SNOAR), Hamdard Institute of Medical Sciences and Research (HIMSR) dt. 26.09.2024.
- **Chairperson**, Workshop on Good Clinical Laboratory Practices (GCLP), VPCI, Delhi dt. 27.09.2024.
- **Expert**, Departmental Scientific Research Committee, DPSRU dt. 14.10.2024.
- **Subject Expert**, Board of Studies Meeting, Department of Pharmacology, SPER, Jamia Hamdard dt. 15.10.2024.
- **Chairperson**, Symposium on Allergic Rhinitis during ICAAICON–2024, Indian College of Allergy, Asthma & Applied Immunology during December 19–22, 2024.
- **Judge**, NS Dhalla Award for Best Poster during Joint International Conference (JIC)–2025, Ahmedabad, Gujarat dt. January 10–12, 2025.
- **Chairperson**, Plenary Lecture and Devendra K Agrawal Oration during Joint International Conference (JIC)–2025, Ahmedabad, Gujarat dt. January 10–12, 2025.
- **Expert**, Institutional Human Ethics Committee (IHEC) meetings, ABVIMS, Dr. RML Hospital, Delhi dt. 24.10.2024, 05.12.2024, 16.01.2025, 14.02.2025.
- **Member**, Sub-committee to assess SAE death in clinical study “ARTEMIS – Effect of Ziltivekimab versus Placebo on Cardiovascular Outcomes in Patients with Myocardial Infarction”, IHEC, ABVIMS, Dr. RML Hospital during 05.02.2025.
- **Subject Expert**, Doctoral Research Committee of Ms. Monika Sharma and Mr. T. Bhanuteja, DIPAS, DRDO during 19.02.2025.
- **Representative**, Multidisciplinary Research Unit (MRU) of VPCI during Medical Colleges Research Connect–2025, Bharat Mandapam, Delhi during March 20–21, 2025.
- **Expert**, Departmental Assessment Board (DAB) for Group A Technical Officers, CCRUM dt. 24.03.2025.
- **Member**, Organizing Committee, ICAAICON–2024, 58th Conference of Indian College of Allergy, Asthma & Applied Immunology (ICAAI) during December 19–22, 2024.

Prof. Mandira Varma Basil

- **Member**, Ethics Committee, Rajan Babu Institute of Pulmonary Medicine and Tuberculosis, Delhi.
- **Executive Member**, Indian Association of Mycoplasmologists.
- **Expert**, ICMR TB Diagnostic Committee.
- **Member**, Strategic Advisory Group of Experts on In Vitro Diagnostics (SAGE IVD), for the term 2023–2025.

Prof. Madhu Khanna

- **Global Health Travel Award**, Conferred by the Bill & Melinda Gates Foundation to Prof. Madhu Khanna for participation in the Keystone Symposium on HIV and (Re)Emerging Viruses: Aligning Lessons Across Pandemics, held at Hannover, Germany, April 8–11, 2024.
- **IVS–Young Scientist Award**, Awarded to Dr. Roopali Rajput, Research Associate-II (C/o Prof. Madhu Khanna, Virology Unit, Department of Microbiology, VPCI), for oral presentation entitled “Potential of engineered phage display antibodies in epitope mapping of influenza A virus antigens” at International VIROCON-2024 on the theme “Emerging Viruses: Pandemic & Biosecurity Perspectives”, organized by DRDO–Defence Research & Development Establishment (DRDE), Gwalior, in association with the Indian Virological Society (IVS), November 11–13, 2024.

- Lead Lecture, Delivered by Prof. Madhu Khanna, Director Professor, Virology Unit, Department of Microbiology, at the Asia-Pacific Forum on RNA Therapeutics and Vaccines (APFRTV), held at Jawaharlal Nehru University, Delhi, February 24–25, 2025.

Prof. Ritu Kulshrestha

- **Co-chairperson**, Research Advisory Committee (LRAC), Department of Health Research, MoHFW, GOI for Model Rural Health Research Unit (MRHRU) at Khotpura, Panipat, Haryana in collaboration with Kalpana Chawla Government Medical College, Karnal under mentorship of ICMR-NICPR, Noida since 2024.
- **Co-chairperson**, Research Advisory Committee (LRAC), Department of Health Research, MoHFW, GOI for Model Rural Health Research Unit (MRHRU) at Dhadha, Gautam Buddha Nagar under mentorship of ICMR-NICPR, Noida since 2024.
- **Expert Member**, TASK Monitoring Committee (TMC), INMAS, DRDO and Specialist Panel Member for 29th 'Soldier Health & Drug Development' review meetings at INMAS, DRDO, Delhi dt. 05.12.2024 and 15.01.2025.
- **Expert Member**, Committee for Design/Review of Syllabus – MLT Subject, meeting held by Centre for Personnel Talent Management (CEPTAM), Metcalfe House, Civil Lines, Delhi dt. 06.02.2025.
- **Member**, Board of Studies, School of Allied Sciences, Delhi Skill & Entrepreneurship University (DESU) since 2023.
- **Member**, Board of Studies, Department of Paramedical Sciences, Faculty of Allied Health Sciences, SGT University, Gurgaon since 2022.
- **Bio-Safety Officer**, Institute Biosafety Committee, Ambedkar Centre of Biomedical Research (ACBR), University of Delhi since 13.06.2024.
- **Biosafety Officer**, Institutional Biosafety Committee (IBSC), Department of Biosciences, Jamia Millia Islamia, New Delhi since 2023.

Prof. Vishwajeet Rohil

- **Chairperson**, Session on "Drug Delivery and Therapeutics" at Symposium-23, during the Golden Jubilee Conference of the Association of Clinical Biochemists of India (ACBICON 2024), organized by the Department of Biochemistry, PGIMER Chandigarh, held on 7th December 2024 at Hotel Mount View, Chandigarh.
- **Expert Panelist**, Panel Discussion on "Use of AI for Outcome-Based Teaching Learning" at the National Symposium on "Empowering Faculty: Advancing Excellence for NextGen Education", organized by Sharda University, Greater Noida, from 31st January – 5th February 2025; session held on February 1, 2025.
- **External Expert**, Comprehensive Review of Pedagogical Proficiency, invited by the Teaching Learning Centre, Sharda University, for the programmes Biochemistry, Clinical Research, Physiology, and BMLT on 1st March 2025, Sharda School of Applied Health Sciences, Greater Noida.
- **Examiner**, Post Graduate MD (Biochemistry) Annual Examination-2025 (Batch-2021), conducted at University College of Medical Sciences, Delhi, on January 29-30, 2025 (Centre of Practical Examination).
- **External Expert**, PhD Open Defence Viva at Jaypee Institute of Information Technology, Noida, on 18th January 2025.

Dr. Parul Mrigpuri

Organising Secretary, ICAAICON-2024 (Annual Conference of Indian College of Allergy, Asthma & Applied Immunology) during December 19–22, 2024.

Dr. Siddharth Raj Yadav

- **Awarded Fellowship in Sleep Medicine (FSM)** through exam-based assessment under the aegis of the Indian Sleep Disorder Association, conferred during SLEEPCON 2024 held at Hotel Ashoka, New Delhi, on June 15-

16, 2024.

- **Conferred Fellowship of ICAAI 2024** during the 58th Annual Conference of the Indian College of Allergy, Asthma and Immunology (ICCAICON-2024), held at Vallabhbhai Patel Chest Institute, University of Delhi, from December 19–22, 2024.

Dr. Ravishankar N

Expert Member, Brainstorming workshop on development of Mizaj assessment tool, held at Central Council for Research in Unani Medicine (CCRUM) Headquarters, Ministry of AYUSH, Delhi dt. 13.06.2024

Dr. Ankit Arora

- **Completed**, NMC-approved Basic Course in Medical Education during September, 25–27, 2024.
- **Member**, Organizing Committee, ICAAI-2024, 58th Conference of Indian College of Allergy, Asthma & Applied Immunology (ICAAI) during December 19–22, 2024.
- **Chairperson**, Session on 'Food Allergy' at 58th Annual Conference of Indian College of Allergy, Asthma & Applied Immunology, VPCI, Delhi during December 19–22, 2024.
- Achieved 2nd Prize in essay competition entitled "Importance of Fitness" organized during Fit India Week, December 2024.

Dr. Kamal Singh

Member, Organizing Committee, ICAAI-2024, 58th Conference of Indian College of Allergy, Asthma & Applied Immunology (ICAAI) during December 19–22, 2024.

Dr. Vishnu Priya V, MD student

Best e-Poster Presentation Award for the paper entitled "To study the PXR gene polymorphisms and its association with the serum aminophylline concentration" at the South Zone ACBI Conference on "Translation from the Bench to the Bedside: Emerging Trends in Clinical Biochemistry to Improve Patient Outcomes", organized by ACBI at JIPMER, Puducherry, January 24–25 2025.

Sponsored Research Projects

S. No.	Faculty Member (Department)	Title of Project	Funding Agency, Date of Sanction/ Implementation and Duration	Total Grant Received (₹)
1.	Dr. Raj Kumar, (Pulmonary Medicine)	National Tobacco Quit Line Services	Ministry of Health & Family Welfare March 12, 2015 (Three Years) [Extended upto 2025- 26]	1702.03 lakhs
2.	Dr. Raj Kumar, (Pulmonary Medicine)	ICMR's Network of Pulmonary Fibrosis	ICMR January 01, 2024 (Three years)	10.23 lakhs
3.	Dr. Kavita Gulati, (Pharmacology)	Multidisciplinary Research Unit (MRU)	DHR-ICMR, MoHFW January 01, 2014 (Five years) [Extended upto 31.03.2026]	455.79 lakhs
4.	Dr. Kavita Gulati (Pharmacology)	Pharmacological studies on <i>Hedychium spicatum</i> on airway inflammation and remodeling in experimental model of bronchial asthma	ICMR June 22, 2021 (Three Years)	21.20 lakhs
5.	Dr. Mandira Varma (Microbiology)	Development and Validation of Artificial Intelligence tool for screening/ detection of pulmonary TB and other lung disease using chest X-ray	ICMR May 15, 2022 (One year) [Extended upto 14.11.2024 and further extended for period 01.04.2025 to 31.03.2026]	47.06 lakhs
6.	Dr. Mandira Varma (Microbiology)	Characterization of phenotypic and molecular determinants of bedaquiline and linezolid resistance in clinical isolates of mycobacterium tuberculosis.	ICMR March 28, 2023 (Three years)	46.49 lakhs
7.	Dr. Mandira Varma (Microbiology)	Antimicrobial Resistance and Labour Migration across Healthcare Boundaries in Northern South Asia	AU-Denmark ICMR April 01, 2023 (Three years)	118.67 lakhs
8.	Dr. Madhu Khanna (Respiratory Virology, Microbiology)	Targeted Exosomes mediated cellular delivery: A potential approach for vaccine development	SERB-DST January 25, 2024 (Three years)	13.59 lakhs

S. No.	Faculty Member (Department)	Title of Project	Funding Agency, Date of Sanction/ Implementation and Duration	Total Grant Received (₹)
9.	Dr. Madhu Khanna (Respiratory Virology, Microbiology)	Setting up of Nation-wide Network of Laboratories for Managing Epidemics and National Calamities - Viral Research and Diagnostic Laboratory (VRDL)	ICMR-DHR-MoHFW February 16, 2024 (upto 31.03.2026)	197.10 lakhs
10.	Prof. Ritu Kulshrestha (Pathology)	Nano therapy of Lung fibrosis using gene editing	LSRB-DRDO August 18, 2023 (Three years)	47.17 lakhs
11.	Prof. Anuradha Chowdhary (Medical Mycology Unit, Microbiology)	Genomic insights of azole and terbinafine resistance in clonal Trichophyton mentagrophytes/ interdigitalis spp. Complex causing alarming difficult to treat dermatophytosis in north India	DST February 10, 2021 (Three Years) [Extended upto 09.08.2024]	39.03 lakhs
12.	Prof. Anuradha Chowdhary (Medical Mycology Unit, Microbiology)	Genomic analysis of diversity, population structure, transmission dynamics and multidrug resistance in <i>Candida auris</i> , an urgent threat to public health	ICMR February 01, 2024 (Three years)	50.41 lakhs
13.	Prof. Anuradha Chowdhary (Medical Mycology Unit, Microbiology)	National Reference Laboratory for Antimicrobial Resistance in fungal pathogens	NCDC September 03, 2021 (Five Years, upto 31.03.2026)	390.22 lakhs
14.	Prof. Anuradha Chowdhary (Medical Mycology Unit, Microbiology)	Pradhan Mantri Ayushman Bharat Infrastructure Mission (PM-ABHIM)	NCDC September 03, 2021 (Five Years, upto 31.03.2026)	220 lakhs
15.	Prof. Anuradha Chowdhary (Medical Mycology Unit, Microbiology)	Exploration of genetic and proteomic basis of Amphotericin B resistance in <i>Candida auris</i>	ICMR March 27, 2023 (Three years)	21.95 lakhs (Budget sanctioned for 1st year)
16.	Prof. Vishal Bansal (Physiology)	To explore the effects of yoga and pulmonary rehabilitation in patients with Interstitial lung disease and examine their molecular basis	CCRYN-AYUSH February 01, 2024 (Three years)	16.23 lakhs

Fellowships

S. No.	Name of the Fellow (Department) and Name of Supervisor	Title of Fellowship	Funding Agency, Date of Sanction/ Implementation and Duration	Total Grants Received (₹)
1.	Mrs. Archana (Senior Research Fellow) (Virology unit, Microbiology) <i>(Supervisor: Dr. Madhu Khanna)</i>	Aptamer functionalized liposome: A way towards immune-targeted RNA based vaccine against influenza Virus	ICMR July 01, 2022 (Three years)	10.87 lakhs
2.	Ms. Varsha Chauhan (Senior Research Fellow) (Microbiology) <i>(Supervisor: Dr. Mandira Varma Basil)</i>	Contribution of efflux pumps to delamanid resistance in clinal isolates of <i>Mycobacterium Tuberculosis</i>	ICMR August 23, 2019 (One and half years) [Extended upto 31.07.2024]	10.91 lakhs
3.	Ms. Suhani Yadav (Junior Research Fellow) (Medical Mycology Unit, Microbiology) <i>(Supervisor : Prof. Anuradha Chowdhary)</i>	Exploration of Multi-Omics Approaches to Reveal Mechanism of Resistance in Multidrug Resistant <i>Candida Auris</i>	DBT November 23, 2023 (Five years)	8.03 lakhs
4.	Ms. Shriya Srivastava (Junior Research Fellow) (Medical Mycology Unit, Microbiology) <i>(Supervisor : Prof. Anuradha Chowdhary)</i>	INSPIRE Fellowship under INSPIRE Program	DST-INSPIRE January 24, 2024 (Five years)	5.84 lakhs

Conferences/Symposia/Seminars/Workshops/CMEs

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
1.	Prof. Raj Kumar	Panel discussion on best practices regarding national quitlines and scope of integrated cessation services	WHO, South-East Asia	South-East Asian Regional Workshop Bangkok, Thailand June 25–27, 2024
2.	Prof. Raj Kumar	Participant	Vallabhbhai Patel Chest Institute, Delhi	Workshop on Good Clinical Laboratory Practices (GCLP) VPCI September 27, 2024
3.	Prof. Raj Kumar	Guest Lecture: “Allergy Diagnosis in-vivo”	NCRAAI, VPCI	48 th Workshop on Respiratory Allergy: Diagnosis & Management VPCI October 21–25, 2024
4.	Prof. Raj Kumar	Practical Training in SPT	NCRAAI, VPCI	48 th Workshop on Respiratory Allergy: Diagnosis & Management VPCI October 21–25, 2024
5.	Prof. Raj Kumar	Panelist: “Clinical Case Discussion – History, Investigation and Interpretation”	NCRAAI, VPCI	48 th Workshop on Respiratory Allergy: Diagnosis & Management VPCI October 21–25, 2024
6.	Prof. Raj Kumar	Guest Lecture: “Food Allergy in Clinical Practice”	NCRAAI, VPCI	48 th Workshop on Respiratory Allergy: Diagnosis & Management VPCI October 21–25, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
7.	Prof. Raj Kumar	Invited Eminent Speaker: "Air Pollution & Health"	ESDA, India	5 th World Environment Summit 2024 NDMC Convention Centre, New Delhi November 16–17, 2024
8.	Prof. Raj Kumar	Special Guest: Presentation of ESDA Green Award 2024	ESDA, India	5 th World Environment Summit 2024 NDMC Convention Centre, New Delhi November 16–17, 2024
9.	Prof. Raj Kumar	Chairperson: Symposium on "New Insights into Food Allergy"	PSG Institute of Medical Sciences and Research	NAPCON 2024 Coimbatore, November 21–24, 2024
10.	Prof. Raj Kumar	Guest Lecture: "Advances in Pharmacologic Treatments and Allergen-Specific Immunotherapy for Food Allergy"	PSG Institute of Medical Sciences and Research	NAPCON 2024 Coimbatore, November 21–24, 2024
11.	Prof. Raj Kumar	Guest Lectures: 1. Diagnosis of Allergy – In Vitro Methods [Specific IgE & CRD] 2. Allergy Focused Patient History 3. Diagnosis of Allergy – In-vivo 4. Subcutaneous Immunotherapy (SCIT) 5. Food Allergy in Clinical Practice 6. Case Discussion – History, Investigation, Interpretation, Allergen Selection and Immunotherapy 7. Case Discussion – History, Investigation, Interpretation, Allergen Selection and Immunotherapy	PSG Institute of Medical Sciences and Research	NAPCON 2024 Coimbatore, November 21–24, 2024
12.	Prof. Raj Kumar	Invited International Speaker: "Mucolytics"	Macleods Pharmaceuticals Ltd.	Hotel The Lalit, Connaught Place, Delhi, December 6, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
13.	Prof. Raj Kumar	Guest Lectures: 1. Food Allergy 2. Case Discussion – History, Investigation, Interpretation, Allergen Selection and Immunotherapy 3. SPT: Practical Demonstration 4. Diagnosis & Management of Food Allergy 5. Debate on SCIT vs SLIT 6. Food Allergy Panel Discussion	VPCI	58 th ICAAICON-2024, VPCI December 19–22, 2024
14.	Prof. Kavita Gulati	Invited talk: “Efficacy studies with herbal drugs in bronchial asthma: an integrated approach”	Conference Mind	5 th International Conference on Traditional & Alternative Medicine, Goa Virtual May 24, 2024
15.	Prof. Kavita Gulati	Invited talk: “Nitric oxide and bronchial asthma: newer perspectives”	Hamdard Institute of Medical Sciences and Research (HIMSR)	National Conference of Society for Nitric Oxide and Allied Radicals (SNOAR) Delhi September 26, 2024
16.	Prof. Kavita Gulati	Keynote lecture: “Integration of Modern Medicine with traditional systems of medicine in bronchial asthma”	Conference Mind	6 th International Hybrid Conference on Traditional & Alternative Medicine Virtual November 22–23, 2024
17.	Prof. Kavita Gulati	Invited talk: “Experimental and clinical studies on the role of nitric oxide (NO) in bronchial asthma”	Indian Pharmacological Society	54 th Annual Conference of IPS-IPSCON AIIMS, Delhi November 28–30, 2024
18.	Prof. Kavita Gulati	Invited talk: “Recent insights on the role of nitric oxide (NO) in bronchial asthma”	IIT Roorkee	National Conference of SNOAR-2025 IIT Roorkee February 21–22, 2025

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
19.	Prof. Kavita Gulati	Invited talk: "Clinical studies on the complementary role of yogic intervention in the management of obstructive airway diseases"	National Institute of Health & Family Welfare (NIHFW)	Training Course on TCIM NIHFW, Delhi February 17-21, 2025
20.	Prof. Kavita Gulati	Invited talk: "Integrating Unani Medicine with Modern Medicine for Sustainable Management of Drug-Induced Liver Injury"	CCRU, Ministry of AYUSH	International Conference on Unani Day Celebrations-2025 Vigyan Bhawan, New Delhi February 12, 2025
21.	Prof. Kavita Gulati	Invited talk: "Informed Consent and Patient Safety"	VPCI, Delhi	Workshop on Good Clinical Practice and Ethics in Human Research HIMSR, Jamia Hamdard, Delhi April 9, 2025
22.	Prof. Kavita Gulati	Delegate	PGIMER, Chandigarh	Advance CME on Pharmacovigilance/ Materiovigilance and Coordinators Meeting Virtual May 25, 2024
23.	Prof. Kavita Gulati	Delegate	ICMR-National Task Force	Webinar on Safe and Rational Use of Medicines (SRUM) Virtual July 31, 2024
24.	Prof. Kavita Gulati	Delegate	Shimadzu and Spinco Biotech Pvt Ltd	Workshop on Mass Spectroscopy in Clinical Diagnostics Delhi July 25, 2024
25.	Prof. Kavita Gulati	Delegate	Sharda University	National Seminar on Clinical Research Awareness Greater Noida August 30, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
26.	Prof. Kavita Gulati	Delegate	Ministry of AYUSH	9 th Ayurveda Day (Dhanvantari Jayanti) All India Institute of Ayurveda, New Delhi October 29, 2024
27.	Prof. Kavita Gulati	Delegate	IPC, Materiovigilance Programme of India	Webinar on Adverse Events for Ophthalmic Medical Devices Ghaziabad December 11, 2024
28.	Prof. Kavita Gulati	Poster Presentation: "Performance since inception of Multidisciplinary Research (MRU-VPCI)"	DHR	Medical Colleges Research Connect-2025 Bharat Mandapam Delhi March 20–21, 2025
29.	Prof. Mandira Basil Varma	Invited Talk: "The changing landscape of clinical mycobacteriology"	Graphic Era University Dehradun	National Conference on Microbial Innovations and Challenges: Opportunities for Sustainability (MICROS 2024) Dehradun May 3–4, 2024
30.	Prof. Mandira Basil Varma	Talk: "Safety Practices in the laboratory"	Department of Biochemistry, Vallabhbhai Patel Chest Institute, University of Delhi	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27, 2024
31.	Prof. Mandira Basil Varma	Invited Talk: "Unlocking Molecular Diagnostics: Addressing Drug Resistance in Tuberculosis"	Miranda House, University of Delhi	Workshop on Emerging Frontiers in Biomedical Research Miranda House, Delhi October 14–16, 2024
32.	Prof. Mandira Basil Varma	Talk: "Clinical Vignettes in Molecular Microbiology"	Department of Microbiology, UCMS & GTB Hospital	IAMM Satellite Workshop on Approach towards Microbiology PG Examination UCMS & GTB Hospital, Delhi November 12–13, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
33.	Prof. Mandira Basil Varma	Invited Talk: "Microbiological diagnosis of tuberculosis"	Miranda House, University of Delhi	Public Lecture on TB Awareness as part of "A 100 days intensified campaign on TB elimination" Miranda House, Delhi January 27, 2025
34.	Prof. Mandira Basil Varma	Invited Talk: "Microbiological diagnosis and drug resistance in non-tuberculous mycobacteria: The way forward"	Hospital Infection Society–India	XVIII National Conference of Hospital Infection Society–India SGPGIMS, Lucknow February 6, 2025
35.	Prof. Mandira Basil Varma	Invited Talk: "Recent advances in diagnosis of Mycobacteria other than Mycobacterium tuberculosis"	Post Graduate Institute of Child Health, Noida	CME Post Graduate Institute of Child Health, Noida March 12, 2025
36.	Prof. Madhu Khanna	Lecture: "Comprehensive dengue vaccine development using multivalent T cell epitopes based immunogen"	International Vaccines Congress	4 th Edition of International Vaccines Congress Baltimore MD, USA October 24–26, 2024
37.	Prof. Madhu Khanna	Invited Lecture: "Development of a Multi-Epitope Dengue Vaccine to Elicit Robust Immune Responses across All Four Serotypes: A Proof of Concept"	The Asia-Pacific Forum on RNA Therapeutics and Vaccines (APFRTV)	The Asia-Pacific Forum on RNA Therapeutics and Vaccines (APFRTV) Jawaharlal Nehru University, Delhi February 24–25, 2025
38.	Prof. Madhu Khanna	Invited Lead Lecture: "Unfolded Protein response pathways and Chikungunya virus replication: A potential antiviral strategy"	Indian Virological Society (IVS) and DRDO-DRDE Gwalior	International VIROCON 2024 Emerging Viruses: Pandemic & Biosecurity Perspectives Gwalior, Madhya Pradesh November 11–13, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
39.	Prof. Kulshrestha Ritu	Paper presented: "Targeting oxidative stress and FGF/FGFR1,2 to attenuate lung injury and remodeling in radiation induced lung fibrosis and chronic lung disease"	INMAS, DRDO, MOD, GOI	International Radiobiology Conference on Biological Effects of Space Radiation Heavy Ions and Human Space Missions – Mechanisms and Biomedical Countermeasures (RAD SPACE 2025) Manekshaw Centre, Delhi February 27 – March 1, 2025
40.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Proteogenomics of Lung Cancer"	Cancer Nanomedicine Consortium, Aligarh Muslim University (AMU)	Symposium on Defeating Cancer through Collaboration: Establishing The Cancer Nanomedicine Consortium AMU, Aligarh, UP February 19–20, 2025
41.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Integrative proteogenomics for early diagnosis, biomarker assay and designing personalised therapy of Lung Adenocarcinoma"	Department of Biosciences and Bioengineering, IIT Mumbai	Advances in Proteomics Technologies 2025 (APT-2025) IIT Mumbai February 14–17, 2025
42.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Investigations and Interpretations of Presumed Ocular Tuberculosis"	North Delhi Women Ophthalmologist	NDWO Meeting Pitampura, New Delhi January 19, 2025
43.	Prof. Kulshrestha Ritu	Chairperson and Paper presented: "Silicosis masquerading as miliary tuberculosis"	Vallabhbhai Patel Chest Institute, University of Delhi	ICCAICON 2024, 58th Annual Conference of the Indian College of Allergy Asthma and Applied Immunology VPCI, Delhi December 19–22, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
44.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Advancing Technologies in Medical Education and Healthcare"	Gangwal School of Medical Sciences and Technology, IIT Kanpur and Faculty of Medicine, Dentistry, and Health Sciences, University of Melbourne	India-Australia Cooperation in Biomedical Education and Medical Technology Research Meeting Melbourne Global Centre, New Delhi November 29, 2024
45.	Prof. Kulshrestha Ritu	Paper presented: "Pathological differential diagnosis of lung granulomatosis: A two year study from a Tertiary Centre in North India"	WASOG 2024	World Association Sarcoidosis and Granulomatosis Bridging Continents Uniting Against ILD Conference Agra November 14–17, 2024
46.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Advances in Lung Pathology and Cytology"	WASOG 2024	World Association Sarcoidosis and Granulomatosis Bridging Continents Uniting Against ILD Conference Agra India November 14–17, 2024
47.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Non-neoplastic Disease Mimicking Lung Tumor"	Korean Society of Pathologists, Seoul, Korea	76 th Annual Fall Meeting and International Congress of Korean Society of Pathologists Seoul Korea October 31 – November 1, 2024
48.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Interpretation of Lung Biopsies in Interstitial Lung Diseases"	Department of Pathology, Subharti Medical College, SVSU	UP PATHCON 2024 Meerut, UP September 28–29, 2024
49.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Good Laboratory Practises"	Department of Biochemistry, V.P. Chest Institute	Workshop on Good Clinical Laboratory Practices VPCI September 27, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
50.	Prof. Kulshrestha Ritu	Participant	Department of Respiratory Medicine, University of Crete	Online Global Southeast Asian Webinars (Session 1) Virtual July 20, 2024
51.	Prof. Kulshrestha Ritu	Invited Faculty Lecture: "Good Clinical Laboratory Practices"	Vallabhbhai Patel Chest Institute	Swachhta Pakhwada VPCI April 1–15, 2024
52.	Prof. Vishwajeet Rohil	Participant	Association of Medical Biochemists of India (AMBI)	Webinar on Preanalytical variables affecting Biochemical Investigations Virtual April 10, 2024
53.	Prof. Vishwajeet Rohil	Participant	Association of Clinical Biochemists of India (ACBI) and APFCB C-LM	Webinar on Point of Care Testing Virtual April 30, 2024
54.	Prof. Vishwajeet Rohil	Participant	Association of Medical Biochemists of India (AMBI)	Webinar on Cell sensitization and adaptation to O ₂ Availability Virtual May 15, 2024
55.	Prof. Vishwajeet Rohil	Participant	International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)	Webinar on Global Supply Chain Issues in Health Care Virtual June 14, 2024
56.	Prof. Vishwajeet Rohil	Participant	Sardar Patel Medical College, Bikaner	Webinar on Biochemistry Update 2024 Virtual August 1 2024
57.	Prof. Vishwajeet Rohil	Organizing Secretary	Department of Biochemistry, VPCI	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
58.	Prof. Vishwajeet Rohil	Participant	Asian & Pacific Federation of Clinical Biochemistry (APFCB)	APFCB Webinar on Cellular and Molecular Biomarkers of Metabolic Syndrome Virtual October 11, 2024
59.	Prof. Vishwajeet Rohil	Participant	College of American Pathologists	Webinar on Essential Steps for Navigating the Accreditation Journey Virtual November 26, 2024
60.	Prof. Vishwajeet Rohil	Chairperson	Department of Biochemistry, PGIMER, Chandigarh	Golden Jubilee Conference of ACBICON 2024 Session on Drug Delivery and Therapeutics Hotel Mount View, Chandigarh December 5–7, 2024
61.	Prof. Vishwajeet Rohil	Chairperson	Vallabhbhai Patel Chest Institute	58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024
62.	Prof. Vishwajeet Rohil	Participant	Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)	Webinar on Advancing Medical Laboratory Practices with ISO 15189:2022 – The Future of Quality and Competence Virtual February 21, 2025

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
63.	Prof. Vishwajeet Rohil	Participant	Association of Clinical Biochemists of India (ACBI)	Webinar on Role of Laboratory Medicine in Improving Diagnosis Virtual January 23, 2025
64.	Prof. Vishal Bansal	Lecture: "Interventions to Improve Hypoxia Tolerance"	Hypobaric Hypoxia Society Delhi	7 th International Leh Symposium 2024 Mahabodhi International Meditation Centre, Leh Ladakh August 4-7, 2024
65.	Prof. Vishal Bansal	Workshop Lecture: "Six Minute Walk Test: Procedure & Interpretation"	Vallabhbhai Patel Chest Institute, University of Delhi	Pre-conference Workshop on PFT in ICAAICON 2024 58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19-22, 2024
66.	Prof. Vishal Bansal	Lecture: 1. Rehabilitation in Pulmonary Disease 2. Interventions to Improve Hypoxia Tolerance	Vallabhbhai Patel Chest Institute, University of Delhi	ICAAICON 2024: 58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19-22, 2024
67.	Prof. Vishal Bansal	Panelist: "Care beyond medical management of TB (Pulmonary Rehabilitation, Palliative Care)"	DHR / ICMR & Central TB Division Ministry of Health and Family Welfare Govt. of India The Union	India Innovation Summit: Pioneering Solutions to End TB Bharat Mandapam, New Delhi March 18-19, 2025
68.	Dr. Uma Tyagi	Special Invitee	Sri Venkateswara College DU in association with SLP and SLA USA	One-day International Seminar on Digital Transformation for Academic Libraries Sri Venkateswara College, Delhi April 27, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
69.	Dr. Uma Tyagi	Participant	DELNET – Developing Library Network	Dr. H. K. Kaul Memorial Lecture 2024 on Data Protection and Data Privacy DELNET, Delhi July 1, 2024
70.	Dr. Uma Tyagi	Participant	National Medical Library and Oxford University Press	Webinar on Discovering Quality Medical Content with Oxford Medical Journal, Virtual July 3, 2024
71.	Dr. Uma Tyagi	Participant	National Medical Library and McGraw Hill	Webinar on Enhancing Medical Education: Unlocking the Full Potential of Access Medicine Virtual July 15, 2024
72.	Dr. Uma Tyagi	Participant	DELNET – Developing Library Network and Somaiya Vidyavihar University	D E L N E T – S V U Mumbai Webinar on Teacher's Role in Integrating Indian Knowledge System in Implementing NEP 2020 Virtual September 5, 2024
73.	Dr. Uma Tyagi	Participant	National Medical Library and Thieme Publisher	Virtual Training Programme for Accessing the Database Hassle Free Virtual October 9, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
74.	Dr. Uma Tyagi	Session Co-Chair	CGLA in collaboration with IGNCA	5 th International Conference of Central Government Library Association (Delhi Branch) on Taking Pride in Legacy – Libraries and Archives for Viksit Bharat Indira Gandhi National Centre for the Arts Samvet Auditorium Hotel Janpath, New Delhi October 17–19, 2024
75.	Dr. Uma Tyagi	Participant	National Medical Library and McGraw Hill	Webinar on Enhancing Medical Education: Unlocking the Full Potential of Access Medicine Virtual October 24, 2024
76.	Dr. Uma Tyagi	Participant	National Medical Library and Thieme Publisher	Author Workshop Webinar on New Drug Approval & Clinical Trials Virtual November 14, 2024
77.	Dr. Uma Tyagi	Participant	National Medical Library and Thieme Publisher	Virtual Training Session on Introduction to MedOne Education's New Interface Design Virtual November 28, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
78.	Dr. Uma Tyagi	Participant	EBSCO Information Services New Delhi	One-day Webinar on Empower Your Research: Tailored Recurring Trainings on EBSCO Databases for ICSSR Scholars – EBSCO Authorship Session Virtual March 17, 2025
79.	Dr. Uma Tyagi	Participant	Springer Nature	One-day Webinar on Training on Springer Nature Journals and Platforms (Open for ONOS members) Virtual March 19, 2025
80.	Dr. Swati Mittal	Delegate	IIT Delhi	AI for Healthcare Professionals IIT Delhi October 7, 2024
81.	Dr. Swati Mittal	Chairperson	Indian Society of Chronomedicine	World Congress on Chronomedicine Rajarshi Dashrath Autonomous State Medical College, Ayodhya November 29 – December 1, 2024
82.	Dr. Swati Mittal	Delegate	MRU, MAMC and ICMR-CCoE-AIIMS New Delhi	Workshop on Research Methodology Maulana Azad Medical College, New Delhi December 11–13, 2024
83.	Dr. Swati Mittal	Chairperson	Vallabhbhai Patel Chest Institute, Delhi	ICAAICON 2024: 58th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
84.	Dr. Parul Mrigpuri	Lecture: 1. 6 Minute Walk Test 2. Global Warming, Climate Change, Air Pollution and Respiratory Allergies	Indian College of Allergy, Asthma & Applied Immunology	57 th ICAAICON Hotel The Lalit, Jaipur Rajasthan January 4, 2024
85.	Dr. Parul Mrigpuri	Conducted Workshop: "Allergy Testing and Allergen Immunotherapy"	Punjab Chapter of ICS	PULMONIS 2024 Government Medical College, Patiala April 6–7, 2024
86.	Dr. Parul Mrigpuri	Conducted Workshop: "Lung cryobiopsy, Argon Plasma Coagulation and Endobronchial electrocautery"	VPCI	VPCI Delhi April 27, 2024
87.	Dr. Parul Mrigpuri	Lecture: 1. Allergen vs Irritant – Which is Relevant? 2. Indian Guidelines for Diagnosis of Respiratory Allergy	VPCI	47 th Workshop on Respiratory Allergy: Diagnosis and Management VPCI, Delhi February 12, 2024
88.	Dr. Parul Mrigpuri	Lecture: "Clinical Dilemmas TB vs Sarcoid"	North Delhi Women Ophthalmologists	NDWO Meeting Hotel City Park, Pitampura Delhi January 19, 2025
89.	Dr. Parul Mrigpuri	Lecture: "Allergen testing – in-vitro and in-vivo"	NITRD New Delhi	Asthma Update-2024 NITRD, New Delhi May 4, 2024
90.	Dr. Parul Mrigpuri	Panelist: 1. Difference in Managing Allergic vs Non-Allergic Asthma 2. When to consider desensitization in Asthma	NITRD New Delhi	Asthma Update-2024 NITRD, New Delhi May 4, 2024
91.	Dr. Parul Mrigpuri	Lecture: "Allergen vs Irritant – Which is Relevant?"	VPCI	48 th Workshop on Respiratory Allergy: Diagnosis and Management VPCI, Delhi October 21, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
92.	Dr. Parul Mrigpuri	Lecture: "Allergen Avoidance" (Allergy Immunotherapy Workshop)	NAPCON 2024	NAPCON 2024 Coimbatore, Tamil Nadu November 19, 2024
93.	Dr. Parul Mrigpuri	Paper presented: 1. Efficacy of Vitamin C Supplementation on COPD: A Systematic Review and Meta-Analysis 2. The Effectiveness of Supplementation with Key Vitamins, Minerals, Antioxidants and Specific Nutritional Supplements in COPD – A Review 3. Evaluating the Effectiveness of Air Filter Equipment in Improving Air Quality: How Useful Are They?	NAPCON 2024	NAPCON 2024 Coimbatore, Tamil Nadu November 24, 2024
94.	Dr. Parul Mrigpuri	Lecture: "Indian Guidelines for Diagnosis of Respiratory Allergy"	VPCI	58 th ICAAICON VPCI, Delhi December 19, 2024
95.	Dr. Parul Mrigpuri	Lecture: "Drug Stockout: Impact on NTEP"	NATCON	79 th NATCON Jaipur October 18–20, 2024
96.	Dr. Parul Mrigpuri	Lecture: "Tru NAAT"	NATCON	79 th NATCON Jaipur October 18–20, 2024
97.	Dr. Parul Mrigpuri	Short Case Discussion	AIIMS	Future Chest: The Prelims 2025 AIIMS, Delhi February 1, 2025
98.	Dr. Parul Mrigpuri	Moderator: HDM Session	Jaypee Sidharth Delhi	Workshop on Allergen Immunotherapy Jaypee Sidharth Delhi February 8, 2025
99.	Dr. Parul Mrigpuri	Lecture: "Tobacco Free Youth Campaign / Cessation Centres"	Ministry of Health & Family Welfare	Non-Communicable Disease Workshop Hyderabad, Telangana January 8–9, 2025

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
100.	Dr. Siddharth Raj Yadav	Speaker: "FENO in clinical practice"	Indian Association of Clinical Medicine	30 th Annual Conference of Indian Association of Clinical Medicine Udaipur September 27–29, 2024
101.	Dr. Siddharth Raj Yadav	Faculty: "PAP Downloads and Troubleshooting"	Indian Sleep Disorder Association, Department of Pulmonary, Critical Care and Sleep VMMC & SJH	SLEEPCON 2024 Asoka Hotel New Delhi June 15–16, 2024
102.	Dr. Siddharth Raj Yadav	Participant	CHEST	CHEST-RISE Hands-on Simulation Workshop on Flexible Bronchoscopy and EBUS Mumbai April 28, 2024
103.	Dr. Siddharth Raj Yadav	Faculty: "Role of Biologicals in Asthma"	Vallabhbhai Patel Chest Institute Delhi	48 th Allergy Workshop VPCI, Delhi October 21–25, 2024
104.	Dr. Siddharth Raj Yadav	Faculty: "Role of Biologicals in Asthma Management"	Vallabhbhai Patel Chest Institute Delhi	Certificate Course on Diagnosis of Respiratory Allergy and Immunotherapy VPCI, Delhi November 29 – December 1, 2024
105.	Dr. Siddharth Raj Yadav	Lecture: "Pharmacological management of Tobacco Cessation"	NBEMS (DNB)	NBEMS Respiratory Medicine Webinar Virtual June 5, 2024
106.	Dr. Siddharth Raj Yadav	Panel: "Clinical Cases Discussion: History, Investigation, Interpretation, Selection of Allergen and Starting of Immunotherapy" and Practical Demonstration: "SPT Hands-on Training"	Vallabhbhai Patel Chest Institute, Delhi	ICAAICON 2024: 58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
107.	Dr. Siddharth Raj Yadav	Chairperson: Symposium on Allergens and Allergy	Vallabhbhai Patel Chest Institute, Delhi	ICAAICON 2024: 58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024
108.	Dr. Siddharth Raj Yadav	Panel Discussion: “Drug Allergy”	Vallabhbhai Patel Chest Institute, Delhi	ICAAICON 2024: 58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024
109.	Dr. Siddharth Raj Yadav	Lecture: “Pet Allergy”	Vallabhbhai Patel Chest Institute, Delhi	ICAAICON 2024: 58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024
110.	Dr. Siddharth Raj Yadav	Panel Discussion: “Home Maintenance Nebulization: An Indian Perspective”	CME Foundation of India (CMEFI)	CHEST Conclave The Lalit Hotel, New Delhi June 9, 2024
111.	Dr. Siddharth Raj Yadav	Workshop: “Rigid Thoracoscopy & Indwelling Pleural Catheter”	VMMC & Safdarjung Hospital	3 rd Bronchoscopy Excellence Workshop Super Speciality Block VMMC & SJH New Delhi September 15, 2024
112.	Dr. Siddharth Raj Yadav	Workshop: “Body Plethysmography”	VMMC & Safdarjung Hospital	5 th Annual Pulmonary Update & PFT Masterclass Super Speciality Block VMMC & SJH May 4–5, 2024
113.	Dr. Siddharth Raj Yadav	Speaker: Webinar on “Non-Pharmacological Management of Smoking Cessation”	NBEMS Medicine Respiratory	NBEMS Respiratory Medicine Webinar Virtual May 1, 2024
114.	Dr. Jayeeta Bhadra	Participant	NMC Centre Regional/Nodal	Basic Course in Medical Education MAMC, New Delhi April 30 – May 2, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
115.	Dr. Jayeeta Bhadra	Participant	ACBI and APFCB C-LM	Webinar on Point of Care Testing Virtual April 30 2024
116.	Dr. Jayeeta Bhadra	Participant	ACCLMP Delhi Chapter	Workshop cum CME on Immunofluorescence & Autoimmune Diseases Amrita Hospitals Faridabad June 1, 2024
117.	Dr. Jayeeta Bhadra	Joint Secretary and Speaker	Department of Biochemistry, VPCI	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27, 2024
118.	Dr. Jayeeta Bhadra	Guide	Association of Clinical Chemistry & Lab Medicine Practitioners (ACCLMP)	National PG Seminar Competition Virtual October 18, 2024
119.	Dr. Jayeeta Bhadra	Chairperson	Vallabhbhai Patel Chest Institute	58 th Annual Conference of the Indian College of Allergy Asthma & Applied Immunology VPCI, Delhi December 19–22, 2024
120.	Dr. Jayeeta Bhadra	Faculty	Association of Clinical Chemistry & Lab Medicine Practitioners (ACCLMP)	11 th Annual Conference of ACCLMP Guwahati January 11–12, 2025
121.	Dr. Juhi Aggarwal	Participant	AIIMS, New Delhi	5 th Yellapragada Subbarow Memorial Oration AIIMS, New Delhi April 15, 2024
122.	Dr. Juhi Aggarwal	Participant	Government Medical College & Hospital, Chandigarh, under AMBI	3 rd National Postgraduate Update cum CME – Virtual Bio-Connect Virtual April 26–28, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
123.	Dr. Juhi Aggarwal	Participant	Wolters Kluwer and ERMED Consortium	Webinar on Ovid Literature Search Virtual June 26, 2024
124.	Dr. Juhi Aggarwal	Participant	International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)	Webinar on Method Evaluation Virtual June 21, 2024
125.	Dr. Juhi Aggarwal	Participant	Association of Medical Biochemists of India (AMBI)	Academics CME – Webinar Virtual June 30, 2024
126.	Dr. Juhi Aggarwal	Participant	NML ERMED	Webinar on Medone Education Virtual July 9, 2024
127.	Dr. Juhi Aggarwal	Participant	AMBI	Webinar on Integrative Bioinformatics: An Essential Tool Leveraging Multi-Omics in Clinical Laboratory Virtual July 19, 2024
128.	Dr. Juhi Aggarwal	Participant	Sardar Patel Medical College, Bikaner	Webinar on Biochemistry Update 2024 Bikaner Virtual August 1, 2024
129.	Dr. Juhi Aggarwal	Participant	Sri Devaraj Urs Academy of Higher Education and Research	Webinar on The Immune System's Competitive Strategies against Pathogens: Survival of the Fittest Virtual September 11, 2024
130.	Dr. Juhi Aggarwal	Joint Secretary and Speaker	Department of Biochemistry, VPCI	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
131.	Dr. Juhi Aggarwal	Participant	Department of Biochemistry, LHMC & Associated Hospitals, New Delhi	6 th Pre-Conference CME & Workshop under ACCLMPCON 2025 LHMC October 15 2024
132.	Dr. Juhi Aggarwal	Participant	Institute of Nano Medical Sciences, University of Delhi & Maharaja Surajmal Brij University, Bharatpur	International Symposium on Nanomedicine Bharatpur, Rajasthan November 27, 2024
133.	Dr. Divya Sharma	Participant	Tata Memorial Hospital, Mumbai	Online Workshop on Clinical Research Method and Protocol Development Virtual April 25–28, 2024
134.	Dr. Divya Sharma	Participant	Pathoindia	Online Pathoindia Lecture Series – Decoding Lung Lesions Virtual August 15, 2024
135.	Dr. Divya Sharma	Participant	MRU-MAMC and ICMR-COE	Workshop on Research Methodology MAMC, Delhi December 11–13, 2024
136.	Dr. Ravishankar N	Resource Person	SUM Nursing College (Faculty of Nursing) Siksha 'O' Anusandhan, Bhubaneswar	Faculty Development Program on Systematic Review and Meta-analysis Virtual February 8, 2025
137.	Dr. Ravishankar N	Participant	Society of Agricultural Research, Applied Technology and Environmental Science	Seven days International Capacity Development Training Program on Research Methodology & Data Analysis using 'R' Programming Virtual January 12-18, 2025

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
138.	Dr. Ravishankar N	Lecture on "Role of Statistics in Medical Practice"	VPCI	ICCAICON 2024, 58 th Annual Conference of the Indian College of Allergy Asthma and Applied Immunology VPCI, Delhi December 19–22, 2024
139.	Dr. Ankit Arora	Participated as a delegate	Saveetha Medical College and Hospital	Webinar on International Conference of the Medical Pharmacologists Society (MPSCON2024) Chennai August 29, 2024
140.	Dr. Ankit Arora	Participated as a delegate	Sharda University, Greater Noida	Clinical Research Awareness Session 2024 Indian Society Clinical Research, UP August 30, 2024
141.	Dr. Ankit Arora	Participated as a delegate	MRU-Maulana Azad Medical College in Collaboration with ICMR-CCoE	Workshop on Research Methodology New Delhi December 11–13, 2024
142.	Dr. Ankit Arora	Participated as a delegate	ICAAICON, VPCI	Annual Conference of the Indian College of Allergy, Asthma & Applied Immunology VPCI December 19–22, 2024
143.	Dr. Rashmi Dhir Supervisor: Prof. Kavita Gulati	Participated as delegate (Online)	Department of Pharmacognosy, Sri Ramchandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India	H E R B O T E C H 2025 Conference – Navigating challenges in the Formulation of Natural Cosmetics, Virtual, February 24, 2025
144.	Dr. Rashmi Dhir Supervisor: Prof. Kavita Gulati	Participated as delegate (Online)	Gujarat United Pharmacologist Network Webinars	Webinar – Ethnopharmacology: The role of traditional medicinal practices in modern healthcare Virtual February 27, 2025

S. No.	Faculty Member (Department)	Title of the Project			Funding Agency, Date of Sanction / Implementation and Duration		Total Grant received (₹)
145.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Participated (Online)	as	delegate	Department of Pharmacology, JSS Medical College, Mysuru	Webinar – National CME on Unleashing Potential: Global Career Opportunities for Pharmacology PGs Virtual April 25, 2024	
146.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Presented a poster (Online) entitled A clinical study to monitor adverse drug reactions in elderly and non-elderly patients of COPD			Conference Mind	5 th International Hybrid Conference on Traditional & Alternative Medicine Virtual May 24–25, 2024	
147.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Participated (Online)	as	delegate	Resilient Foundation for Academic Innovation and Scientific Research	Workshop – Advanced Statistical Data Analysis New Delhi June 22–28, 2024	
148.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Participated (Online)	as	delegate	AIIMS, Bilaspur	Webinar – Building ADR Reporting Culture for Patient Safety Virtual September 17, 2024	
149.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Participated (Offline)	as	delegate	Hamdard Institute of Medical Sciences, New Delhi	Annual Conference of SNOAR – Impact of Nitric Oxide on Health and Disease New Delhi September 26, 2024	
150.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Participated as delegate (Offline)			Department of Biochemistry, VPCI, Delhi	Workshop – Good Clinical Laboratory Practices VPCI September 27, 2024	
151.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Presented a poster (Offline) – A clinical study to monitor adverse drug reactions in elderly and non-elderly patients of COPD			Indian Pharmacological Society, AIIMS	Annual Conference of the Indian Pharmacological Society AIIMS, New Delhi November 28, 2024	
152.	Dr. Akhil Sathyanathan Supervisor: Prof. Kavita Gulati	Participated (Online)	as	delegate	B. J. Medical College, Ahmedabad	Workshop – Advance Level Training in Pharmacovigilance Virtual March 12, 2025	

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
153.	Dr. Sumit Biswas Supervisor: Prof. Kavita Gulati	Participated as delegate (Online)	National Association of Pharmacology & Therapeutics with AIIMS, Nagpur	Good Clinical Practice (GCP) Workshop Virtual March 6, 13, 20, 27, 2025
154.	Dr. Karishma Birde (MD student)	Participant	ACBI Delhi Chapter	CME on Precision Medicine: Actualising the Frontier AIIMS, New Delhi April 15, 2024
155.	Dr. Karishma Birde (MD student)	Participant	Bio-Rad India	CME on 9 th Hemoglobin Update 2024 Hotel Holiday Inn Aerocity, Delhi April 16, 2024
156.	Dr. Karishma Birde (MD student)	Organising Member	Department of Biochemistry, VPCI	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27, 2024
157.	Dr. Mohd. Azharuddin Mulla (MD student)	Participant	ACBI Delhi Chapter	CME on Precision Medicine: Actualising the Frontier AIIMS, New Delhi April 15, 2024
158.	Dr. Mohd. Azharuddin Mulla (MD student)	Participant	Bio-Rad India	CME on 9 th Hemoglobin Update 2024 Hotel Holiday Inn Aerocity, Delhi April 16, 2024
159.	Dr. Mohd. Azharuddin Mulla (MD student)	Participant	ACCLMP Delhi State Chapter	CME on Immunofluorescence & Autoimmune Diseases Amrita Hospital, Faridabad June 1, 2024
160.	Dr. Mohd. Azharuddin Mulla (MD student)	Participant	AMBKCON – Karnataka Chapter	Workshop on Primer Designing Adichunchungiri Institute of Medical Sciences, Karnataka July 11–13, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
161.	Dr. Mohd. Azharuddin Mulla (MD student)	Participant	CAHO North Zone	Workshop on World Patient Safety Day Sehgal Neo Hospital, New Delhi September 12, 2024
162.	Dr. Mohd. Azharuddin Mulla (MD student)	Joint Treasurer	Department of Biochemistry, VPCI	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27, 2024
163.	Dr. Vishnu Priya (1st Year PG Student)	Participant	Flow Cytometry Solutions (P) Ltd Jaipur India	CME on CRISPR-CAS: The Molecular Toolkit – Principles and Applications Virtual April 10–12, 2024
164.	Dr. Vishnu Priya (MD student)	Participant	ACBI Delhi Chapter	CME on Precision Medicine: Actualising the Frontier AIIMS, New Delhi April 15, 2024
165.	Dr. Vishnu Priya (MD student)	Participant	Bio-Rad India	CME on 9 th Hemoglobin Update 2024 Hotel Holiday Inn Aerocity, Delhi April 16, 2024
166.	Dr. Vishnu Priya (MD student)	Participant	SNMC Medical College	Hands-on Workshop on Molecular Techniques SNMC Medical College Agra April 20–21, 2024
167.	Dr. Vishnu Priya (MD student)	Participant	Dept. of Biochemistry Govt. Medical College & Hospital Chandigarh under AMBI	3 rd National PG Update Virtual April 26–28, 2024
168.	Dr. Vishnu Priya (MD student)	Participant	CAHO	CME on Intracellular Homocysteine – A Better Indicator for B12 Deficiency Virtual May 4, 2024

S. No.	Faculty Member (Department)	Title of the Project	Funding Agency, Date of Sanction / Implementation and Duration	Total Grant received (₹)
169.	Dr. Vishnu Priya (MD student)	Participant	Dept. of Biochemistry Madurai Medical College	CME and Workshop on Gel Journey: Decoding Monoclonal Mysteries Madurai July 6, 2024
170.	Dr. Vishnu Priya (MD student)	Participant	IIT Kharagpur	Workshop on Good Clinical Laboratory Practices IIT Kharagpur July 12, 2024
171.	Dr. Vishnu Priya (MD student)	Participant	Dept. of Biochemistry Sardar Patel Medical College Bikaner	CME Bikaner August 1, 2024
172.	Dr. Vishnu Priya (MD student)	Organising Member	Department of Biochemistry, VPCI	Workshop on Good Clinical Laboratory Practices VPCI, Delhi September 27, 2024
173.	Dr. Vishnu Priya (MD student)	Participant	ACBI	South Zone ACBI Conference on Translation from the Bench to the Bedside: Emerging Trends in Clinical Biochemistry to Improve Patient Outcomes JIPMER, Puducherry January 24–25, 2025
174.	Dr. Roopali Rajput (Research Associate-II, Supervisor: Prof. Madhu Khanna)	Paper presented: "Potential of engineered phage display antibodies in epitope mapping of influenza A virus antigens"	DRDO-Defence Research & Development Establishment (DRDE) Gwalior in association with Indian Virological Society (IVS)	International VIROCON 2024 Emerging Viruses: Pandemic & Biosecurity Perspectives Gwalior, Madhya Pradesh November 11–13, 2024

Participation in Advanced and Specialised Training Programme by Faculty Members

S. No.	Participant (Department)	Course Title/ Topic	Training Duration	Host
1.	Prof. Raj Kumar	Organized 48 th Workshop on Respiratory Allergy Diagnosis & Management	October 21-25, 2024	Vallabhbhai Patel Chest Institute (VPCI), University of Delhi, Delhi
2.	Prof. Raj Kumar	Organized Certificate Course on Diagnosis of Respiratory Allergy and Immunotherapy	November 29- December 1, 2024	Vallabhbhai Patel Chest Institute (VPCI), University of Delhi, Delhi
3.	Prof. Ritu Kulshrestha	INSA-NCGG- LEADS) Leadership Training programme	July 8-14, 2024	Indian National Science Academy-National Centre for Good Governance
4.	Prof. Ritu Kulshrestha	INSA National Brain Storming Session on Transforming Science, Technology and Innovation System in India	May 22, 2024	INSA, New Delhi
5.	Prof. Madhu Khanna	One-day Symposium and Laboratory Tour on Molecular Biology Techniques in Medical Virology	March 4, 2025	Virology Unit, Department of Microbiology, Vallabhbhai Patel Chest Institute (VPCI), University of Delhi, Delhi
6.	Dr. Jayeeta Bhadra	Basic Course in Medical Education	April 30 – May 02, 2024	MAMC, New Delhi

Short-term Specialised Training Imparted by Faculty Members

S. No.	Name, Subject and University/ Institute/College	Course Title/ Topic	Faculty Member (Department)	Period
1.	Ms. Swayanka Rawat, B.Sc. (Life Science) (Prog.) Sri Aurobindo College, University of Delhi, (Delhi)	Student of B.Sc. Life Science (Prog.)	Prof. Vishwajeet Rohil (Biochemistry)	June 13 – July 12, 2024
2.	Mr. Nikhil, B.Sc. (Life Science) (Prog.) Sri Aurobindo College, University of Delhi, (Delhi)	Student of B.Sc. Life Science (Prog.)	Prof. Vishwajeet Rohil (Biochemistry)	June 13 – July 26, 2024
3.	Mr. Rahul, B.Sc. (Life Science) (Prog.) Sri Aurobindo College, University of Delhi, (Delhi)	Student of B.Sc. Life Science (Prog.)	Prof. Vishwajeet Rohil (Biochemistry)	June 13 – July 26, 2024

S. No.	Name, Subject and University/ Institute/College	Course Title/ Topic	Faculty Member (Department)	Period
4.	Ms. Akanksha Srivastava, M.Sc. (Virology), Amity University Campus, Gautam Buddha Nagar, (Uttar Pradesh)	Student of M.Sc. (Virology)	Dr. Jayeeta Bhadra (Biochemistry)	May 15 – June 30, 2024
5.	Ms. Moslam Dolma, B.Sc. (Life Science) (Prog.) Sri Aurobindo College, University of Delhi, (Delhi)	Student of B.Sc. Life Science (Prog.)	Dr. Jayeeta Bhadra (Biochemistry)	June 13 – July 12, 2024
6.	Mr. Aman, B.Sc. (Life Science) (Prog.) Sri Aurobindo College, University of Delhi, (Delhi)	Student of B.Sc. Life Science (Prog.)	Dr. Jayeeta Bhadra (Biochemistry)	June 13 – July 26, 2024
7.	Mr. Anirudh Gahlot, B. Tech (Biotechnology), Amity University Campus, Gautam Buddha Nagar, (Uttar Pradesh)	Student of B. Tech (Biotechnology)	Dr. Juhi Aggarwal (Biochemistry)	May 15 – June 30, 2024
8.	Ms. Vriddhi Rastogi, B.Sc. (Life Science) (Prog.) Sri Aurobindo College, University of Delhi, (Delhi)	Student of B.Sc. Life Science (Prog.)	Dr. Juhi Aggarwal (Biochemistry)	June 13 – July 12, 2024
9.	Ms. Aparajita, B.Sc. (H) (Biotechnology), IMS, Ghaziabad (University Course Campus), (Uttar Pradesh)	Student of B.Sc. (H) Biotechnology	Dr. Juhi Aggarwal (Biochemistry)	December 9, 2024 – January 23, 2025
10.	Mr. Ankit Sharma, M.Sc. (Respiratory Therapy), VPCI, University of Delhi, (Delhi)	Student of M.Sc Respiratory Therapy	Prof. Ritu Kulshrestha & Dr. Divya sharma (Pathology)	September 1 – November 30, 2024
11.	Mr. Shubrokanti Das, M.Sc. (Respiratory Therapy), VPCI, University of Delhi, (Delhi)	Student of M.Sc Respiratory Therapy	Prof. Ritu Kulshrestha & Dr. Divya sharma (Pathology)	September 1 – November 30, 2024
12.	Mr. Dev Kumar, B.Sc (H) (Microbiology), Galgotias University, Greater Noida, (Uttar Pradesh)	Student of B.Sc. (H) Microbiology	P Prof. Mandira Varma Basil (Microbiology)	October 7 – November 7, 2024
13.	Ms. Shefali Dwivedi, B.Sc. (H) (Microbiology), IMS, Ghaziabad (University Course Campus), (Uttar Pradesh)	Student of B.Sc. (H) Microbiology	Prof. Ritu Kulshrestha (Pathology)	January 10 – February 9, 2025

S. No.	Name, Subject and University/ Institute/College	Course Title/ Topic	Faculty Member (Department)	Period
14.	Ms. Siddhantika Viad, M.Sc (Immunology), Amity University Campus, Gautam Buddha Nagar, (Uttar Pradesh)	Student of B. Tech (Biotechnology)	Prof. Ritu Kulshrestha q(Pathology)	May 21 – July 15, 2024
15.	Ms. Tulsi Pandey, M.Sc (Microbiology), Galgotias University, Greater Noida, (Uttar Pradesh)	Student of M.Sc Microbiology	Prof. Ritu Kulshrestha (Pathology)	January 10 – July 10, 2024
16.	Ms. Sonam Sharma, M.Sc (Microbiology), Galgotias University, Greater Noida, (Uttar Pradesh)	Student of M.Sc Microbiology	Prof. Ritu Kulshrestha (Pathology)	January 10 – July 10, 2024
17.	Ms. Deeksha Mehta, M.Sc (Immunology), Amity University, Gautam Budh Nagar, (Uttar Pradesh)	Student of M.Sc Immunology	Prof. Madhu Khanna (Virology Unit)	May 10, 2024 to June 30, 2024
18.	Mr. Prohit Jumrani, M.Sc (Virology), Amity University, Gautam Budh Nagar, (Uttar Pradesh)	Student of M.Sc Virology	Prof. Madhu Khanna (Virology Unit)	May 10, 2024 to June 30, 2024
19.	Ms. Jasna Shaji, M.Sc (Virology), Amity University, Gautam Budh Nagar, (Uttar Pradesh)	Student of M.Sc Virology	Prof. Madhu Khanna (Virology Unit)	May 10, 2024 to June 30, 2024
20.	Ms. Shabiya, M.Sc (Virology) Jamia Millia Islamia, (Delhi)	Student of M.Sc Virology	Prof. Madhu Khanna (Virology Unit)	May 20, 2024 to July 20, 2024
21.	Ms. Aneena Vinod, M.Sc (Virology) Jamia Millia Islamia, (Delhi)	Student of M.Sc Virology	Prof. Madhu Khanna (Virology Unit)	March 03, 2025 to May 02, 2025
22.	Ms. Mariya Fozail, M.Sc (Virology) Jamia Millia Islamia, (Delhi)	Student of M.Sc Virology	Prof. Madhu Khanna (Virology Unit)	March 03, 2025 to May 02, 2025

Glimpses of the Events held at VPCI

1. Swachhta Pakhwada (April 1-15, 2024)

During the Swachhta Pakhwada observed from April 1-15, 2024, Vallabhbhai Patel Chest Institute organized a comprehensive series of cleanliness and awareness initiatives in line with directives from the Ministry of Health & Family Welfare. The campaign commenced with a Swachhta Pledge and distribution of badges and stickers. Throughout the fortnight, rigorous cleaning and sanitization efforts were carried out across hospital premises and residential areas. Engaging seminars on hand hygiene, biomedical waste management, lab practices, pollution and fire safety were conducted by subject experts. Visual communication was amplified through posters, banners, murals, and the installation of segregation bins. Special attention was given to residential quarters, where hygiene inspections, distribution of indoor plants, and swachhta camps were held. The initiative culminated with a final inspection and submission of a comprehensive cleanliness report to the Ministry.

Key Events at a Glance

- **April 1, 2024:** Swachhta Pledge & badge distribution
- **April 2, 2024:** Visitor sensitization programme & leaflet distribution
- **April 3, 2024:** Seminars on hygiene, waste management & lab practices
- **April 6-7, 2024:** Cleaning of departments and outdoor areas (Holidays)
- **April 8, 2024:** Lecture on pollution and health effects
- **April 9, 2024:** Swachhta rally with distribution of promotional material
- **April 10-11, 2024:** Hygiene inspection of residential quarters & student hostel
- **April 12, 2024:** Fire safety seminar and mock drill
- **April 13-14, 2024:** Swachhta camps in residential complexes (Holidays)
- **April 15, 2024:** Final cleanliness inspection and report preparation





2. Foundation Day and 23rd Prof. Raman Viswanathan–VPCI Oration (April 8, 2024)

Vallabhbhai Patel Chest Institute proudly celebrated its Foundation Day alongside the 23rd Prof. Raman Viswanathan–VPCI Oration on April 8, 2024. The commemorative event was held in the Paintal Memorial Golden Jubilee Auditorium and commenced at 3:00 PM. Lt. Gen. Ajith Nilakantan, Commandant, Army Hospital (Research & Referral), New Delhi, graced the occasion as Chief Guest, while Dr. B. Srinivas, ADG (ME) and Prof. Sunita Kalra, Dean, Faculty of Medical Sciences, University of Delhi, Delhi honored the ceremony as Guests of Honour. Prof. Raj Kumar, Director, VPCI, graced the stage alongside the distinguished guests. The oration was eloquently delivered by Prof. A.K. Janmeja, Prof. & HOD, Dept. of Pulmonary Medicine, MM Institute of Medical Sciences & Research, Solan. The presence of faculty, staff, and students of the Institute added vibrance to the program, reflecting the Institute's legacy and academic excellence.



3. World Pulmonary Hypertension Awareness Day (May 3, 2024)

Vallabhbhai Patel Chest Institute observed World Pulmonary Hypertension Awareness Day on May 3, 2024 with an informative lecture aimed at raising awareness of Pulmonary Hypertension and honoring individuals affected by the condition. The program was held at 3:00 PM in the Paintal Memorial Auditorium and featured a talk by Dr. Neeraj Awasthy, Director, Paediatric Cardiology, Fortis Escorts Heart Institute, New Delhi. Dr. Awasthy delivered a compelling lecture on the “Diagnosis of PAH,” offering valuable insights into clinical approaches and advancements in pediatric cardiology. The event was attended by faculty members and students, reflecting the Institute’s commitment to promoting health education and community awareness.

4. Talk on “How to be Successful in Medical Research” (May 10, 2024)

The Multi-disciplinary Research Unit (MRU) of Vallabhbhai Patel Chest Institute organized an insightful talk titled “How to be Successful in Medical Research” as part of its training activities on May 10, 2024. The lecture was delivered by Prof. B.C. Koner, Department of Biochemistry, Maulana Azad Medical College, and was held in the 100 Seater Hall of the Golden Jubilee Paintal Memorial Auditorium at 2:30 PM. The session provided valuable guidance on navigating a career in medical research, inspiring both faculty and students who attended with keen interest. The event underscored the Institute’s ongoing commitment to fostering research excellence and academic growth.



5. World No Tobacco Day (May 31, 2024)

Vallabhbhai Patel Chest Institute organized an observance of “World No Tobacco Day” on May 31, 2024, at 3:30 p.m. in the Paintal Memorial Golden Jubilee Auditorium of the Institute. The programme was graced by Dr. L. Swasticharan, Additional DDG, Dte. GHS, Ministry of Health & Family Welfare, Government of India, as the Chief Guest. Guests of Honour included Dr. D. Behera, Emeritus Professor, Ex-Professor & Head, Department of Pulmonary Medicine, PGIMER, Chandigarh; Dr. Viveka Kumar, Principal Director & renowned Cardiologist; Prof. Dinesh Khattar, Principal, Kirori Mal College, University of Delhi; and Mr. Srikant Verma, Cine Star. Prof. Raj Kumar, Director, VPCI, presided over the occasion and shared the stage with the esteemed dignitaries, Faculty, staff, and students of the Institute attended with enthusiastic participation, contributing to the success of the event and strengthening the Institute’s mission of promoting public health awareness.



6. International Day of Yoga (IDY) 2024 (June 21, 2024)

Vallabhbhai Patel Chest Institute celebrated the International Day of Yoga, 2024 in collaboration with the Morarji Desai National Institute of Yoga on the morning of June 21, 2024. The event was organized in front of the Paintal Memorial Golden Jubilee Auditorium and saw enthusiastic participation from faculty, staff, students, and their families. To encourage engagement and foster community spirit, participants were provided with T-shirts and caps. Yoga mats, carpets, banners, a selfie point, and an audio-visual setup created a vibrant and welcoming atmosphere. The programme began at 6:15 AM, with guests arriving fifteen minutes early to settle in. After the yoga session, attendees enjoyed light refreshments, concluding the celebration on a healthy and harmonious note.



7. Observance of Indian Organ Donation Day (August 2, 2024)

In observance of Indian Organ Donation Day and as part of the “Angdaan Jan Jagrukta Abhiyaan,” Vallabhbhai Patel Chest Institute organized a pledge ceremony on August 2, 2024, at 3:00 PM in the 100 Seater Lecture Hall of the Paintal Memorial Golden Jubilee Auditorium. The event aimed to raise awareness about the noble cause of organ donation and encourage participation from the academic community. Prof. Raj Kumar, Director, VPCI, administered the pledge, which was solemnly repeated by all attendees, reaffirming their commitment to this humanitarian mission. Faculty, staff, and students participated in the event, reflecting the Institute’s active role in promoting socially responsible healthcare initiatives.

8. Independence Day Celebration (August 15, 2024)

Vallabhbhai Patel Chest Institute celebrated the 78th Independence Day of India with a flag hoisting ceremony held on August 15, 2024, at 9:30 AM. Prof. Raj Kumar, Director, VPCI unfurled the national flag, reflecting the spirit of patriotism and unity. The event witnessed the enthusiastic presence of faculty members, staff, students, and their families, all gathered to honor the nation’s journey and sacrifices. The celebration served as a moment of collective pride and reflection, reinforcing the Institute’s reverence for India’s heritage and its continued commitment to public service.



9. Inauguration of New Toilet Block and 'May I Help You' Desk (September 18, 2024)

A ceremonial inauguration was held at Vallabhbhai Patel Chest Institute for the new Toilet Block and the 'May I Help You' Desk on September 18, 2024, at 3:30 PM, near the Registration Counter of the VCH building, Gate No. 4. Faculty, staff, and students attended the event. The facilities were formally inaugurated by Prof. Raj Kumar, Director, VPCI, in the presence of Shri Omkar Nath Pandit, Deputy Registrar, VPCI. These additions contribute to a more accessible, responsive, and people-friendly campus environment.



10. 18th Prof. Autar Singh Paintal Memorial Oration (September 24, 2024)

Vallabhbhai Patel Chest Institute organized the 18th “Prof. Autar Singh Paintal Memorial Oration” on September 24, 2024, at 3:30 PM in the Paintal Memorial Golden Jubilee Auditorium. The oration was delivered by Prof. Ashok Shah, Former Director-Professor, VPCI. The programme was graced by Prof. Balaram Pani, Dean of Colleges, University of Delhi, as the Chief Guest, and Prof. Anil Agarwal, Medical Director, GB Pant Institute of Postgraduate Medical Education & Research (GIPMER), as the Guest of Honour. Prof. Raj Kumar, Director, VPCI, was also present on the dais alongside the distinguished guests, further enriching the significance of the event. Faculty, staff, and students attended the oration with great enthusiasm, celebrating the Institute’s proud tradition of scholarly distinction.



11. Vigilance Awareness Week 2024 (October 28 – November 3, 2024)

Vallabhbhai Patel Chest Institute observed Vigilance Awareness Week 2024 from October 28 to November 3, 2024 under the theme “Culture of Integrity for Nation’s Prosperity.” The observance commenced with a solemn Integrity Pledge taken by all faculty, staff, and students at 11:00 AM on October 28, 2024 at the Institute’s main entrance (Gate No. 1). Prof. Raj Kumar, Director, VPCI, read out the pledge, which was repeated by faculty, staff, and students gathered for the occasion. The gathering emphasized the importance of transparency, honesty, and ethical conduct across all spheres of institutional functioning. This initiative reflected the Institute’s unwavering commitment to integrity and its role in fostering accountable governance within the academic ecosystem.



12. 8th Dr. V.K. Vijayan Oration (October 28, 2024)

Vallabhbhai Patel Chest Institute organized the 8th “Dr. V.K. Vijayan Oration” on October 28, 2024, at 3:30 PM in the Paintal Memorial Golden Jubilee Auditorium. The oration was delivered by Dr. Radha P. Munje, Professor & Head, Department of Pulmonary Medicine, Indira Gandhi Government Medical College & Hospital, Nagpur, on the topic “Role of TB Preventive Therapy in National TB Elimination Program.” The programme was graced by Prof. Anu Singh Lather, Vice-Chancellor, Dr. B.R. Ambedkar University, Delhi, as the Chief Guest, and Dr. Manashvi Kumar, Joint Secretary, Ministry of Health & Family Welfare, Government of India, as the Guest of Honour. The function was presided over by Dr. Vijay Chauthaiwale, Chairman, Governing Body, VPCI. Prof. Raj Kumar, Director, VPCI, was also present on the dais with the distinguished guests, lending institutional stature to the prestigious occasion. Faculty members, staff, and students of the Institute attended the event with great enthusiasm, emphasizing its academic spirit and shared commitment to excellence.





13. Samvidhan Diwas (Constitution Day) (November 26, 2024)

Vallabhbhai Patel Chest Institute commemorated Samvidhan Diwas (Constitution Day) on November 26, 2024, at 11:00 AM in the 100 Seater Paintal Memorial Golden Jubilee Auditorium. The event aimed to celebrate the adoption of the Constitution of India and to reaffirm the values of democracy, liberty, equality, and justice enshrined in it. Faculty members, staff, and students of the Institute participated in the event. Prof. Raj Kumar, Director, VPCI, read out the pledge, which was repeated by all attendees, creating a unified moment of constitutional reflection and institutional pride.

14. Felicitation of Housekeeping Staff (November 20, 2024)

As part of the Special Campaign 4.0 aimed at institutionalizing Swachhta and minimizing pendency, Vallabhbhai Patel Chest Institute organized a felicitation ceremony for its housekeeping staff on November 20, 2024 at 11:00 AM in the 100-Seated Hall of the Paintal Memorial Golden Jubilee Auditorium. The event acknowledged the vital role and dedicated efforts of the housekeeping personnel in maintaining cleanliness and hygiene across the Institute premises. Through this gesture, VPCI reaffirmed its appreciation for frontline service providers and highlighted their contribution to a cleaner and more efficient institutional environment.



15. ICAAICON 2024 (December 19-22, 2024)

Vallabhbhai Patel Chest Institute hosted the 58th Annual National Conference of the Indian College of Allergy, Asthma & Applied Immunology (ICAAICON 2024) from December 19-22, 2024 at the Paintal Memorial Golden Jubilee Auditorium. The four-day academic event brought together leading experts, clinicians, and researchers from across India and abroad to deliberate on recent advances in allergy, asthma, and immunology. The conference featured a rich scientific programme comprising 19 seminars, 88 lectures, panel discussions, case-based sessions, and hands-on workshops on topics such as food and drug allergy, immunotherapy, and allergy diagnostics. Over 70 research papers were presented through oral and poster sessions, and several young scientists were recognized through prestigious awards including the V. Raju Award, UCB-ICAAI Award, and M. Sundaramma Young Scientist Award. An exhibition showcasing the latest medical technologies and innovations in respiratory care was also held alongside the conference. Notably, Prof. Raj Kumar, Director, VPCI, served as the Organizing Chairman and was honoured with the Lifetime Achievement Award by ICAAI for his outstanding contributions to the field.





16. Fit India Week Celebration (December 23-29, 2024)

In alignment with the national campaign to promote holistic health and wellness, Vallabhbhai Patel Chest Institute observed Fit India Week from December 23-29, 2024. A variety of engaging and participatory activities were organised throughout the week to encourage fitness, mental well-being, and healthy living among faculty, staff, and students. The inaugural day, 23rd December, commenced with the Health Pledge at 2:00 PM in the Paintal Memorial Golden Jubilee Auditorium, symbolizing the Institute's commitment to a healthier lifestyle. This was followed by sessions of Yoga Practice at the VPCI Yoga Centre and Gymnasium Practice at the Institute's gymnasium in the evening. On 24th December, an Essay Writing Competition on the theme "Importance of Fitness" was conducted at 11:00 AM in the Auditorium Cafeteria, allowing participants to reflect on and express the significance of physical well-being. Gym and yoga sessions continued to encourage consistent engagement. The highlight of 26th December was the spirited participation in an Indigenous Sport (Tug of War) conducted at the Badminton Court between 12:00 Noon and 2:00 PM, fostering teamwork and enthusiasm. Complementary gym and yoga activities were also held. On 27th December, the Institute hosted a Morning Walk around the campus at 7:00 AM followed by a Yoga Session at 8:00 AM in the Yoga Centre/Car Parking Area. Post-yoga refreshments were provided, further enhancing the sense of community. Regular gym and yoga sessions were also held throughout the day. Each activity was met with enthusiastic participation, reinforcing the Institute's dedication to fostering a culture of health and vitality. The week-long celebration emphasized not only physical activity but also the collective spirit of well-being within the academic environment.





17. 72nd Institute Day Celebration and 9th Prof. H.S. Randhawa Oration (January 13, 2025)

Vallabhbhai Patel Chest Institute celebrated its 72nd Institute Day on January 13, 2025, at 3:00 PM in the Paintal Memorial Golden Jubilee Auditorium. The event was graced by Shri Amarjeet Sinha, IAS, Member, Public Enterprises Selection Board, as the Chief Guest, along with Prof. Sunita Kalra, Dean, Faculty of Medical Sciences, and Prof. Debajyoti Choudhary, Dean, Faculty of Sciences, University of Delhi, as Guests of Honour. The occasion also featured the 9th Prof. H.S. Randhawa Oration, delivered by Dr. C.P. Baveja, Former Professor of Excellence and Head, Department of Microbiology, Maulana Azad Medical College, New Delhi, on the topic "HIV Prevention." Prof. Raj Kumar, Director, VPCI, presided over the event and shared the dais with the dignitaries, reflecting the Institute's leadership and continued commitment to academic excellence and public health. Faculty members, staff, and students of the Institute participated in the celebration, marking the day with institutional pride and scholarly reflection.



18. Republic Day Celebration (January 26, 2025)

Vallabhbhai Patel Chest Institute celebrated the 76th Republic Day on January 26, 2025 in the lawns in front of the VCH Building. Faculty, staff, students, and their families attended the event with patriotic spirit. The national flag was hoisted by Prof. Raj Kumar, Director, VPCI, followed by the national anthem. The ceremony reflected respect for the Constitution and the Institute's commitment to national values.





19. Martyrs' Day Observance (January 30, 2025)

Vallabhbhai Patel Chest Institute observed Martyrs' Day on January 30, 2025 in honour of those who sacrificed their lives during India's freedom struggle. In accordance with the instructions from the Ministry of Home Affairs and the Ministry of Health & Family Welfare, two minutes of silence was observed at 11:00 AM in all the departments of the Institute to pay tribute to the nation's martyrs.

List of Publications

Journals

1. Agarwal S, Mishra L, Singh NR, Behera R, Kumar M, Ravishankar N, et al. Effect of different irrigating solutions on root canal dentin microhardness—a systematic review with meta-analysis. *J Funct Biomater*. 2024;15(5):132.
2. Bhat S, Mittal S, Sinha S, et al. Evaluating Emotional Intelligence in Medical Students: A Comparative Analysis of Their Trait Emotional Intelligence (TEI) Scores Before and During the COVID-19 Pandemic. *Cureus*. 2024;16(11):e74335.
3. Chauhan M, Gulati K, Ray A. Newer insights into the role of nitric oxide (NO) in bronchial asthma: an experimental study. *EC Pharmacol Toxicol*. 2025;13(4):01–13.
4. Chauhan V, Singh A, Arora R, et al. Draft genome sequence of *Mycolicibacterium conceptionense* isolated from the sputum sample of a patient with pulmonary tuberculosis. *Microbiol Resour Announc*. 2024;13(11):e0072424.
5. D'Souza PJJ, George LS, Paramasivam G, Devasia T, Ravishankar N, Nayak BS, et al. Symptom perception, health-related quality of life and predicted survival in heart failure patients. *Clin Epidemiol Glob Health*. 2024;29:101754.
6. Dubey H, Ray A, Dube A, Gulati K. S-nitrosoglutathione attenuates oxidative stress and improves retention memory dysfunctions in intracerebroventricular-streptozotocin rat model of sporadic Alzheimer's disease via activation of BDNF and NRF-2 antioxidant signalling pathway. *Neuropsychobiology*. 2024;83(2):101–113.
7. Gavadia R, Rasgania J, Sahu N, et al. Design and synthesis of isatin-tagged isoniazid conjugates with cogent antituberculosis and radical quenching competence: in-vitro and in-silico evaluations. *Chem Biodivers*. 2024;21(10):e202400765.
8. Gavadia R, Rasgania J, Sahu N, et al. Synthesis of indole-functionalized isoniazid conjugates with potent antimycobacterial and antioxidant efficacy. *Future Med Chem*. 2024;16(17):1731–1747.
9. Gonuguntla HK, Vidyasagar P, Mrigpuri P. Cone-beam computed tomography-guided transbronchial lung biopsies: leading the way to precision. *Lung India*. 2024;41(6):480–482.
10. Gulati K, Sharma H, Thokchom S, Verma P, Ray A. Pharmacological evaluation of cellular and molecular mechanism of anti-inflammatory and immunomodulatory effects of traditional herbal drug extract of *Hedychium spicatum* in experimental models of bronchial asthma. *Asian J Pharm Res Dev*. 2024;12(3):257–266.
11. Gupta A, Chandra E, Anand S, Kumar N, Arora R, Rana D, Mrigpuri P. Latent tuberculosis diagnostics: current scenario and review. *Monaldi Arch Chest Dis*. 2024 May 3.
12. Aggarwal J, Batra J, Midha U, Aggarwal A, Khan MA, Rohil V. Study of some biological markers in cord blood of preterm and term infants and their association with neonatal sepsis. *Pediatr Endocrinol Diabetes Metab*. 2025;31(1):17–24.
13. Khanna M, Sharma K, Saxena SK, Sharma JG, Rajput R, Kumar B. Unravelling the interaction between influenza virus and the nuclear pore complex: insights into viral replication and host immune response. *Virus Dis*. 2024;35:231–242.
14. Kumar M, Kumar R, Arisham DK, Gupta RK, Naudiyal P, Goutam G, Mavi AK. Emerging AI impact in the

- healthcare sector: a review. *Eur J Environ Public Health*. 2025;9(1).
15. Kumar R, Kumar M, Arisham DK. Artificial intelligence: magical tool in the health sciences. *Indian J Allergy Asthma Immunol*. 2024;38:1–2.
 16. Kumar R, Kumar M, Raj S, et al. Quitting tobacco through quitline services: impact in India. *Monaldi Arch Chest Dis*. 2024.
 17. Kumar R, Singh K, Mavi AK, Nagar JK, Raj S, Kumar M, Ravishakar N. Combustion of biomass fuel and chronic obstructive pulmonary disease in rural population of India. *Indian J Chest Dis Allied Sci*. 2024;66(1):1–6.
 18. Kumar R, Singhal M, Ravishankar N, Sinha AP, Verma A, Kumar B, et al. Enhancing latent tuberculosis infection treatment adherence with mobile health intervention: a quasi-experimental study. *Natl J Community Med*. 2024;15(10):792–799.
 19. Manocha N, Laubretton D, Robert X, Marvel J, Gueguen-Chaignon V, Gouet P, Kumar P, Khanna M. Unveiling a shield of hope: a novel multiepitope-based immunogen for cross-serotype cellular defense against dengue virus. *Vaccines*. 2024;12(3):316.
 20. Manocha N, Jha P, Kumar P, Khanna M, Chopra M, Pai SS. Immunoinformatic approach to design T cell epitope-based chimeric vaccine targeting multiple serotypes of dengue virus. *J Biomol Struct Dyn*. 2024;28:1–19.
 21. Mrigpuri P, Yadav S, Sharma D, Spalgais S, Goel N, Menon BK, Kumar R. Virtual bronchoscopic navigation and guided radial endobronchial ultrasound for peripheral pulmonary lesions: harmonizing modalities to optimize accuracy. *Monaldi Arch Chest Dis*. 2025 Jan.
 22. Naqvi M, Gulati K, Rehman S, Ali NH, Sharma H, Ray A. Medicinal plants with therapeutic potential in bronchial asthma: an overview. *Int J Toxicol Pharmacol Res*. 2024;14(6):120–135.
 23. Nikitha S, Sabeena S, Guruvare S, Ravishankar N, Varma M, Saravu K, Shenoy RP. Trends in malignancies among patients having human immunodeficiency virus infection attending a tertiary care hospital in southwest India. *Med J Armed Forces India*. 2024;80(1):123–129.
 24. Noronha FS, Jose TT, George LS, Bhandary RP, Praharaj SK, Ravishankar N, et al. Mental health literacy, attitude, and help-seeking intention among a particularly vulnerable tribe. *Clin Epidemiol Glob Health*. 2024;29:101706.
 25. Priyanka, Sharma S, Varma-Basil M, Sharma M. C-terminal region of Rv1039c (PPE15) protein of Mycobacterium tuberculosis targets host mitochondria to induce macrophage apoptosis. *Apoptosis*. 2024;29(9–10):1757–1779.
 26. Ravishankar N, Ather I, Teles M, Sumit K. A perspective on alternative forms of tobacco. *Indian J Chest Dis Allied Sci*. 2024;66(4):132–136.
 27. Sarma M, Mrigpuri P, Spalgais S, Menon BK. Subpleural lipoma mimicking pulmonary embolism in a patient of chronic obstructive pulmonary disease: a case report. *Indian J Respir Care*. 2025.
 28. Sharma H, Gulati K, Ray A. Cellular and molecular mechanisms involved in the protective effects of Aerva lanata on airways remodeling in experimental model of bronchial asthma in rats. *Asian J Pharm Res Dev*. 2024;12(2):139–145.
 29. Sonowal T, Shariff M. Phenotypic and molecular characterization of multidrug-resistant uropathogenic Escherichia coli. *Int J Sci Res*. 2024;13(7):605–611.
 30. Spalgais S, Mathew L, Mrigpuri P, Kulshrestha R, Kumar R. Bilateral diffuse multiple cavitary nodules: a

radiological presentation of adenocarcinoma. *Egypt J Chest Dis Tuberc.* 2025;74:124–127.

31. Spalgais S, Mrigpuri P, Dhilnaz AS, et al. Pulmonary sarcomatoid carcinoma presenting as massive pleural effusion. *Indian J Chest Dis Allied Sci.* 2023;65(3):142–146.
32. Spalgais S, Mrigpuri P, Ravishankar N, Kumar R. Pulmonary function and diffusing capacity of carbon monoxide in hypersensitivity pneumonitis: an observational study of 152 patients. *Thorac Res Pract.* 2024;25(2):51–56.
33. Spalgais S, Mrigpuri P, Ravishankar N, Kumar R. Comment on: pulmonary function and diffusing capacity of carbon monoxide in hypersensitivity pneumonitis: an observational study of 152 patients. *Thorac Res Pract.* 2024;25(5):195–196.
34. Spalgais S, Ranga V, Mavi AK, Kumar R. House dust protein level of pigeon droppings and feathers in environmental bird exposure-related hypersensitivity pneumonitis: a pilot study. *Lung India.* 2025;42:11–15.
35. Spalgais S, Safwan MA, Mrigpuri P, Kumar R. Exfoliative dermatitis and hepatitis to all first-line anti-tubercular therapy with treatment of drug-sensitive tuberculosis with second-line anti-tubercular therapy: a roller coaster ride. *Chest Dis Rep.* 2024;12:12626.
36. Spalgais S, Yadav SR, Mrigpuri P, Kumar R. Spirometry findings of chronic lung disease in high-altitude residents of Ladakh (>11,000 feet above sea level). *Monaldi Arch Chest Dis.* 2024.
37. Tatikola SP, Natarajan V, Amaravadi SK, Desai VK, Asirvatham AR, Ravishankar N. Effect of pain neuroscience education+ (PNE+) in people with different mechanisms of chronic pain: a systematic review and meta-analysis. *J Bodyw Mov Ther.* 2025;41:215–237.
38. Sonowal T, Shariff M. Direct detection of atypical bacteria in clinical samples from patients with chronic obstructive pulmonary disease (COPD) by PCR and RT-PCR. *Int J Curr Microbiol Appl Sci.* 2024;13(6):24–31.
39. Verma A, Behera A, Ravishankar N, Islam M, Vaishali K, Sinha MK, et al. Characteristics of COPD patients for the implementation of the smartphone application for COPD: an implementation study. *Natl J Community Med.* 2024;15(8):685–690.

Books

1. Gaur SN, Kumar R, Singh AB, Aggarwal MK, Arora N. Guidelines for practice of allergen immunotherapy in India – A 2017 update. In: 47th Workshop on Respiratory Allergy, Diagnosis and Management. Delhi: NCRAAI, VP Chest Institute; 2024. ISBN: 968-81-920556-2-9.
2. Kumar R, Behera D, Singh AB, Gaur SN, Aggarwal MK, Prasad R, Memon B, Goel N, Mrigpuri P, Spalgais S, Mahesh PA, Kant S, Janmeja AK, Mohan A, Jain VK, Prasad KV, Goyal M, Nagaraju K, Arora N, Priya A, Kumar K, Meena R, Sankararaman N, Verma AK, Gupta VB, Prakash SA, Safwan MA. Indian guidelines for diagnosis of respiratory allergy. In: 47th Workshop on Respiratory Allergy, Diagnosis and Management. Delhi: NCRAAI, VP Chest Institute; 2024. ISBN: 968-81-920556-2-9.
3. Kumar R, Jain R. Parapneumonic effusions and empyema. In: Prakash AK, Jaiswal A, Guleria R, Datta B, editors. Textbook of Pleural Diseases. Delhi: Jaypee Brothers Medical Publishers; 2024. p.61–70. ISBN: 978-93-5696-892-9.
4. Kumar R, Kulshrestha R, editors. Compendium of VPCI Newsletter (2012–2023). Delhi: Vidyanilyam Prakashan; 2025. ISBN: 982-91-911549-1-4.
5. Kumar R, Kumar M, Mehta RK, Singh K, Mavi AK. Cockroach (*Periplaneta americana*) exposure and its allergy

sensitization in asthma patients in North Delhi region. In: 47th Workshop on Respiratory Allergy, Diagnosis and Management. Delhi: NCRAAI, VP Chest Institute; 2024. p.264–265. ISBN: 968-81-920556-2-9.

6. Kumar R. Allergy situation in India. In: 47th Workshop on Respiratory Allergy, Diagnosis and Management. Delhi: NCRAAI, VP Chest Institute; 2024. ISBN: 968-81-920556-2-9.
7. Kumar R. Food allergy in bronchial asthma. In: 47th Workshop on Respiratory Allergy, Diagnosis and Management. Delhi: NCRAAI, VP Chest Institute; 2024. ISBN: 968-81-920556-2-9.
8. Prasad R, Kumar R. Allergy testing. In: 47th Workshop on Respiratory Allergy, Diagnosis and Management. Delhi: NCRAAI, VP Chest Institute; 2024. ISBN: 968-81-920556-2-9.
9. Rohil V, Bhadra J, Aggarwal J. Handbook on Good Clinical Laboratory Practices (GCLP). 1st ed. Delhi: IP Innovative Publication; 2024. ISBN: 978-81-19613-33-5.

Chapters in Books

1. Gulati K, Arora A. The herbal medicines *Clitoria ternatea* (butterfly pea) and *Evolvulus alsinoides* (dwarf morning glory) from traditional use to scientific assessment, especially in Alzheimer's and Parkinson's diseases. In: Akhtar J, Sarwat M, Bashir F, editors. Medicinal plants for the management of neurodegenerative diseases. CRC Press; 2024. p.169–181.
2. Gulati K, Dubey H, Tanwar A, Arora A, Ray A. Metabolic syndrome and associated cognitive dysfunction: a pharmacological perspective. In: Gandhi T, Mehta A, editors. Biochemical mechanisms for metabolic syndrome. Adv Biochem Health Dis. Cham: Springer; 2024. p.457–476.
3. Kulshrestha R. Good clinical laboratory practices—introduction and scope. In: Handbook of Good Clinical Laboratory Practices (GCLP). Delhi: Innovative Publication Pvt Ltd; 2024. Chapter 1, p.1–9. ISBN: 978-81-19613-33-5.
4. Kulshrestha R. Pathophysiology of interstitial lung disease. In: Interstitial Lung Disease—Untangling the Complexities. Delhi: Kothari Medical Subscription Services Pvt Ltd; 2025. Chapter 3, p.10–17. ISBN: 978-93-83989-94-2.
5. Yadav SR, Kumar R. Pneumothorax. In: Thekkinkattil M, editor. Navigating Pulmonary Crisis: A Comprehensive Guide. New Delhi: Jaypee Brothers Medical Publishers; 2024.

Media Recognition

NEWS PAPER CUTTING

दिल्ली के वल्लभभाई चैस्ट इंस्टीट्यूट में 18वां औतार सिंह पेंटल मेमोरियल ओरेशन का आयोजन।

The 8th Professor Autar Singh Paintal Memorial Oration was held today at Vallabhbhai Chest Institute in New Delhi. The event saw participation from the institute's faculty, former students, professors, and doctors. Director Professor Rajkumar welcomed Professor Ashok Shah, appreciating his invaluable contributions to chest disease education. The institute is celebrating its 75th anniversary, having been established in 1949, and continues to play a vital role in clinical research and medical education related to chest diseases. The oration, first initiated in 2005, commemorates Professor Autar Singh Paintal, renowned for his 1955 discovery of J-receptors, which significantly advanced the understanding of respiratory problems.



You tube link: https://youtu.be/_EWZSWoKBns?si=FvX8Lav77wD9vu8T

NEWS PAPER CUTTING



भारत में 46 प्रतिशत तम्बाकू सेवन छोड़ दिया उत्तर प्रदेश सबसे आगे



नई दिल्ली : भारत में 46 प्रतिशत से अधिक युवा वयस्कों ने तम्बाकू का सेवन छोड़ दिया, उत्तर प्रदेश सबसे आगे सरकार की राष्ट्रीय तम्बाकू क्विटलाइन सेवाओं (एनटीक्यूएलएस) द्वारा प्राप्त कॉलों के सर्वेक्षण के आधार पर वल्लभभाई पटेल चेस्ट इंस्टीट्यूट (वीपीसीआई) द्वारा गुरुवार को जारी एक रिपोर्ट के अनुसार, भारत में 18-24 वर्ष की आयु के लगभग 46.96 प्रतिशत युवा वयस्कों ने तम्बाकू का सेवन छोड़ दिया है। सरकार की राष्ट्रीय तम्बाकू क्विटलाइन सेवाओं (एनटीक्यूएलएस) द्वारा प्राप्त कॉलों के सर्वेक्षण के आधार पर वल्लभभाई पटेल चेस्ट इंस्टीट्यूट (वीपीसीआई) द्वारा गुरुवार को जारी एक रिपोर्ट के अनुसार, भारत में 18-24 वर्ष की आयु के लगभग 46.96 प्रतिशत युवा वयस्कों ने तम्बाकू का सेवन छोड़ दिया है।

विश्व तंबाकू निषेध दिवस हर साल 31 मई को मनाया जाता है। छज़रै डेटा पर आधारित टच्छ सर्वेक्षण से पता चला है कि तंबाकू छोड़ने वाली लाइन ने 4,77,585 पंजीकृत कॉलों में से 1,44,938 लोगों को तंबाकू छोड़ने के लिए पंजीकृत किया, जिसमें मई 2016 और अप्रैल 2024 के बीच इंटरैक्टिव वॉयस रिसर्प्स (प्ट) पर कुल 8.2 मिलियन कॉल आए। छज़रै को कुल 46.96 प्रतिशत पंजीकृत कॉल 18-24 वर्ष के युवाओं से थे, जिन्होंने 12वीं कक्षा तक शिक्षा भी प्राप्त की थी - जो उन्हें छोड़ने वालों का सबसे बड़ा समूह बनाता है। टच्छ ने कहा, यह डेटा भारत के युवाओं में तंबाकू की लत से लड़ने के लिए बढ़ती जागरूकता और दृढ़ संकल्प को दर्शाता है। 43 प्रतिशत से अधिक लोगों ने बताया कि वे स्व-रोजगार में लगे हैं, 75.85 प्रतिशत लोगों का तंबाकू सेवन का कोई पारिवारिक इतिहास नहीं था, जबकि 68.63 प्रतिशत लोग धुआं रहित तंबाकू का सेवन करते पाए गए। इसके अलावा, आंकड़ों से पता चला कि उत्तर प्रदेश में 1,50,925 (31.6 प्रतिशत) कॉल और 29.68 प्रतिशत धूम्रपान छोड़ने वालों के साथ सबसे आगे रहा। इसके अलावा, 72.96 प्रतिशत कॉल ऐसे व्यक्तियों से की गई थीं जो 1-10 वर्षों से तंबाकू का सेवन कर रहे हैं और 77.74 प्रतिशत लोगों का शराब के सेवन का कोई इतिहास नहीं है। वल्लभभाई पटेल चेस्ट इंस्टीट्यूट के निदेशक डॉ. राज कुमार ने कहा, एनटीक्यूएलएस देश भर में तंबाकू उपयोगकर्ताओं को मुफ्त, गोपनीय परामर्श और मार्गदर्शन प्रदान करता है, जिससे उन्हें अपने स्वास्थ्य की जिम्मेदारी लेने में मदद मिलती है। यह भी पढ़ें - तंबाकू छोड़ने में एपी को पहला स्थान मिल "तंबाकू छोड़ना सिर्फ इच्छाशक्ति की बात नहीं है। हम मनोवैज्ञानिक और व्यवहारिक कारकों को संबोधित करते हैं जो लत में योगदान करते हैं, लालसा को प्रबंधित करने और वापसी के लक्षणों को दूर करने के लिए रणनीतियाँ पेश करते हैं," डॉ. राज ने कहा, जो नवंबर 2001 से वीपीसीआई में तंबाकू समाप्ति क्लिनिक (टीसीसी) का नेतृत्व कर रहे हैं। पिछले 23 वर्षों में, वीपीसीआई में टीसीसी ने 376 जन जागरूकता कार्यक्रम, तंबाकू विरोधी अभियान और सेमिनार आयोजित किए हैं, जो 1.3 मिलियन से अधिक लोगों तक पहुँचे हैं। इन पहलों ने 57,243 डॉक्टरों को प्रशिक्षित किया है, 44,652 छात्रों को लाभान्वित किया है, और 61,129 सामाजिक कार्यकर्ताओं को सशक्त बनाया है, जिससे जागरूकता और शिक्षा का एक बड़ा प्रभाव पैदा हुआ है।

Janta Se Rista
(May 30, 2024)

NEWS PAPER CUTTING



Vallabhbhai Patel Chest Institute's Landmark Achievement on World No Tobacco Day

On World No Tobacco Day, the Vallabhbhai Patel Chest Institute (VPCI) proudly announces a significant milestone in the battle against tobacco addiction. The institute's tobacco Quitline has documented a remarkable 144,938 individuals who have successfully quit smoking out of a total of 477,585 registered calls, with an astounding 8.2 million calls recorded on the IVR platform. What's particularly striking is that nearly half of these registered calls, totaling 46.96%, originate from young adults aged between 18 to 24 years, indicating a growing determination among India's youth to combat the scourge of tobacco addiction. Dr. Raj Kumar, Director of the Vallabhbhai Patel Chest Institute, elaborates on the institute's pivotal role in tobacco control: "Since its establishment, our Tobacco Cessation Clinic at VPCI has been spearheading efforts to combat tobacco addiction, offering crucial support to individuals grappling with this habit. Our comprehensive approach, combining counselling and pharmacotherapy, has significantly enhanced quit rates and contributed to improved public health outcomes. Safeguarding the youth from the perils of tobacco remains our top priority, as our efforts today will shape a healthier, tobacco-free future for the next generation."

An intriguing aspect of the data reveals that close to half, or 46.96%, of the registered calls to the National Tobacco Quitline Service (NTQLS) come from the 18 to 24 age bracket, with a majority of callers possessing a 12th-grade education. Furthermore, over 43% of these individuals are self-employed, 75.85% have no family history of tobacco use, and a staggering 68.63% are users of smokeless tobacco. Uttar Pradesh leads the tally with 150,925 calls (31.6%) and contributes to 29.68% of quitters. Additionally, the majority of calls, accounting for 72.96%, are from individuals with 1-10 years of tobacco use, and an overwhelming 77.74% have no history of alcohol consumption. The Vallabhbhai Patel Chest Institute has emerged as a beacon of hope in the nationwide fight against tobacco addiction. Notably, it was the site of India's first Tobacco Cessation Clinic, established in November 2001. In 2016, the Ministry of Health and Family Welfare launched the National Tobacco Quitline Service (NTQLS), a prestigious project operating toll-free from 8 AM to 8 PM, offering counselling in 15 languages. The service has been instrumental in guiding callers through the quitting process, providing personalized advice, and addressing concerns, with satellite centres now operational at Tata Memorial Hospital in Mumbai, NIMHANS in Bengaluru, and Dr. Bhubaneswar Borooah Cancer Institute in Guwahati.

Dr. Raj Kumar emphasizes the vital role played by the NTQLS in providing free, confidential counselling and guidance to tobacco users nationwide, empowering them to take control of their health. He stresses that quitting tobacco requires more than just willpower, as the psychological and behavioural aspects of addiction must also be addressed. Over the past 23 years, the Tobacco Cessation Clinic at VPCI has conducted 376 public awareness programs, anti-tobacco campaigns, and seminars, reaching out to over 1.3 million individuals. These initiatives have trained 57,243 doctors, educated 44,652 students, and empowered 61,129 social workers, creating a ripple effect of awareness and education across communities. As World No Tobacco Day approaches, the Vallabhbhai Patel Chest Institute and the Society for Tobacco Control are observing the occasion under the theme "Protecting Children from Tobacco Industry Interference," underscoring the importance of safeguarding youth from the harmful effects of tobacco. Dr. Raj Kumar's illustrious career, punctuated by accolades such as the Lifetime Achievement Award (2024) and the WHO-World No Tobacco Day Award (2019), reflects his unwavering commitment to tobacco control and public health. His extensive contributions to over 545 research papers, books, and publications have solidified his standing as a prominent figure in the global medical fraternity.

Durg Today
(May 30, 2024)

NEWS PAPER CUTTING

Over 46 pc young adults quit tobacco in India, UP leads: Report

New Delhi, May 30 (IANS) About 46.96 per cent of young adults, aged 18-24, have quit tobacco in India, according to a report on Thursday by Vallabhbhai Patel Chest Institute (VPCI) based on a survey of calls received by the government's National Tobacco QuitLine Services (NTQLS). World No Tobacco Day is observed every year on May 31. The VPCI survey based on NTQLS data showed that the tobacco quitline recorded 1,44,938 quitters from 4,77,585 registered calls, with a total of 8.2 million calls hitting the interactive voice response (IVR) between May 2016 and April 2024.

A total of 46.96 per cent of registered calls to the NTQLS were from 18-24-year-olds, who also had a 12th-grade education -- making them the largest group of quitters. "This data highlights the growing awareness and determination among India's youth to combat tobacco addiction," the VPCI said.

Over 43 per cent reported to be self-employed, 75.85 per cent had no family history of tobacco use, while 68.63 per cent were found to use smokeless tobacco. Further, the data showed that Uttar Pradesh led with 1,50,925 (31.6 per cent) calls and 29.68 per cent of quitters. In addition, 72.96 per cent of calls were made from individuals with 1-10 years of tobacco use, and 77.74 per cent have no history of alcohol use.

"The NTQLS provides free, confidential counselling and guidance to tobacco users across the country, empowering them to take charge of their health," said Dr. Raj Kumar, Director, Vallabhbhai Patel Chest Institute. "Quitting tobacco is not just about willpower. We address the psychological and behavioural factors that contribute to addiction, offering strategies to manage cravings and overcome withdrawal symptoms," added Dr. Raj, leading the Tobacco Cessation Clinic (TCC) at VPCI since November 2001.

Over the past 23 years, TCC at VPCI has organised 376 public awareness programmes, anti-tobacco campaigns, and seminars, reaching over 1.3 million people. These initiatives have trained 57,243 doctors, benefited 44,652 students, and empowered 61,129 social workers, creating a ripple effect of awareness and education.

Sakshi Post
(May 30, 2024)

NEWS PAPER CUTTING**Over 46 pc young adults quit tobacco in India, UP leads: Report**

New Delhi, May 30 (IANS) About 46.96 per cent of young adults, aged 18-24, have quit tobacco in India, according to a report on Thursday by Vallabhbhai Patel Chest Institute (VPCI) based on a survey of calls received by the government's National Tobacco QuitLine Services (NTQLS). World No Tobacco Day is observed every year on May 31. The VPCI survey based on NTQLS data showed that the tobacco quitline recorded 1,44,938 quitters from 4,77,585 registered calls, with a total of 8.2 million calls hitting the interactive voice response (IVR) between May 2016 and April 2024.

A total of 46.96 per cent of registered calls to the NTQLS were from 18-24-year-olds, who also had a 12th-grade education -- making them the largest group of quitters. "This data highlights the growing awareness and determination among India's youth to combat tobacco addiction," the VPCI said. Over 43 per cent reported to be self-employed, 75.85 per cent had no family history of tobacco use, while 68.63 per cent were found to use smokeless tobacco.

Further, the data showed that Uttar Pradesh led with 1,50,925 (31.6 per cent) calls and 29.68 per cent of quitters. In addition, 72.96 per cent of calls were made from individuals with 1-10 years of tobacco use, and 77.74 per cent have no history of alcohol use. "The NTQLS provides free, confidential counselling and guidance to tobacco users across the country, empowering them to take charge of their health," said Dr. Raj Kumar, Director, Vallabhbhai Patel Chest Institute.

"Quitting tobacco is not just about willpower. We address the psychological and behavioural factors that contribute to addiction, offering strategies to manage cravings and overcome withdrawal symptoms," added Dr. Raj, leading the Tobacco Cessation Clinic (TCC) at VPCI since November 2001. Over the past 23 years, TCC at VPCI has organised 376 public awareness programmes, anti-tobacco campaigns, and seminars, reaching over 1.3 million people.

These initiatives have trained 57,243 doctors, benefited 44,652 students, and empowered 61,129 social workers, creating a ripple effect of awareness and education

Investing .com
(May 30, 2024)

NEWS PAPER CUTTING

अमर उजाला

No Tobacco Day : हर साल 1000 बच्चों की लत छुड़वा रहा है एनटीसीपी, पटेल चेस्ट के विशेषज्ञ करते हैं निगरानी

दिल्ली के अस्पताल में पंजीकृत हो रहे कुछ बच्चे अपनी इसी चाहत की वजह से नशे की लत को छोड़ रहे हैं। यह सब कुछ वल्लभ भाई पटेल चेस्ट इंस्टिट्यूट (वीपीसीआई) के विशेषज्ञों की निगरानी में हो रहा है



चाहत से किसी भी मंजिल को हासिल किया जा सकता है। दिल्ली के अस्पताल में पंजीकृत हो रहे कुछ बच्चे अपनी इसी चाहत की वजह से नशे की लत को छोड़ रहे हैं। यह सब कुछ वल्लभ भाई पटेल चेस्ट इंस्टिट्यूट (वीपीसीआई) के विशेषज्ञों की निगरानी में हो रहा है। डॉक्टर बच्चों को तंबाकू छोड़ने की राह दिखाते हैं। बच्चों को थोड़ी कठिनाई होती है, लेकिन वह तंबाकू से तौबा करने की मंजिल पा ही लेते हैं। दरअसल, राष्ट्रीय तंबाकू नियंत्रण कार्यक्रम (एनटीसीपी) के तहत तंबाकू छोड़ने के लिए हेल्पलाइन चलाई जा रही है। कोई भी टोल फ्री नंबर 1800112356 पर कॉल करके तंबाकू छोड़ने के कार्यक्रम से जुड़ सकता है। इस हेल्पलाइन पर प्रतिदिन पांच से छह हजार लोग कॉल करते हैं। इसमें बड़ी संख्या में बच्चे होते हैं। नशे की लत से परेशान होकर बच्चे खुद आगे आते हैं और इसे छोड़ने की बात करते हैं। वल्लभभाई पटेल चेस्ट इंस्टिट्यूट (वीपीसीआई) के निदेशक डॉ. राज कुमार ने बताया कि साल 2016 से अभी तक आए कॉल में से चार लाख लोगों को तंबाकू छोड़ने के कार्यक्रम में पंजीकृत किया गया। इसमें करीब 8000 बच्चे (18 साल से कम) हैं। बच्चों की संख्या करीब 2% है। उन्होंने कहा कि इस हेल्पलाइन पर हर दिन 5000 से अधिक कॉल आती हैं। इनमें से जो व्यक्ति तंबाकू छोड़ना चाहते हैं उन्हें कार्यक्रम के तहत पंजीकृत किया जाता है। तय होती है तंबाकू छोड़ने की तारीख डॉ. कुमार ने बताया कि मरीज को कार्यक्रम के तहत पंजीकृत करने के दौरान तंबाकू छोड़ने की तारीख तय कर दी जाती है। इलाज शुरू करने से पहले मरीज का पूरा मूल्यांकन किया जाता है। उसके बाद उसकी तंबाकू छुड़वाई जाती है।

- एक साल तक मरीज की निगरानी की जाती है। इसमें देखा जाता है कि उक्त फिर से तंबाकू का सेवन तो नहीं कर रहा। इसमें परिवार का सहयोग भी लिया जाता है। मरीज को पूरे समय काउंसलिंग भी दी जाती है।

आसानी से आते हैं चपेट में बच्चे विशेषज्ञों का कहना है कि बच्चे आसानी से तंबाकू सेवन की चपेट में आते हैं। बच्चे प्रभावशाली प्रचार, दूसरों को देखकर, पढ़ाई या दूसरे कारणों के तनाव के कारण तंबाकू का सहारा लेते हैं। इसमें सबसे ज्यादा बच्चे विदेशी धूम्रपान, गुटखा, हुक्का का इस्तेमाल करना पसंद करते हैं।

बच्चों पर केंद्रित है इस साल की थीम विश्व तंबाकू निषेध दिवस 2024 की थीम बच्चों को तंबाकू उद्योग के हस्तक्षेप से बचाना है। विशेषज्ञों का कहना है कि देश के युवाओं खासकर बच्चों में तंबाकू सेवन का चलन बढ़ रहा है। इसे रोकने के लिए बड़े स्तर पर अभियान चलाने की जरूरत है।

Amar Ujala
(May 31, 2024)

NEWS PAPER CUTTING



Report says over 46% young adults quit tobacco in India, UP leads



About 46.96% of young adults, aged 18-24, have quit tobacco in India, according to a report on Thursday by Vallabhbhai Patel Chest Institute (VPCI) based on a survey of calls received by the government's National Tobacco QuitLine Services (NTQLS). World No Tobacco Day is observed every year on May 31. The VPCI survey based on NTQLS data showed that the tobacco quitline recorded 1,44,938 quitters from 4,77,585 registered calls, with a total of 8.2 million calls hitting the interactive voice response (IVR) between May 2016 and April 2024. A total of 46.96 per cent of registered calls to the NTQLS were from 18-24-year-olds, who also had a 12th-grade education — making them the largest group of quitters. "This data highlights the growing awareness and determination among India's youth to combat tobacco addiction," the VPCI said. Over 43% reported to be self-employed, 75.85% had no family history of tobacco use, while 68.63 per cent were found to use smokeless tobacco. Further, the data showed that Uttar Pradesh led with 1,50,925 (31.6 per cent) calls and 29.68 per cent of quitters. In addition, 72.96 per cent of calls were made from individuals with 1-10 years of tobacco use, and 77.74 per cent have no history of alcohol use. "The NTQLS provides free, confidential counselling and guidance to tobacco users across the country, empowering them to take charge of their health," said Dr. Raj Kumar, Director, Vallabhbhai Patel Chest Institute. "Quitting tobacco is not just about willpower. We address the psychological and behavioural factors that contribute to addiction, offering strategies to manage cravings and overcome withdrawal symptoms," added Dr. Raj, leading the Tobacco Cessation Clinic (TCC) at VPCI since November 2001. Over the past 23 years, TCC at VPCI has organised 376 public awareness programmes, anti-tobacco campaigns, and seminars, reaching over 1.3 million people. These initiatives have trained 57,243 doctors, benefited 44,652 students, and empowered 61,129 social workers, creating a ripple effect of awareness and education.

Nagaland Post
(May 31, 2024)

NEWS PAPER CUTTING

**VPCI Report Says More Than 46% Young Adults Quit Tobacco In India; Tips To Quit Smoking**

A recent report says that nearly 46.96 per cent of young adults between the ages of 18 and 24 years have quit tobacco in India. Among the ones who quit tobacco, 43 per cent reported to be self-employed, 75.85 per cent had no family history of tobacco use and 68.63 per cent were found to use smokeless tobacco. Read on to know tips that can help you quit smoking.



Debosmita Ghosh

Updated May 31, 2024, 11:00 IST



VPCI Report Says More Than 46 Young Adults Quit Tobacco In India

A recent report released by Vallabhbhai Patel Chest Institute (VPCI) revealed that nearly 46.96 per cent of young adults between the ages of 18 and 24 years have quit tobacco in India. This survey was based on calls received by the government's National Tobacco QuitLine Services (NTQLS). The VPCI survey based on NTQLS data showed that the tobacco quitline recorded 1,44,938 quitters from 4,77,585 registered calls, with a total of 8.2 million calls hitting the interactive voice response (IVR) between May 2016 and April 2024.

Time Now
(May 31, 2024)

NEWS PAPER CUTTING

देश की खबरें। राष्ट्रीय हेल्पलाइन पर कॉल करने वाले 1.44 लाख से अधिक लोगों ने तंबाकू छोड़ा : अधिकार



नयी दिल्ली, 31 मई केंद्र की तंबाकू निषेध के लिए संचालित राष्ट्रीय हेल्पलाइन पर प्राप्त 4.77 लाख कॉल में से 1,44,938 कॉल करने वालों ने तंबाकू का सेवन छोड़ दिया है। अधिकारियों ने शुक्रवार को यह जानकारी दी।

इस राष्ट्रीय हेल्पलाइन का संचालन वल्लभभाई पटेल चेस्ट इंस्टीट्यूट (वीपीसीआई) द्वारा किया जाता है। वर्ष 2016 में शुरुआत के बाद से 'नेशनल टोबैको क्विट लाइन सर्विसेज' (एनटीक्यूएलएस) की हेल्पलाइन पर करीब 82 लाख कॉल प्राप्त हुई हैं।

इस संबंध में किए गए सर्वेक्षण के निष्कर्ष रविवार को विश्व तंबाकू निषेध दिवस (31 मई) पर वीपीसीआई द्वारा जारी किए गए। वीपीसीआई के निदेशक डॉ. राजकुमार ने कहा कि कॉल करने वाले 46.96 प्रतिशत लोग 18 से 24 वर्ष की आयु वर्ग के थे, जो तंबाकू का सेवन छोड़ने वालों का सबसे बड़ा समूह था।

उन्होंने कहा, “ये आंकड़े भारत के युवाओं में तंबाकू की लत से लड़ने के लिए बढ़ती जागरूकता और दृढ़ संकल्प को दर्शाते हैं।” उन्होंने कहा कि कॉल करने वाले 43 प्रतिशत से अधिक लोग स्वरोजगार में लगे थे, 75.85 प्रतिशत के परिवार में तंबाकू सेवन का कोई इतिहास नहीं था और 68.63 प्रतिशत लोग खाने वाले तंबाकू का सेवन करते थे।

वीपीसीआई के निदेशक ने कहा कि धूम्रपान छोड़ने वालों की सूची में उत्तर प्रदेश सबसे ऊपर है, जहां 1,50,925 (31.6 प्रतिशत) कॉल आए जिनमें से 29.68 प्रतिशत ने तंबाकू छोड़ा। इसके अलावा, 72.96 प्रतिशत कॉल ऐसे व्यक्तियों से थे जो एक से 10 साल तक तंबाकू का सेवन कर रहे थे। (यह सिंडिकेटेड न्यूज फीड से अनएडिटेड और ऑटो-जेनरेटेड स्टोरी है, ऐसी संभावना है कि लेटेस्टली स्टाफ द्वारा इसमें कोई बदलाव या एडिट नहीं किया गया है)

Latest Li
(May 31, 2024)

NEWS PAPER CUTTING



विश्व तम्बाकू निषेध दिवस पर कार्यक्रम आयोजित

आगरा (एसएनबी)। शुक्रवार को रेडियोथेरेपी विभाग, सरोजिनी नायडू मेडिकल कालेज में विश्व तम्बाकू निषेध दिवस के उपलक्ष्य में एक जन जागरूकता कार्यक्रम का आयोजन किया गया। कार्यक्रम में मरीजों के तीमारदारों ने बड़ी संख्या में प्रतिभाग किया। कार्यक्रम की अध्यक्षता प्राचार्य डॉ. प्रशांत गुप्ता ने की। कार्यक्रम का संचालन विभागाध्यक्ष डॉ. सुरभि गुप्ता ने किया। कार्यक्रम में लोगों को तम्बाकू के दुष्प्रभाव को दर्शाने वाली वीडियो दिखायी गई। रेडियोथेरेपी विभाग के पीजी छात्र-छात्राओं ने नुक्कड़ नाटक के माध्यम से आम जनता को तम्बाकू किस तरह लोगों को अपनी गिरफ्त में लेकर उनका जीवन बर्बाद करता है और कैसे उनके परिवार को भी पतन की ओर लेकर जाता है यह दर्शाया। प्रधानाचार्य डॉ. प्रशांत गुप्ता ने कार्यक्रम में उपस्थित सभी लोगों को तम्बाकू छोड़ने और इसका सेवन न करने के लिए शपथ दिलाई।

फिरोजाबाद। उप्र राज्य विधिक सेवा प्राधिकरण लखनऊ व जिला विधिक सेवा

प्राधिकरण अध्यक्ष जनपद न्यायाधीश हरवीर सिंह के निर्देशानुसार एवं अपर जिला जज के निर्देशन और प्राधिकरण सचिव अपर जिला एवं सत्र न्यायाधीश पीयूष सिद्धार्थ की अध्यक्षता में विश्व तम्बाकू निषेध दिवस के अवसर पर फिरोजाबाद स्कूल ऑफ नर्सिंग में संगोष्ठी का आयोजन किया गया। जिसमें सभी को आस

**छात्र-छात्राओं ने नुक्कड़
नाटक का मंचन कर
लोगों को किया जागरूक**

पास के व्यक्तियों व परिवार में तम्बाकू से होने वाले नुकसान के प्रति जागरूक करने के लिए प्रोत्साहित किया गया और उनके

उज्ज्वल भविष्य की कामना की गई। डिप्टी लीगल एड डिफेंस काउंसिल आदित्य प्रताप सिंह ने भी तम्बाकू के सेवन से होने वाले हानिकारक प्रभावों के विषय में जागरूक करते हुए लीगल एड डिफेंस काउंसिल सिस्टम और विचाराधीन बंदियों व पात्र व्यक्तियों को दी जाने वाली निःशुल्क विधिक सहायता के विषय में बताया। शिविर में मौजूद डॉ. पालीवाल एवं तहसीलदार सदर ने भी तम्बाकू से होने वाली गंभीर बीमारियों और उससे बचाव के उपायों के विषय पर विस्तार से बताया।

Rastriya Shahara
(June 1, 2024)

NEWS PAPER CUTTING

नवोदय टाइम्स

डेढ़ लाख लोगों को तंबाकू सेवन की लत से मिला छुटकारा: VPCI

नई दिल्ली, 3 जून (नवोदय टाइम्स): भारत में तंबाकू सेवन में कमी लाए जाने को लेकर चलाए जा रहे तमाम जागरूकता अभियानों के बावजूद हर साल 13 लाख लोग न सिर्फ अपनी जिंदगी गंवा रहे हैं। बल्कि फेफड़े व दिल संबंधी रोगों और कैंसर के इलाज पर जीवनभर की कमाई तक खर्च करने को मजबूर हो रहे हैं। ऐसे में वल्लभभाई पटेल चेस्ट इंस्टीट्यूट (वीपीसीआई) ने लगभग 1.5 लाख लोगों को तंबाकू सेवन की आदत से छुटकारा दिलाकर बड़ी कामयाबी हासिल की है।



प्रोफेसर डॉ.
राज कुमार



वीपीसीआई के निदेशक प्रोफेसर डॉ. राज कुमार ने बताया कि संस्थान की राष्ट्रीय तंबाकू क्विटलाइन सेवा (एनटीक्यूएलएस) के माध्यम से 18 लाख लोगों ने तंबाकू छोड़ने के लिए मदद मांगी थी, जिनमें से पांच लाख लोगों ने तंबाकू छोड़ने के लिए विकसित कार्यक्रम में भाग लेने के लिए पंजीकरण कराया। इनमें से लगभग 1.5 लाख पंजीकृत लोगों ने सफलतापूर्वक तंबाकू का सेवन करना छोड़ दिया जो 30% की दर से प्राप्त एक अच्छा परिणाम है।

राष्ट्रीय तंबाकू क्विटलाइन सेवा

डॉ. राज कुमार ने बताया कि एनटीक्यूएलएस हेल्पलाइन सोमवार को छड़कर, रोजाना सुबह 8 से रात 8 बजे तक टोल-फ्री नंबर 1800-11-2356 पर उपलब्ध है। यह हिंदी के अलावा 15 अन्य भाषाओं में परामर्श प्रदान करती है। एनटीक्यूएलएस में प्रशिक्षित परामर्शदाताओं की टीम काम करती है जो कॉल करने वालों को तंबाकू सेवन छोड़ने के लिए मार्गदर्शन प्रदान करती है। चिंताओं को दूर करती है और तंबाकू छोड़ने के इच्छुक व्यक्ति के लिए एक व्यक्तिगत योजना बनाती है।

तंबाकू का सेवन छोड़ने में यूपी अव्वल

तंबाकू का सेवन छोड़ने के मामले में सबसे आगे उत्तर प्रदेश के लोग हैं। देशभर में सबसे ज्यादा 31.6% यानी 150925 कॉल एनटीक्यूएलएस को की है। इनमें से 29.68% लोगों ने तंबाकू छोड़ दिया है। वहीं, 72.96% कॉल उन लोगों ने की है जिनका तंबाकू उपयोग का इतिहास 1-10 साल का है, 77.74% कॉल ऐसे लोगों ने की जिन्होंने कभी शराब नहीं पी।

सबसे ज्यादा युवाओं ने दिखाया उत्साह

तंबाकू की लत छोड़ने में ज्यादा कॉल 12वीं कक्षा तक पढ़े लिखे युवाओं की ओर से की गई है। यह संख्या 43.3% है। कुल कॉल में से 75.85% कॉल उन लोगों ने की है जिनके परिवार में तंबाकू के उपयोग का कोई इतिहास नहीं है, 68.63% कॉल धूम रहित तंबाकू उपयोगकर्ताओं ने की है।

Navodaya Times

(June 3, 2023)

NEWS PAPER CUTTING



Vallabhbhai Patel Chest Institute Celebrates 75 Years of Excellence in Chest Medicine



The Vallabhbhai Patel Chest Institute (VPCI) commemorated its 75th anniversary with a grand celebration that reflected on its remarkable legacy and contributions to pulmonary medicine and chest diseases. Speaking at the event, Prof. Raj Kumar, Director of VPCI, expressed immense pride in the institute's achievements and its ongoing dedication to advancing healthcare.

"As we celebrate 75 years of service to the nation, we look back at our accomplishments in chest medicine while maintaining our commitment to innovation, education, and patient care," Prof. Kumar stated. He also extended gratitude to the dignitaries and attendees for being part of VPCI's journey, which began with its foundation in 1949.

Since its inception, VPCI has played a critical role in pulmonary research, education, and clinical care. Founded by Sardar Vallabhbhai Patel, India's first Home Minister, the institute was inaugurated in 1953 by Union Health Minister Raj Kumari Amrit Kaur. The hospital wing, now known as Viswanathan Chest Hospital, was opened in 1957 by India's first President, Dr. Rajendra Prasad. Over the years, VPCI has established itself as a premier institution, renowned for world-class chest medicine services, training medical professionals, and conducting cutting-edge research in respiratory diseases.

Prof. Kumar emphasized the institute's success in training postgraduates in pulmonary medicine and allied sciences, along with its numerous research breakthroughs. The institute's alumni have continued to excel both in India and abroad, carrying forward the knowledge and expertise they gained at VPCI.

Among the institute's landmark contributions is the work of the late Prof. Autar Singh Paintal, a former director and renowned physiologist who led the institute from 1964 to 1990. Prof. Paintal is best known for his discovery of Type J receptors, which linked breathlessness to tachypnoea. His pioneering research transformed the field of physiology and earned him international recognition. In his honor, the 18th Prof. Autar Singh Paintal Memorial Oration was delivered by Prof. Nikhil Tandon from AIIMS on the topic "Harnessing Technology and Task Sharing to Improve the Management of Non-Communicable Diseases."

In addition to its academic and research excellence, VPCI provides comprehensive diagnostic and treatment services. With a 128-bed inpatient facility and specialized services in critical care, CT scanning, pulmonary function studies, and sleep studies, the institute caters to patients not only from India but also from neighboring countries, including Bangladesh, Sri Lanka, Afghanistan, Pakistan, Nepal, and Bhutan. Annually, VPCI registers between 12,000 to 15,000 new cases and handles 50,000 to 60,000 follow-up cases. Further underscoring its commitment to quality healthcare, VPCI received NABH accreditation in May 2023, recognizing its adherence to international standards of excellence.

As an academic leader, VPCI is home to several national centers of importance, including the VPCI-DHR-ICMR Multi-disciplinary Research Unit, the National Tobacco Quit Line Services, and the National Centre of Respiratory Allergy, Asthma, and Immunology. It has also been designated as a Centre of Excellence for Allergic Diseases and Climate Change. In 2023, the institute expanded its educational offerings, introducing 14 short-term courses and launching its first M.Sc. course in Respiratory Therapy. It has also seen active involvement in national and international research projects, funded by agencies such as ICMR, CSIR, and DBT. VPCI has maintained its focus on providing advanced training in chest medicine and allied sciences to medical professionals across India.

Recent events commemorating VPCI's 75th year included the celebration of National Pharmacovigilance Week and World Idiopathic Pulmonary Fibrosis (IPF) Awareness Week, alongside several public lectures on respiratory health issues such as TB, asthma, and air pollution. The institute also hosted a CME on Pharmacovigilance and participated in a super-speciality respiratory camp in Ladakh. Prof. Kumar announced VPCI's plans for future expansion, with 13 acres of land allocated for developing the institute's facilities. As part of its long-term vision, the institute aims to review and update its objectives to meet the evolving healthcare needs of society.

"As we continue to advance in research and patient care, we remain committed to the vision set by our mentors, including the pioneering contributions of Prof. Autar Singh Paintal," Prof. Kumar remarked. "We will strive to uphold the highest standards in service to the nation." As VPCI moves into its next phase, the institute's legacy of excellence in chest medicine, education, and research ensures its ongoing role as a leader in respiratory health and allied sciences in India and beyond..

Drug Today
(September 24, 2024)





Vallabhbhai Patel Chest Institute

University of Delhi, Delhi-110007, India

Phone: 91-011-27667102, 27667441, 27667667, 27666182

Fax: 91-011-27667420, Website: www.vpci.org.in